| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
AR2 A COST EFFECTIVENESS ANALYSIS OF INFLIXIMAB TREATMENT IN PATIENTS WITH RHEUMATOID ARTHRITIS (RA) IN SWEDEN, BASED ON DATA FROM THE STURE REGISTRY
|
Lekander, I
|
|
2008
|
11 |
6 |
p. A356-
1 p.
|
artikel
|
| 2 |
AR4 MEASUREMENT AND RATES OF ADHERENCE TO BIOLOGICS IN PATIENTS WITH RHEUMATOID ARTHRITIS
|
Kim, MM
|
|
2008
|
11 |
6 |
p. A356-A357
nvt p.
|
artikel
|
| 3 |
AR1 PRODUCTIVITY LOSS AT WORK IN PATIENTS WITH EARLY RHEUMATOID ARTHRITIS
|
Braakman-Jansen, LM
|
|
2008
|
11 |
6 |
p. A355-A356
nvt p.
|
artikel
|
| 4 |
AR3 TO INVESTIGATE THE BENEFIT OF ANTI-TNF THERAPY ION PHYSICAL AND MENTAL FUNCTIONING VIA THE SHORT FORM-36 QUALITY OF LIFE QUESTIONNAIRE IN PATIENTS WITH RHEUMATOID ARTHRITIS
|
Adams, R
|
|
2008
|
11 |
6 |
p. A356-
1 p.
|
artikel
|
| 5 |
Author Index
|
|
|
2008
|
11 |
6 |
p. A669-A680
nvt p.
|
artikel
|
| 6 |
CASE3 A CHANGE IN REIMBURSEMENT STRATEGY IN ICELAND: AIMING AT VALUE-BASED PRICING
|
Hauksdottir, R
|
|
2008
|
11 |
6 |
p. A349-A350
nvt p.
|
artikel
|
| 7 |
CASE2 DOTECHNOLOGY EVALUATIONS BASED ON EVIDENCE FROM CONDITIONAL FUNDING LEAD TO AN INCREASE IN POLICY FORMATION?: FINDINGS FROM, AND IMPLICATIONS OF, ONTARIO'S EVIDENCE-BASED HTA PROCESS
|
Goeree, RA
|
|
2008
|
11 |
6 |
p. A349-
1 p.
|
artikel
|
| 8 |
CASE1 IMPLEMENTATION OF TRANSPARENT PROCESS OF DRUG REIMBURSEMENT DECISIONS IN POLAND
|
Zagorska, A
|
|
2008
|
11 |
6 |
p. A348-A349
nvt p.
|
artikel
|
| 9 |
CN8 AN ECONOMIC EVALUATION OF DASATINIB (SPRYCEL®) IN CHRONIC PHASE CHRONIC MYELOID LEUKEMIA (CP-CML) IN CENTRAL AND EASTERN EUROPE
|
Nagy, B
|
|
2008
|
11 |
6 |
p. A358-
1 p.
|
artikel
|
| 10 |
CN6 COST-EFFECTIVENESS OF A HUMAN PAPILLOMAVIRUS VACCINE IN REDUCING THE RISK OF CERVICAL CANCER IN IRELAND USING ATRANSMISSION DYNAMIC MODEL
|
Usher, C
|
|
2008
|
11 |
6 |
p. A357-
1 p.
|
artikel
|
| 11 |
CN3 COST OF INITIAL PROSTATE CANCERTREATMENT FOLLOWING DIAGNOSIS PER PATIENT BY STAGE: ESTIMATES FROM THE UK, FRANCE, GERMANY, ITALY AND SPAIN
|
Benedict, Á
|
|
2008
|
11 |
6 |
p. A351-
1 p.
|
artikel
|
| 12 |
CN2 ESTIMATING TARGET POPULATION SIZE FOR BUDGET IMPACT: AN EPIDEMIOLOGICAL MODEL OF BREAST CANCER AND PROGRESSION TO BONE METASTASIS IN THE UK.
|
Gauthier, A
|
|
2008
|
11 |
6 |
p. A350-A351
nvt p.
|
artikel
|
| 13 |
CN5 EXPLORATORY ECONOMIC EVALUATION OF ADJUVANT TREATMENT OF NON-SMALL-CELL LUNG CANCER (NSCLC) WITH BEVACIZUMAB IN ADDITION TO A CISPLATIN-BASED TREATMENT REGIMEN IN THE UNITED KINGDOM
|
Gyldmark, M
|
|
2008
|
11 |
6 |
p. A357-
1 p.
|
artikel
|
| 14 |
CN7 MODELING THE COST-EFFECTIVENESS OF A NEW AND EXPENSIVE TREATMENT MODALITY IN LUNG CANCER: THE CASE OF PARTICLE THERAPY
|
Grutters, JP
|
|
2008
|
11 |
6 |
p. A357-A358
nvt p.
|
artikel
|
| 15 |
CN1 PHARMACOECONOMIC APPLICATIONS IN FORMULARY MANAGEMENT: BUDGET IMPACT ANALYSIS OF PACLITAXEL PROTEIN-BOUND AT A MAJOR CANCER CENTER
|
Miller, LA
|
|
2008
|
11 |
6 |
p. A350-
1 p.
|
artikel
|
| 16 |
CN4 YEARS OF POTENTIAL LIFE LOST AND PRODUCTIVITY COSTS DUETO CANCER MORTALITY AND FOR SPECIFIC CANCER SITES WHERE HPV MAY BE A RISK FACTOR FOR CARCINOGENESIS—UNITED STATES, 2003
|
Ekwueme, DU
|
|
2008
|
11 |
6 |
p. A351-
1 p.
|
artikel
|
| 17 |
CV2 A NEW MEASURE FOR ASSESSING HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN PATIENTS WITH A TRIAL FIBRILLATION:AF-QOL
|
Arribas, F
|
|
2008
|
11 |
6 |
p. A342-
1 p.
|
artikel
|
| 18 |
CV4 COST-EFFECTIVENESS ANALYSIS OF IVABRADINE IN STABLE ANGINA PATIENTS IN THE NETHERLANDS
|
Nuijten, MJ
|
|
2008
|
11 |
6 |
p. A342-A343
nvt p.
|
artikel
|
| 19 |
CV3 PREDICTED OPTIMAL LIPID VALUE ATTAINMENT WITH THE CO-ADMINISTRATION OF FENOFIBRIC ACID AND A STATIN COMPARED TO STATIN MONOTHERAPY IN PATIENTS WITH MULTIPLE LIPID ABNORMALITIES
|
Sorensen, SV
|
|
2008
|
11 |
6 |
p. A342-
1 p.
|
artikel
|
| 20 |
CV1 WHAT IS THE CLINICAL BENEFIT OF PREVENTING NON-FATAL MYOCARDIAL INFARCTIONS?
|
Eisenstein, EL
|
|
2008
|
11 |
6 |
p. A341-A342
nvt p.
|
artikel
|
| 21 |
DB4 COST OF MANAGING SEVERE HYPOGLYCAEMIA IN INSULIN-TREATED DIABETES IN THREE EUROPEAN COUNTRIES
|
Hammer, M
|
|
2008
|
11 |
6 |
p. A359-
1 p.
|
artikel
|
| 22 |
DB1 ESTIMATING THE LONG-TERM CLINICAL AND ECONOMIC BENEFITS OF INSULIN LISPRO IN TYPE 1 DIABETES IN THE UNITED KINGDOM: A COST-EFFECTIVENESS ANALYSIS BASED ON THE RESULTS OF A RECENT META-ANALYSIS
|
Smith, HT
|
|
2008
|
11 |
6 |
p. A358-
1 p.
|
artikel
|
| 23 |
DB3 HEALTH CARE RESOURCE UTILIZATION AND COSTS IN INSULIN-DEPENDENT PATIENTS WITH TYPE 2 DIABETES UNDER REALWORLD CONDITIONS IN GERMANY: LIVE-SPP STUDY
|
Schöffski, O
|
|
2008
|
11 |
6 |
p. A359-
1 p.
|
artikel
|
| 24 |
DB2 IMPACT OF OVERWEIGHT OR OBESITY ON TREATMENT COSTS IN PATIENTS WITH DIABETES IN THE USA: QUANTILE REGRESSION APPROACH
|
Suh, DC
|
|
2008
|
11 |
6 |
p. A358-A359
nvt p.
|
artikel
|
| 25 |
Disclosure Information
|
|
|
2008
|
11 |
6 |
p. A660-A668
nvt p.
|
artikel
|
| 26 |
EE4 CAREER INTERRUPTIONS AND SICK LEAVES AMONG FIBROMYALGIA PATIENTS
|
Le Lay, K
|
|
2008
|
11 |
6 |
p. A336-
1 p.
|
artikel
|
| 27 |
EE5 COST-EFFECTIVENESS OF ATORVASTATIN IN TYPE 2 DIABETES PATIENTS: A PHARMACO-ECONOMIC ANALYSIS OF THE COLLABORATIVE ATORVASTATIN DIABETES STUDY (CARDS) IN THE BELGIAN POPULATION
|
Marbaix, S
|
|
2008
|
11 |
6 |
p. A343-
1 p.
|
artikel
|
| 28 |
EE8 COST EFFECTIVENESS OF CAPECITABINE IN COMBINATION WITH OXALIPLATIN (XELOX) COMPARED TO FOLFOX (5-FU, LV, OXALIPLATIN) FOR THE TREATMENT OF METASTATIC CARCINOMA OF THE COLON OR RECTUM (CRC) FROM A UK NATIONAL HEALTH SERVICE (NHS) PERSPECTIVE
|
Millar, DR
|
|
2008
|
11 |
6 |
p. A344-
1 p.
|
artikel
|
| 29 |
EE6 COST-EFFECTIVENESS OF THE ADDITION OF RITUXIMAB TO FIRST-LINE CHEMOTHERAPY TREATMENT REGIMENS IN PATIENTS WITH ADVANCED FOLLICULAR LYMPHOMA IN THE UK
|
Ray, JA
|
|
2008
|
11 |
6 |
p. A343-
1 p.
|
artikel
|
| 30 |
EE1 DISCRETE CHOICE EXPERIMENTS OF COMPLEX HEALTH CARE DECISIONS: DOES HIERARCHICAL INFORMATION INTEGRATION OFFER A SOLUTION?
|
Van Helvoort Postulart, D
|
|
2008
|
11 |
6 |
p. A335-
1 p.
|
artikel
|
| 31 |
EE7 ECONOMIC ANALYSIS OF PROPHYLACTIC CERVICAL CANCERVACCINATION IN ITALY: THE NATIONAL AND REGIONAL LEVEL
|
Cavallo, M
|
|
2008
|
11 |
6 |
p. A343-A344
nvt p.
|
artikel
|
| 32 |
EE2 STANDARDIZED TYPE 2 DIABETES COMPLICATION COSTS FROM US COMMERCIAL PAYERS TO BE USED IN MODELING THE LONG-TERM ECONOMIC OUTCOMES OF DIABETES COMPLICATIONS
|
Minshall, ME
|
|
2008
|
11 |
6 |
p. A355-
1 p.
|
artikel
|
| 33 |
EE3 VARIATION IN DIRECT MEDICAL COSTS BY DISEASE SEVERITY AMONG PERSONS WITH CHRONIC HEPATITIS CVIRUS
|
Davis, KL
|
|
2008
|
11 |
6 |
p. A335-A336
nvt p.
|
artikel
|
| 34 |
HP1 ANALYSIS OF THE ORPHAN DRUG DESIGNATIONS AND APPROVALS GRANTED BY THE EMEA AND THE USA FDA BETWEEN 2000 AND 2007
|
Seoane-Vazquez, E
|
|
2008
|
11 |
6 |
p. A359-A360
nvt p.
|
artikel
|
| 35 |
HP2 NEONATAL INTENSIVE CARE UNITS (NICUS) IN GREECE: FACTORS AFFECTING THE LENGTH OF STAY (LOS) OF THE NEONATES AND THE DRIVERS OF COST
|
Hatzikou, M
|
|
2008
|
11 |
6 |
p. A360-
1 p.
|
artikel
|
| 36 |
HP4 THE IMPACT OF A MEDICAID EXPANSION TO INCLUDE POPULATION WITH LOW INCOME ON THE PREVENTABLE HOSPITALIZATIONS
|
Shin, H
|
|
2008
|
11 |
6 |
p. A360-A361
nvt p.
|
artikel
|
| 37 |
HP3 TREATMENTS PATTERNS, RESOURCE USE AND RELATED HEALTH CARE COSTS IN DEPRESSED PATIENTS WITH CO-MORBID ANXIETY IN A LARGE US CLAIMS DATABASE
|
Guelfucci, F
|
|
2008
|
11 |
6 |
p. A360-
1 p.
|
artikel
|
| 38 |
HT3 A COMPARISON OF REASONS FOR RECOMMENDATION AND REJECTION IN FOUR HEALTHTECHNOLOGY APPRAISAL SYSTEMS: NICE, SMC, CADTH AND PBAC
|
Cann, K
|
|
2008
|
11 |
6 |
p. A338-
1 p.
|
artikel
|
| 39 |
HT1 A SYSTEMATIC FRAMEWORK FOR COMPARING METHODS, PROCEDURES, AND IMPACT ACROSS HTA AGENCIES
|
Schwarzer, R
|
|
2008
|
11 |
6 |
p. A337-A338
nvt p.
|
artikel
|
| 40 |
HT4 HEALTH TECHNOLOGY ASSESSMENTS: ARE THEY RELEVANT TO CLINICAL PRACTICE?
|
Zhang, B
|
|
2008
|
11 |
6 |
p. A338-A339
nvt p.
|
artikel
|
| 41 |
HT2 UPDATE OF RESULTS AND OUTCOMES OF NICE SINGLE TECHNOLOGY APPRAISALS—ECONOMIC CRITICISMS
|
Karia, R
|
|
2008
|
11 |
6 |
p. A338-
1 p.
|
artikel
|
| 42 |
IN4 ACHIEVING SUSTAINED VIROLOGIC RESPONSE WITH CHRONIC HEPATITIS CTREATMENT IS ASSOCIATED WITH IMMEDIATE HEALTH CARE UTILIZATION BENEFITS IN EUROPE
|
Zhang, H
|
|
2008
|
11 |
6 |
p. A352-
1 p.
|
artikel
|
| 43 |
IN1 COST EFFECTIVENESS ANALYSIS OF REYATAZ® VERSUS KALETRA® IN THE TREATMENT OF NAÏVE HIV PATIENTS IN ITALY
|
Thuresson, PO
|
|
2008
|
11 |
6 |
p. A351-
1 p.
|
artikel
|
| 44 |
IN2 MODELING LONG-TERM MORTALITY AND MORBIDITY IMPACT WITH ENTECAVIR TREATMENT IN CHB PATIENTS IN BELGIUM
|
Lescrauwaet, B
|
|
2008
|
11 |
6 |
p. A352-
1 p.
|
artikel
|
| 45 |
IN3 PHARMACOECONOMIC ANALYSIS OF ITRACONAZOLE ORAL SOLUTION IN THE PROPHYLAXIS OF INVASIVE FUNGAL INFECTIONS IN TURKEY
|
Kanbur, B
|
|
2008
|
11 |
6 |
p. A352-
1 p.
|
artikel
|
| 46 |
MD2 COST-EFFECTIVENESS AND BUDGET IMPACT ANALYSIS OF ENDEVOR® DRUG-ELUTING STENT COMPARED TO BARE-METAL STENTS AND CORONARY ARTERY BYPASS GRAFT SURGERY IN SPAIN
|
Rodriguez Barrios, JM
|
|
2008
|
11 |
6 |
p. A419-
1 p.
|
artikel
|
| 47 |
MD3 COST-EFFECTIVENESS OF LUMBAR DISC ARTHROPLASTY VERSUS LUMBAR FUSION FROM A HEALTH CARE SYSTEM'S PERSPECTIVE IN AUSTRIA
|
Tuschel, A
|
|
2008
|
11 |
6 |
p. A337-
1 p.
|
artikel
|
| 48 |
MD1 HEALTH ECONOMIC ANALYSIS OF CONTINUOUS SUBCUTANEOUS INSULIN INFUSION COMPARED TO MULTIPLE DAILY INJECTIONS FOR THE TREATMENT OF TYPE 1 DIABETES IN POLAND
|
Clegg, JP
|
|
2008
|
11 |
6 |
p. A336-
1 p.
|
artikel
|
| 49 |
MD4 UNCOVERING ATRIAL FIBRILLATION (AF) IN PATIENTS WITH STROKE OF UNDETERMINED AETIOLOGY: COST-EFFECTIVENESS OF ADDING IMPLANTABLE CARDIAC MONITORS (ICMS) TO THE DIAGNOSTIC PATHWAY
|
Murthy, A
|
|
2008
|
11 |
6 |
p. A337-
1 p.
|
artikel
|
| 50 |
MH6 ADHERENCE, PERSISTENCE, COSTS AND QUALITY OF LIFE IN PATIENTS TREATED WITH ANTIPSYCHOTIC DRUGS: RESULTS FROM THE COMETA STUDY
|
Mantovani, LG
|
|
2008
|
11 |
6 |
p. A344-A345
nvt p.
|
artikel
|
| 51 |
MH3 COST-EFFECTIVENESS OF LONG-ACTING METHYLPHENIDATE FOR TREATMENT OF ATTENTIONDEFICIT/HYPERACTIVITY DISORDER (ADHD) IN CHILDREN AND ADOLESCENTS IN FINLAND: AN EVALUATION BASED UPON A RANDOMIZED CLINICAL TRIAL (RCT)
|
Schlander, M
|
|
2008
|
11 |
6 |
p. A339-A340
nvt p.
|
artikel
|
| 52 |
MH8 DIRECT COST OF TREATING PATIENTS WITH SCHIZOPHRENIA IN GREECE: REAL-WORLD DATA FROM THE ELECTRONIC SCHIZOPHRENIA TREATMENT ADHERENCE REGISTRY (E-STAR)
|
Geitona, M
|
|
2008
|
11 |
6 |
p. A345-
1 p.
|
artikel
|
| 53 |
MH5 EFFECT OF A NURSE TELEPHONE FOLLOW-UP ON THERAPEUTIC ADHERENCE OF PATIENTS WITH SCHIZOPHRENIA
|
Maurino, J
|
|
2008
|
11 |
6 |
p. A344-
1 p.
|
artikel
|
| 54 |
MH4 HEALTH SERVICE EXPENDITURES FOR CHILDREN AND ADOLESCENTS WITH AND WITHOUT ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD) IN GERMANY—IMPACT OF COEXISTING CONDITIONS
|
Schlander, M
|
|
2008
|
11 |
6 |
p. A340-
1 p.
|
artikel
|
| 55 |
MH1 HOW MUCH SHOULDWE BE PREPARED TO PAY FOR PSYCHOSOCIAL INTERVENTIONS FOR PATIENTS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)?
|
Schlander, M
|
|
2008
|
11 |
6 |
p. A339-
1 p.
|
artikel
|
| 56 |
MH7 PATIENT REPORTED OBJECTIVES AND PRIORITIES FOR THE TREATMENT OF SCHIZOPHRENIA IN GERMANY: A MIXED METHODS APPROACH TO CAPTURING THE PATIENT'S PERSPECTIVE
|
Kinter, ET
|
|
2008
|
11 |
6 |
p. A345-
1 p.
|
artikel
|
| 57 |
MH2 THE SUSTAINED DIAGNOSIS OF ATTENTION-DEFICIT HYPERACTIVITY DISORDER FROM CHILDHOODTO ADULTHOOD: A MEDICAID STUDY
|
Chen, H
|
|
2008
|
11 |
6 |
p. A339-
1 p.
|
artikel
|
| 58 |
MO1 ADVANTAGES AND DISADVANTAGES OF MARKOV MODELS VERSUS DISCRETE EVENT MODELS FOR SIMULATING PATIENT FLOWS
|
Al, MJ
|
|
2008
|
11 |
6 |
p. A346-
1 p.
|
artikel
|
| 59 |
MO3 COMPARING METHODS OF DATA SYNTHESIS: UPDATING PARAMETERS OF AN EXISTING PROBABILISTIC COST-EFFECTIVENESS MODEL
|
Oppe, M
|
|
2008
|
11 |
6 |
p. A346-
1 p.
|
artikel
|
| 60 |
MO2 INCORPORATING CALIBRATED MODEL PARAMETERS INTO SENSITIVITY ANALYSES: DETERMINISTIC AND PROBABILISTIC APPROACHES
|
Taylor, DC
|
|
2008
|
11 |
6 |
p. A346-
1 p.
|
artikel
|
| 61 |
MO4 TRANSFERABILITY OF MODEL-BASED ECONOMIC EVALUATIONS: THE CASE OF TRASTUZUMAB FOR THE ADJUVANT TREATMENT OF HER2-POSITIVE EARLY BREAST CANCER IN THE NETHERLANDS
|
Joore, MA
|
|
2008
|
11 |
6 |
p. A347-
1 p.
|
artikel
|
| 62 |
MS4 GOLIMUMAB SIGNIFICANTLY IMPROVES PRODUCTIVITY IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS: RESULTS FROM THE PHASE 3 GO-RAISE STUDY
|
Braun, J
|
|
2008
|
11 |
6 |
p. A354-
1 p.
|
artikel
|
| 63 |
MS2 LINGUISTIC VALIDATION OF SIX QUALITY OF LIFE QUESTIONNAIRES FOR FIBROMYALGIA PATIENTS IN TWELVE LANGUAGES
|
Nadjar, A
|
|
2008
|
11 |
6 |
p. A353-
1 p.
|
artikel
|
| 64 |
MS3 POPULATION HEALTH-STATE UTILITIES FOR FIBROMYALGIA IN THE UNITED KINGDOM
|
Hauber, AB
|
|
2008
|
11 |
6 |
p. A353-
1 p.
|
artikel
|
| 65 |
MS1 PREVALENCE OF FIBROMYALGIA IN EUROPE- A TIP OF THE ICEBERG.RESULTS FROM A LARGE-SCALE SURVEY
|
Le Lay, K
|
|
2008
|
11 |
6 |
p. A353-
1 p.
|
artikel
|
| 66 |
OR3 ADJUSTING ICERS FOR FUTURE UNRELATED MEDICAL COSTS: DEVELOPMENT AND APPLICATION OF A TOOLKIT
|
De Wit, GA
|
|
2008
|
11 |
6 |
p. A361-A362
nvt p.
|
artikel
|
| 67 |
OR1 EXAMINING ASSOCIATION BETWEEN PATIENT-REPORTED OUTCOMES AND CLINICAL OUTCOMES USING PROBIT REGRESSION ANALYSIS
|
Conlon, J
|
|
2008
|
11 |
6 |
p. A361-
1 p.
|
artikel
|
| 68 |
OR2 INCORPORATING DIFFUSION OF NEW MEDICINES IN A BUDGET IMPACT ANALYSIS
|
ter Borg, J
|
|
2008
|
11 |
6 |
p. A361-
1 p.
|
artikel
|
| 69 |
OR4 UTILITIES SHOULD NOT BE MULTIPLIED: EVIDENCE FROM THE PREFERENCE-BASED SCORES IN THE UNITED STATES
|
Fu, AZ
|
|
2008
|
11 |
6 |
p. A362-
1 p.
|
artikel
|
| 70 |
PCASE4 BRIDGING THE GAP OF EVIDENCE AND COSTEFFECTIVENESS: THE PRAGMATIC APPROACH USING ECONOMIC MODELLING TO ASSESS THE COSTEFFECTIVENESS FOR ASSISTIVE TECHNOLOGIES (AT) IN THE UK-BOTH PRE-AND POSTMARKETED
|
Retsa, MP
|
|
2008
|
11 |
6 |
p. A659-
1 p.
|
artikel
|
| 71 |
PCASE1 ESTABLISHMENT OF A COST-EFFECTIVENESS (CE) THRESHOLD AT KING HUSSEIN CANCER CENTER: IMATINIB IN CHRONIC MYELOGENOUS LEUKEMIA (CML)
|
Jabr, MF
|
|
2008
|
11 |
6 |
p. A657-
1 p.
|
artikel
|
| 72 |
PCASE2 PHARMACOECONOMIC APPLICATIONS IN FORMULARY MANAGEMENT: A CASE STUDY OF CETUXIMAB AT A MAJOR ACADEMIC CANCER CENTER
|
Miller, LA
|
|
2008
|
11 |
6 |
p. A658-
1 p.
|
artikel
|
| 73 |
PCASE3 USING IN-HOUSE STRATEGIES TO OVERCOME INCONSISTENCIES BETWEEN EXPENDITURES AND BUDGETING
|
Oren, M
|
|
2008
|
11 |
6 |
p. A658-A659
nvt p.
|
artikel
|
| 74 |
PCN104 A BUDGET IMPACT MODEL FOR THE INTRODUCTION OF PANITUMUMAB, A NEWTHERAPY FOR THE MANAGEMENT OF METASTATIC COLORECTAL CANCER (MCRC) IN GREECE
|
Papagiannopoulou, V
|
|
2008
|
11 |
6 |
p. A493-
1 p.
|
artikel
|
| 75 |
PCN15 A COST-EFFECTIVENESS ANALYSIS OF IXABEPILONE FOR BREAST CANCER AT ATERTIARY CANCER CENTER
|
Lal, LS
|
|
2008
|
11 |
6 |
p. A464-
1 p.
|
artikel
|
| 76 |
PCN26 A COST-EFFECTIVENESS ANALYSIS OF XELOX AND FOLFOX-4 COMBINED WITH OR WITHOUT BEVACIZUMAB FOR THE TREATMENT OF METASTATIC COLORECTAL CANCER IN SPAIN
|
Darba, J
|
|
2008
|
11 |
6 |
p. A467-
1 p.
|
artikel
|
| 77 |
PCN14 A MODELTO DEMONSTRATE THE COMPARATIVE COSTS BETWEEN PANITUMUMAB AND CETUXIMAB FOR THIRD-LINE METASTATIC COLORECTAL CANCER PATIENTS IN ITALY
|
Lamarque, H
|
|
2008
|
11 |
6 |
p. A463-A464
nvt p.
|
artikel
|
| 78 |
PCN7 ANALYSIS AND CATEGORISATION OF DRUG-RELATED PROBLEMS ASSOCIATED WITH SYSTEMIC BREAST CANCER THERAPY
|
Reineking, N
|
|
2008
|
11 |
6 |
p. A461-
1 p.
|
artikel
|
| 79 |
PCN16 ANALYSIS OF COSTS AND CONSEQUENCES IN CANCER PATIENTS RECEIVING CAPECITABINE
|
Roth, S
|
|
2008
|
11 |
6 |
p. A464-
1 p.
|
artikel
|
| 80 |
PCN22 AN ECONOMIC EVALUATION OF CAPECITABINE/CISPLATIN PLUS 5-FU/CISPLATIN REGIMENS IN TREATMENT OF ADVANCED GASTRIC CANCER IN SPAIN
|
Darba, J
|
|
2008
|
11 |
6 |
p. A466-
1 p.
|
artikel
|
| 81 |
PCN18 AN EVALUATION OF THE COST SAVINGS GENERATED WITH THE USE OF AN INTRA-OPERATIVE ASSAY FOR THE DETECTION OF METASTASES IN THE SENTINEL LYMPH NODES OF PATIENTS WITH BREAST CANCER
|
Durbecq, V
|
|
2008
|
11 |
6 |
p. A465-
1 p.
|
artikel
|
| 82 |
PCN75 AN UPDATED GEOGRAPHIC SUBPOPULATION ANALYSIS OF HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (MRCC) ENROLLED IN A PHASE III TRIAL OF SUNITINIB VERSUS INTERFERON-ALFA
|
Cella, D
|
|
2008
|
11 |
6 |
p. A483-
1 p.
|
artikel
|
| 83 |
PCN65 A PHARMACOECONOMIC MODEL FOR THE MANAGEMENT OF CANCER PAIN: OPIOID MARKET WITH OR WITHOUT OROS HYDROMORPHINE IN TURKEY
|
Kanbur, B
|
|
2008
|
11 |
6 |
p. A480-
1 p.
|
artikel
|
| 84 |
PCN42 A SENSITIVITY ANALYSIS ON THE COST UTILITY OF BEVACIZUMAB, CAPECITABINE, AND OXALIPLATIN COMPARED WITH FOLFOX FOR THE TREATMENT OF METASTATIC COLORECTAL CANCER (CRC): A UK PERSPECTIVE
|
Ducournau, P
|
|
2008
|
11 |
6 |
p. A472-A473
nvt p.
|
artikel
|
| 85 |
PCN74 A SERVICE EVALUATION TO COMPARE SECONDARY CARE RESOURCE USE BETWEEN XELOX AND FOLFOX-6 REGIMENS IN THE TREATMENT OF METASTATIC COLORECTAL CANCER (MCRC) FROM A UK NATIONAL HEALTH SERVICE (NHS) PERSPECTIVE
|
Millar, DR
|
|
2008
|
11 |
6 |
p. A483-
1 p.
|
artikel
|
| 86 |
PCN96 ASSOCIATION BETWEEN RESPONDENT- AND PRACTICE-RELATED CHARACTERISTICS AND RADIATION ONCOLOGY STAFF-REPORTED BURDEN ON MUCOSITIS MANAGEMENT FOR HEAD AND NECK CANCER (HNC) PATIENTS
|
Xu, X
|
|
2008
|
11 |
6 |
p. A490-
1 p.
|
artikel
|
| 87 |
PCN111 A STRUCTURED REVIEW OF STUDIES ON HEALTH-RELATED QUALITY OF LIFE IN KIDNEY CANCER, HEPATOCELLULAR CARCINOMA AND LEUKEMIA
|
Liu, J
|
|
2008
|
11 |
6 |
p. A484-
1 p.
|
artikel
|
| 88 |
PCN99 AVAILABILITY AND SPATIAL DISTRIBUTION OF ONCOLOGY SPECIFIC RESOURCES IN GREECE
|
Souliotis, K
|
|
2008
|
11 |
6 |
p. A491-
1 p.
|
artikel
|
| 89 |
PCN12 BUDGETARY IMPACT OF XELOX IN COLORECTAL CANCER IN ITALY
|
Nuijten, MC
|
|
2008
|
11 |
6 |
p. A463-
1 p.
|
artikel
|
| 90 |
PCN11 BUDGET IMPACT ANALYSIS OF DIFFERENT TREATMENT PROTOCOLS FORTRASTUZUMAB
|
Purmonen, T
|
|
2008
|
11 |
6 |
p. A462-
1 p.
|
artikel
|
| 91 |
PCN13 BUDGET IMPACT ANALYSIS OF THE CONTINUATION OF DOCETAXEL REIMBURSEMENT IN THE NEOADJUVANT THERAPY OF LOCALLY ADVANCED BREAST CANCER AND PALLIATIVE THERAPY OF METASTATIC BREAST CANCER IN POLAND
|
Walczak, J
|
|
2008
|
11 |
6 |
p. A463-
1 p.
|
artikel
|
| 92 |
PCN60 CLINICAL AND ECONOMIC ASPECTS OF THE MANAGEMENT OF PATIENTS WITH MALIGNANT ASCITES—RESULTS OF A PILOT STUDY
|
Berger, K
|
|
2008
|
11 |
6 |
p. A478-
1 p.
|
artikel
|
| 93 |
PCN100 CONSUMPTION AND ACCESS TO INNOVATIVE CANCER DRUGS IN SLOVAKIA
|
Tomek, D
|
|
2008
|
11 |
6 |
p. A491-A492
nvt p.
|
artikel
|
| 94 |
PCN20 COST-EFFECTIVENESS ANALYSIS OF ADJUVANT TRASTUZUMAB FOR TREATMENT OF HER2-POSITIVE EARLY BREAST CANCER IN THE SAUDI ARABIAN SETTING
|
AlOmar, H
|
|
2008
|
11 |
6 |
p. A465-A466
nvt p.
|
artikel
|
| 95 |
PCN25 COST-EFFECTIVENESS ANALYSIS OF TRASTUZUMAB THERAPY IN EARLY HER-2 POSITIVE BREAST CANCER PATIENTS: THE BRAZILIAN PUBLIC HEALTH CARE SYSTEM CASE
|
Santos, EA
|
|
2008
|
11 |
6 |
p. A467-
1 p.
|
artikel
|
| 96 |
PCN94 COST-EFFECTIVENESS AND PREFERENCE FOR FOLLOW-UP SCENARIOS FOLLOWING BREAST CANCER
|
Sibma, TS
|
|
2008
|
11 |
6 |
p. A489-A490
nvt p.
|
artikel
|
| 97 |
PCN30 COST-EFFECTIVENESS OF APREPITANT IN PATINENTS RECEIVING ANTIEMETIC PROPHYLAXIS FOR HIGHLY EMETOGENIC CHEMOTHERAPY IN HUNGARY
|
Nagy, L
|
|
2008
|
11 |
6 |
p. A469-
1 p.
|
artikel
|
| 98 |
PCN19 COST EFFECTIVENESS OF CETUXIMAB IN FIRST LINE TREATMENT OF METASTATIC COLORECTAL CANCER: A MODELLING APPROACH FOR THE UK
|
Garrell, D
|
|
2008
|
11 |
6 |
p. A465-
1 p.
|
artikel
|
| 99 |
PCN23 COST EFFECTIVENESS OF CLODRONATE AND ZOLENDRONATE FOR THE TREATMENT OF METASTATIC BONE DISEASE IN BRAZIL: PUBLIC HEALTH PERSPECTIVE
|
Fonseca, M
|
|
2008
|
11 |
6 |
p. A466-A467
nvt p.
|
artikel
|
| 100 |
PCN38 COST-EFFECTIVENESS OF EXTENDED ADJUVANT TREATMENT WITH LETROZOLE IN SWEDEN
|
Lundkvist, J
|
|
2008
|
11 |
6 |
p. A471-
1 p.
|
artikel
|
| 101 |
PCN21 COST-EFFECTIVENESS OF LAPATINIB PLUS CAPECITABINE FORWOMEN WITH HER2+ METASTATIC BREAST CANCER PREVIOUSLY TREATED WITH TRATSTUZUMAB IN FINLAND
|
Färkkilä, N
|
|
2008
|
11 |
6 |
p. A466-
1 p.
|
artikel
|
| 102 |
PCN71 COST-EFFECTIVENESS OF ORALTOPOTECAN PLUS BEST SUPPORTIVE CARE VERSUS BEST SUPPORTIVE CARE ALONE IN PATIENTS WITH RELAPSED SMALL–CELL LUNG CANCER (SCLC) IN THE UK
|
Lykopoulos, K
|
|
2008
|
11 |
6 |
p. A482-
1 p.
|
artikel
|
| 103 |
PCN40 COST-EFFECTIVENESS OF TREATMENT WITH TRASTUZUMAB IN PATIENTS WITH EARLY BREAST CANCER FROM THE PORTUGUESE SOCIETAL PERSPECTIVE
|
Macedo, A
|
|
2008
|
11 |
6 |
p. A472-
1 p.
|
artikel
|
| 104 |
PCN53 COST IMPACT OF CAPECITABINE THERAPY INTRODUCTION IN BREAST CANCER PATIENTS
|
Camacho, F
|
|
2008
|
11 |
6 |
p. A476-
1 p.
|
artikel
|
| 105 |
PCN49 COST-MINIMISATION ANALYSIS OF MAINTENANCE THERAPIES FOR PROSTATE CANCER IN THE UK
|
Lloyd, AC
|
|
2008
|
11 |
6 |
p. A475-
1 p.
|
artikel
|
| 106 |
PCN44 COST MINIMIZATION ANALYSIS OF ADVANCED GASTRIC CANCERTREATMENT WITH CAPECITABINE/CISPLATIN (XP) VS. 5-FU/CISPLATIN (FP) REGIMENS IN POLISH SETTING
|
Kawalec, P
|
|
2008
|
11 |
6 |
p. A473-
1 p.
|
artikel
|
| 107 |
PCN46 COST-MINIMIZATION ANALYSIS OF CAPECITABINE VERSUS UFT/LEUCOVORIN FOR THE TREATMENT OF METASTATIC COLORECTAL CANCER (MCRC) IN BRAZIL
|
Saggia, MG
|
|
2008
|
11 |
6 |
p. A474-
1 p.
|
artikel
|
| 108 |
PCN50 COST-MINIMIZATION ANALYSIS OF ERLOTINIB VERSUS DOCETAXEL OR PEMETREXED AS A SECOND-LINE TRETAMENT OF ADVANCED NON-SMALL LUNG CANCER (NSCLC) IN THE CONDITIONS OF THE CZECH REPUBLIC
|
Suchankova, E
|
|
2008
|
11 |
6 |
p. A475-
1 p.
|
artikel
|
| 109 |
PCN48 COST-MINIMIZATION ANALYSIS OF XELOXVERSUS FOLFOX-6 IN THE FIRST LINE TREATMENT OF METASTATIC COLORECTAL CANCER IN BRAZIL
|
Caponero, R
|
|
2008
|
11 |
6 |
p. A474-A475
nvt p.
|
artikel
|
| 110 |
PCN9 COST OF MANAGEMENTVERSUS REIMBURSEMENT COST OF THE MANAGEMENT OF PATIENTS WITH SOLIDTUMORS PRESENTING A FEBRILE NEUTROPENIA
|
Borget, I
|
|
2008
|
11 |
6 |
p. A462-
1 p.
|
artikel
|
| 111 |
PCN28 COST-UTILITY ANALYSIS IN A SPANISH SETTING OF ADJUVANT THERAPY WITH TRASTUZUMAB (HERCEPTIN®) IN PATIENTS WITH HER-2 POSITIVE BREAST CANCER
|
Polanco, C
|
|
2008
|
11 |
6 |
p. A468-
1 p.
|
artikel
|
| 112 |
PCN67 COST UTILITY ANALYSIS OF ALEMTUZUMAB COMPARED TO CHLORAMBUCIL IN UNTREATED PATIENTS WITH HIGH-RISK (17P-) CHRONIC LYMPHOCYTIC LEUKEMIA IN THE UNITED KINGDOM
|
Lloyd, AC
|
|
2008
|
11 |
6 |
p. A480-A481
nvt p.
|
artikel
|
| 113 |
PCN68 COST-UTILITY ANALYSIS OF DOCETAXEL VERSUS STANDARD REGIMEN IN THE NEOADJUVANT THERAPY OF LOCALLY ADVANCED BREAST CANCER IN POLAND
|
Walczak, J
|
|
2008
|
11 |
6 |
p. A481-
1 p.
|
artikel
|
| 114 |
PCN81 CROSS-CULTURAL ADAPTATION INTO SPANISH AND ITEM REDUCTION OF THE UCLA-PROSTATIC CANCER INDEX (UCLA-PCI): A SPECIFIC HEALTH RELATED QUALITY OF LIFE (HRQOL) QUESTIONNAIRE FOR PROSTATIC CANCER
|
Vera-Donoso, C
|
|
2008
|
11 |
6 |
p. A485-
1 p.
|
artikel
|
| 115 |
PCN109 DEALING WITH QUALITY OF LIFE MISSING DATA IN A SINGLE ARM STUDY. COMPARISON OF MULTIPLE IMPUTATION METHODS
|
Arnault, A
|
|
2008
|
11 |
6 |
p. A494-A495
nvt p.
|
artikel
|
| 116 |
PCN77 DERIVING UTILITY VALUES FROM THE GENERAL POPULATION FOR INDUCTION CHEMOTHERAPY ADMINISTERED BEFORE CONCURRENT CHEMOTHERAPY-RADIATION THERAPY IN THE TREATMENT OF HEAD AND NECK CANCER
|
Cordony, A
|
|
2008
|
11 |
6 |
p. A484-
1 p.
|
artikel
|
| 117 |
PCN73 DEVELOPING A COMPREHENSIVE COSTS TOOLKIT TO FACILITATE ECONOMIC EVALUATIONS OF CANCER CARE IN FRANCE
|
Baffert, S
|
|
2008
|
11 |
6 |
p. A482-
1 p.
|
artikel
|
| 118 |
PCN90 DEVELOPMENT OF AN EFFECTIVE HOME PALLIATIVE CARE SYSTEM ADOPTING A MULTIDISCIPLINARYTEAM APPROACH—SATISFACTION OF THE PATIENTS' FAMILY FOR THE DOMICILIARY PALLIATIVE CARE “OKAYAMA” MODEL
|
Saito, S
|
|
2008
|
11 |
6 |
p. A488-
1 p.
|
artikel
|
| 119 |
PCN108 DEVELOPMENT OF AN INTERACTIVE MODEL OF FINANCIAL ACCESS TO CANCERTHERAPY
|
Lines, LM
|
|
2008
|
11 |
6 |
p. A494-
1 p.
|
artikel
|
| 120 |
PCN32 ECONOMIC ANALYSIS OF CHEMO RADIOTHERAPY IN HEAD AND NECK CANCER
|
Brentani, A
|
|
2008
|
11 |
6 |
p. A469-
1 p.
|
artikel
|
| 121 |
PCN52 ECONOMIC ANALYSIS OF ERLOTINIB, DOCETAXEL, PEMETREXED AND BEST SUPPORTIVE CARE AS 2ND OR 3RD LINE TREATMENT OF NON-SMALL CELL LUNG CANCER
|
Negreiro, F
|
|
2008
|
11 |
6 |
p. A476-
1 p.
|
artikel
|
| 122 |
PCN45 ECONOMIC ANALYSIS OF THE CLINICAL OUTCOMES OF SURGICAL THERAPY (COST) TRIAL COMPARING LAPAROSCOPICALLY-ASSISTED COLECTOMY (LAC) WITH OPEN COLECTOMY (OC) FOR COLON CANCER
|
Weeks, JC
|
|
2008
|
11 |
6 |
p. A473-A474
nvt p.
|
artikel
|
| 123 |
PCN62 ECONOMIC BURDEN OF TOXICITIES ASSOCIATED WITH SALVAGE TREATMENT IN ADVANCED AND METASTATIC BREAST CANCER
|
Kowal-Podmore, S
|
|
2008
|
11 |
6 |
p. A479-
1 p.
|
artikel
|
| 124 |
PCN59 ECONOMIC BURDEN OF TREATING VIN AND VAIN 2/3 IN GERMANY
|
Schulz-Holstege, O
|
|
2008
|
11 |
6 |
p. A478-
1 p.
|
artikel
|
| 125 |
PCN47 ECONOMIC EVALUATION IN THE POSTOPERATIVE MANAGEMENT OF COLORECTAL CANCER PATIENTS IN GREECE
|
Maniadakis, N
|
|
2008
|
11 |
6 |
p. A474-
1 p.
|
artikel
|
| 126 |
PCN27 ECONOMIC EVALUATION OF A TOBACCO CESSATION PROGRAM AT A MAJOR CANCER CENTER
|
Miller, LA
|
|
2008
|
11 |
6 |
p. A468-
1 p.
|
artikel
|
| 127 |
PCN31 ECONOMIC EVALUATION OF CLODRONATE AND ZOLENDRONATE IN PATIENTS DIAGNOSED WITH METASTATIC BONE DISEASE FROM THE PERSPECTIVE OF THIRD PARTY PAYORS IN BRAZIL
|
Machado, M
|
|
2008
|
11 |
6 |
p. A469-
1 p.
|
artikel
|
| 128 |
PCN35 ECONOMIC EVALUATION OF CYCLOPHOSPHAMIDE, DOXORUBICIN, VINCRISTINE AND PREDNISONE (CHOP) CHEMOTHERAPY REGIME WITH OR WITHOUT RITUXIMAB (R) IN THE 2ND LINE TREATMENT OF FOLLICULAR NON-HODGIN LYMPHOMA
|
Soini, EJ
|
|
2008
|
11 |
6 |
p. A470-
1 p.
|
artikel
|
| 129 |
PCN33 ECONOMIC EVALUATION OF FIRST-LINE TREATMENT FOR METASTATIC COLORECTAL CANCER (MCRC) BASED ON IRINOTECAN (FOLFIRI) + BEVACIZUMAB OR CETUXIMAB, ADJUSTED BY KRAS GENE (WILD-TYPE (WT) OR MUTANT (MT))
|
Torrecillas, L
|
|
2008
|
11 |
6 |
p. A469-A470
nvt p.
|
artikel
|
| 130 |
PCN29 ECONOMIC EVALUATION OF SUNITINIB FIRST-LINE FOR METASTATIC RENAL CELL CARCINOMAVERSUS SORAFENIB, TEMSIROLIMUS AND BEVACIZUMAB + INTERFERON-ALFA IN THE SWEDISH HEALTH SERVICE SETTING
|
Munir, U
|
|
2008
|
11 |
6 |
p. A468-
1 p.
|
artikel
|
| 131 |
PCN41 ECONOMIC EVALUATION OF TRASTUZUMAB FOR THE ADJUVANT TREATMENT OF HER2 POSITIVE EARLY BREAST CANCER IN THE NETHERLANDS
|
Essers, BA
|
|
2008
|
11 |
6 |
p. A472-
1 p.
|
artikel
|
| 132 |
PCN2 EFFICACY OF LEUPRORELIN 3.75MG COMPARED TO 7.5MG IN THE TREATMENT OF PROSTATE CANCER: SYSTEMATIC REVIEW AND META-ANALYSIS
|
Payne, HA
|
|
2008
|
11 |
6 |
p. A459-
1 p.
|
artikel
|
| 133 |
PCN4 EFFICACY OF OPIOIDS IN THE TREATMENT OF BREAKTHROUGH CANCER PAIN: A BAYESIAN MIXED TREATMENT COMPARISON
|
Stam, W
|
|
2008
|
11 |
6 |
p. A460-
1 p.
|
artikel
|
| 134 |
PCN17 ESTIMATING THE COST SAVINGS FROM THE INTRODUCTION OF KRAS TESTING IN THE MANAGEMENT OF METASTATIC COLORECTAL CANCER (MCRC) PATIENTS RECEIVING PANITUMUMAB IN GREECE
|
Papagianopoulou, V
|
|
2008
|
11 |
6 |
p. A464-A465
nvt p.
|
artikel
|
| 135 |
PCN39 EXPLORATORY COST EFFECTIVENESS ANALYSIS OF BEVACIZUMAB IN ADDITION TO FOLFOX-4 IN THE ADJUVANT TREATMENT OF STAGE III COLON CANCER: A UK PERSPECTIVE
|
Ducournau, P
|
|
2008
|
11 |
6 |
p. A471-A472
nvt p.
|
artikel
|
| 136 |
PCN76 HEALTH-RELATED QUALITY OF LIFE EVALUATION IN ROMANIAN CANCER PATIENTS
|
Mihailov, MD
|
|
2008
|
11 |
6 |
p. A483-
1 p.
|
artikel
|
| 137 |
PCN87 HEALTH-RELATED QUALITY OF LIFE (HRQOL) AND COLORECTAL CANCER (CRC) SYMPTOMS IN METASTATIC CRC: PANITUMUMAB PLUS BEST SUPPORTIVE CARE (BSC) VS. BSC ALONE BY KRASTUMOR STATUS
|
Odom, D
|
|
2008
|
11 |
6 |
p. A487-
1 p.
|
artikel
|
| 138 |
PCN79 HEALTH STATE PREFERENCE STUDY MAPPING THE CHANGE OVER THE COURSE OF THE DISEASE PROCESS IN CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL)
|
Ferguson, J
|
|
2008
|
11 |
6 |
p. A485-
1 p.
|
artikel
|
| 139 |
PCN103 HETEROGENEITY IN THE APPROACH TAKEN TO CONDUCTING CHART AUDITS IN AUSTRALIAN HOSPITALS
|
O'Leary, BA
|
|
2008
|
11 |
6 |
p. A492-A493
nvt p.
|
artikel
|
| 140 |
PCN56 HOSPITAL BURDEN OF DISEASE ASSOCIATED WITH METASTATIC BONE DISEASE (MBD) AND SKELETAL-RELATED EVENTS (SRES) IN PATIENTS WITH BREAST CANCER (BC) AND PROSTATE CANCER (PC) IN SPAIN
|
Oglesby, A
|
|
2008
|
11 |
6 |
p. A477-
1 p.
|
artikel
|
| 141 |
PCN54 HOSPITAL BURDEN OF DISEASE ASSOCIATED WITH METASTATIC BONE DISEASE (MBD) AND SKELETAL-RELATED EVENTS (SRES) IN PATIENTS WITH BREAST CANCER (BC) AND PROSTATE CANCER (PC) IN THE UNITED KINGDOM (UK)
|
Oglesby, A
|
|
2008
|
11 |
6 |
p. A476-
1 p.
|
artikel
|
| 142 |
PCN66 HOW COSTLY IS RADIOTHERAPY WITH PARTICLES? COST ANALYSIS OF EXTERNAL BEAM RADIOTHERAPY WITH CARBON IONS, PROTONS AND CONVENTIONAL PHOTONS
|
Peeters, A
|
|
2008
|
11 |
6 |
p. A480-
1 p.
|
artikel
|
| 143 |
PCN61 INVASIVE FUNGAL INFECTION (IFI) IN PATIENTS WITH ACUTE MYELOGENOUS LEUKAEMIA (AML) OR MYELODYSPLASTIC SYNDROME (MDS)—TREATMENT COST FROM HOSPITAL PERSPECTIVE
|
Berger, K
|
|
2008
|
11 |
6 |
p. A478-A479
nvt p.
|
artikel
|
| 144 |
PCN55 MANAGAMENT COSTS OF PATIENTS WITH VULVAR AND VAGINAL CANCER IN FRANCE
|
Remy, V
|
|
2008
|
11 |
6 |
p. A477-
1 p.
|
artikel
|
| 145 |
PCN58 MEDICAL RESOURCE CONSUMPTION RELATED TO THE TREATMENT OF IRINOTECAN REFRACTORY ADVANCED COLORECTAL CANCER PATIENTS
|
Strens, D
|
|
2008
|
11 |
6 |
p. A477-A478
nvt p.
|
artikel
|
| 146 |
PCN105 MEDICARE PART D'S MARKET IMPACT ON UTILIZATION, AVERAGE RETAIL PRICE AND OUT-OF-POCKET SPENDING FOR ORAL CHEMOTHERAPEUTICS AND A COMPARATIVE MARKET BASKET OF DRUGS
|
Horowicz-Mehler, N
|
|
2008
|
11 |
6 |
p. A493-
1 p.
|
artikel
|
| 147 |
PCN63 METASTATIC COLORECTAL CANCER: MEDICAL COSTS OF FIRST LINE INFUSIONAL 5-FLUOROURACIL OR ORAL CAPECITABINE IN ITALIAN PATIENTS
|
Lopatriello, S
|
|
2008
|
11 |
6 |
p. A479-
1 p.
|
artikel
|
| 148 |
PCN6 MODELING LUNG AND BREAST CANCER INCIDENCE IN SPAIN: A ZERO INFLATED NEGATIVE BINOMIAL REGRESSION APPROACH
|
Villa, G
|
|
2008
|
11 |
6 |
p. A461-
1 p.
|
artikel
|
| 149 |
PCN43 MODELING THE COST-EFFECTIVENESS OF PROSTATE CANCERTREATMENT WITH PARTICLE THERAPY
|
Peeters, A
|
|
2008
|
11 |
6 |
p. A473-
1 p.
|
artikel
|
| 150 |
PCN107 NEW OPPORTUNITIES FOR DRUG OUTCOMES RESEARCH IN CANCER PATIENTS: VALIDATION OF THE LINKAGE OF THE EINDHOVEN CANCER REGISTRY AND THE PHARMO RECORD LINKAGE SYSTEM
|
Sukel, MPP
|
|
2008
|
11 |
6 |
p. A494-
1 p.
|
artikel
|
| 151 |
PCN57 PALLIATIVE CARE FOR CANCER PATIENTS IN BRAZIL: A COST-OF-ILLNESS STUDY
|
Fernandes, RA
|
|
2008
|
11 |
6 |
p. A477-
1 p.
|
artikel
|
| 152 |
PCN85 PATIENT PREFERENCES IN THE THERAPY OF MULTIPLE MYELOMA
|
Mühlbacher, AC
|
|
2008
|
11 |
6 |
p. A486-A487
nvt p.
|
artikel
|
| 153 |
PCN80 PATIENT REPORTED QUALITY OF LIFE IN CANCER PATIENTS ON OPIOID THERAPY IS INFLUENCED BY CONSTIPATION
|
Van der Linden, MW
|
|
2008
|
11 |
6 |
p. A485-
1 p.
|
artikel
|
| 154 |
PCN24 PEGYLATED LIPOSOMAL DOXORUBICIN IN COMBINATION WITH BORTEZOMIB FOR THE TREATMENT OF RELAPSED MULTIPLE MYELOMA—A COST-EFFECTIVENESS STUDY FOR SCOTLAND
|
Gibbons, CJ
|
|
2008
|
11 |
6 |
p. A467-
1 p.
|
artikel
|
| 155 |
PCN83 PERFORMANCE AND ADEQUACY OF PATIENT-PERSPECTIVE CRITERIA IN THE ASSESSMENT OF TEST-RETEST RELIABILITY: THE CASE OF THE PERFORM QUESTIONNAIRE
|
Baro, E
|
|
2008
|
11 |
6 |
p. A486-
1 p.
|
artikel
|
| 156 |
PCN69 PHARMACOECONOMIC ANALYSIS OF THE ADDITION OF RITUXIMAB TO FIRST-LINE CHEMOTHERAPY TREATMENT REGIMENS IN SPANISH PATIENTS WITH ADVANCED FOLLICULAR LYMPHOMA
|
Rubio-Terrés, C
|
|
2008
|
11 |
6 |
p. A481-
1 p.
|
artikel
|
| 157 |
PCN36 PHARMACOECONOMIC COMPARISON OF TWO PROTOCOLS FACVS. CMF IN THE TREATMENT OF EARLY BREAST CANCER
|
Ilic, M
|
|
2008
|
11 |
6 |
p. A470-A471
nvt p.
|
artikel
|
| 158 |
PCN34 PHARMAECONOMIC EVALUATION OF THE USE OF ERLOTINIB IN NON-SMALL CELLS LUNG CANCER (NSCLC) WITH FAILURE TO PREVIOUS CHEMOTHERAPY
|
Tenorio, C
|
|
2008
|
11 |
6 |
p. A470-
1 p.
|
artikel
|
| 159 |
PCN95 POLICY-MAKING FOR EXPENSIVE INNOVATIVE DRUGS IN FRANCE: ECONOMIC IMPACT AND INFLUENCE ON STAKEHOLDERS!' BEHAVIOURS OF POTENTIAL DECISIONS ABOUT TAXANES
|
Spath, HM
|
|
2008
|
11 |
6 |
p. A490-
1 p.
|
artikel
|
| 160 |
PCN51 POTENTIAL ECONOMIC AND HEALTH IMPACT OF GENOMICS AND PROTEOMICSTECHNOLOGY FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA
|
Redekop, WK
|
|
2008
|
11 |
6 |
p. A475-
1 p.
|
artikel
|
| 161 |
PCN106 PROSTATE CANCER DIAGNOSIS IN SPAIN: HOW IS IT PERFORMED? HOW MUCH DOES IT COST FOR SPANISH NHS?
|
Herranz, F
|
|
2008
|
11 |
6 |
p. A493-A494
nvt p.
|
artikel
|
| 162 |
PCN8 QUALITY OF LIFE-ADJUSTED SURVIVAL FOR FIRST LINE TREATMENT WITH RITUXIMAB PLUS CYCLOPHOSPHAMIDE AND VINCRISTINE (CVP) VERSUS CVP ALONE FOR PATIENTS WITH ADVANCED FOLLICULAR LYMPHOMA
|
Aultman, R
|
|
2008
|
11 |
6 |
p. A461-
1 p.
|
artikel
|
| 163 |
PCN78 QUALITY OF LIFE (QOL) IN PATIENTS WITH METASTATIC BREAST CANCER (MBC) IN TREATMENT WITH PLACITAXEL WITH/WITHOUT BEVACIZUMAB, RELATED WITH TREATMENT RESPONSE (REMISSION AND PROGRESSION)
|
Tenorio, C
|
|
2008
|
11 |
6 |
p. A484-
1 p.
|
artikel
|
| 164 |
PCN88 QUESTIONNAIRE OF TREATMENT PREFERENCES IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER
|
Garcia, R
|
|
2008
|
11 |
6 |
p. A487-A488
nvt p.
|
artikel
|
| 165 |
PCN89 RACE AND SHARED DECISION MAKING AMONG PROSTATE CANCER PATIENTS, FAMILY MEMBERS AND PHYSICIANS
|
Ramsey, SD
|
|
2008
|
11 |
6 |
p. A488-
1 p.
|
artikel
|
| 166 |
PCN98 RACIAL DIFFERENCES IN MEDICATION-RELATED HEALTH CARE COSTS AND SERVICE UTILIZATION IN HORMONE RECEPTOR POSITIVE PRIMARY BREAST CANCER PATIENTS
|
Bhosle, MJ
|
|
2008
|
11 |
6 |
p. A491-
1 p.
|
artikel
|
| 167 |
PCN101 RELATIONSHIP BETWEEN HEALTH CARE SUPPLY AND MAMMOGRAPHY SCREENING?
|
Khan, N
|
|
2008
|
11 |
6 |
p. A492-
1 p.
|
artikel
|
| 168 |
PCN64 SHIFT OF PUBLIC HEALTH CARE EXPENDITURES FOR PALLIATIVE CANCER PATIENTS FROM INPATIENT TO OUTPATIENT EFFECTED BY HOME CARE SUPPORT TEAMS PROVIDED BY A UNIVERSITY HOSPITAL IN AUSTRIA
|
Spat, S
|
|
2008
|
11 |
6 |
p. A479-A480
nvt p.
|
artikel
|
| 169 |
PCN110 STATISTICAL METHODOLOGY IS CRUCIAL IN PROGNOSTIC FACTOR ANALYSIS OF HEALTH-RELATED QUALITY OF LIFE
|
Mauer, M
|
|
2008
|
11 |
6 |
p. A495-
1 p.
|
artikel
|
| 170 |
PCN86 SYMPTOM PREVALENCE IN HORMONE REFRACTORY PROSTATE CANCER (HRPC)
|
Romanus, D
|
|
2008
|
11 |
6 |
p. A487-
1 p.
|
artikel
|
| 171 |
PCN82 TESTING THE MEASUREMENT EQUIVALENCE OF PAPER AND INTERACTIVE VOICE RESPONSE (IVR) VERSIONS OF THE EQ-5D
|
Lundy, JJ
|
|
2008
|
11 |
6 |
p. A485-A486
nvt p.
|
artikel
|
| 172 |
PCN102 THE BURDEN OF RENAL CELL CANCER: A RETROSPECTIVE LONGITUDINAL STUDY ON OCCURRENCE, OUTCOMES AND COST USING AN ADMINISTRATIVE CLAIMS DATABASE
|
Mantovani, LG
|
|
2008
|
11 |
6 |
p. A492-
1 p.
|
artikel
|
| 173 |
PCN93 THE IMPACT OF A COST ATTRIBUTE ON PREFERENCES
|
Essers, BA
|
|
2008
|
11 |
6 |
p. A489-
1 p.
|
artikel
|
| 174 |
PCN72 THE IMPACT OF INITIAL TREATMENT CHOICE AND DISEASE PROGRESSION ON THE ECONOMIC BURDEN OF PATIENTS AND THEIR CAREGIVERS—A LONGITUDINAL STUDY OF STAGE IV NON-SMALL CELL LUNG CANCER (NSCLC)
|
Romanus, D
|
|
2008
|
11 |
6 |
p. A482-
1 p.
|
artikel
|
| 175 |
PCN84 THE PATIENT-REPORTED OUTCOMES MEASUREMENT INFORMATION SYSTEM CANCER PAIN ITEM BANK (PROMIS-CA PAIN)
|
Lai, JS
|
|
2008
|
11 |
6 |
p. A486-
1 p.
|
artikel
|
| 176 |
PCN1 THIRD-GENERATION AROMATASE INHIBITORS VS TAMOXIFEN IN THE TREATMENT OF EARLY AND ADVANCED BREAST CANCER: A SYSTEMATIC REVIEW OF RANDOMISED CONTROLLED TRIALS
|
von Maltzahn, R
|
|
2008
|
11 |
6 |
p. A459-
1 p.
|
artikel
|
| 177 |
PCN5 TREATMENT EFFECT OF RITUXIMAB, FLUDARABINE AND CYCLOPHOSPHAMIDE (R-FC) VERSUS FC IN CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL) IN AN OBSERVATIONAL SETTING: AN INVESTIGATION OF PROGNOSTIC FACTORS AND LIFETIME HEALTH OUTCOMES
|
Keating, MJ
|
|
2008
|
11 |
6 |
p. A460-
1 p.
|
artikel
|
| 178 |
PCN70 TREATMENT OF CHRONIC LYMPHOCYTIC LEUKAEMIA WITH THE RITUXIMAB, FLUDARABINE AND CYCLOPHOSPHAMIDE REGIMEN—AN ECONOMIC EVALUATION BASED ON OBSERVATIONAL DATA
|
Keating, MJ
|
|
2008
|
11 |
6 |
p. A481-A482
nvt p.
|
artikel
|
| 179 |
PCN97 TREATMENT OF PATIENTS WITH METASTATIC BREAST CANCER (MBC) IN THE UKWHO PROGRESS ON TRASTUZUMAB AND HAVE PREVIOUSLY RECEIVED AN ANTHRACYCLINE AND ATAXANE: A NEED FOR EVIDENCE BASED THERAPIES?
|
Walker, M
|
|
2008
|
11 |
6 |
p. A490-A491
nvt p.
|
artikel
|
| 180 |
PCN91 TREATMENT PREFERENCE AND WILLINGNESS-TO-PAY (WTP) FOR METHYLNALTREXONE, A NOVEL PERIPHERAL OPIOID ANTAGONIST FOR OPIOID INDUCED CONSTIPATION
|
Wang, M
|
|
2008
|
11 |
6 |
p. A488-A489
nvt p.
|
artikel
|
| 181 |
PCN92 VALUE OF ALOPECIA FOR LUNG CANCER PATIENT TREATED BY SECOND LINE CHEMOTHERAPY: A WILLINGNESS TO PAY STUDY
|
Brignone, M
|
|
2008
|
11 |
6 |
p. A489-
1 p.
|
artikel
|
| 182 |
PCV96 ACCEPTABILITY OF TECHNOLOGICAL TREATMENT AND THE EFFECT OF RESPONDENT CHARACTERISTICS ON TREATMENT PREFERENCE
|
van Til, JA
|
|
2008
|
11 |
6 |
p. A411-
1 p.
|
artikel
|
| 183 |
PCV99 A CROSS-NATIONAL COMPARISON ON PRICES OF PHARMACEUTICAL PRODUCT
|
Sakamaki, H
|
|
2008
|
11 |
6 |
p. A412-
1 p.
|
artikel
|
| 184 |
PCV118 ADVANCING SYNCOPE DIAGNOSISTHROUGH IMPLANTABLE LOOP RECORDERS (ILRS) IN SWEDEN: COST-EFFECTIVENESS ANALYSIS OF NEW DIAGNOSTIC STRATEGIES
|
Gadler, F
|
|
2008
|
11 |
6 |
p. A418-A419
nvt p.
|
artikel
|
| 185 |
PCV54 A EUROPEAN MULTI-COUNTRY COMPARISON OF THE COST-EFFECTIVENESS OF IODIXANOL VERSUS IOHEXOL BASED ON THE RESULTS OF THE NEPHRIC CLINICAL TRIAL
|
Patel, P
|
|
2008
|
11 |
6 |
p. A397-A398
nvt p.
|
artikel
|
| 186 |
PCV12 AN ANALYSIS OF THE ANTIHYPERTENSIVE EFFECTIVENESS OF ARBS VS. ACE INHIBITORS
|
Sharplin, P
|
|
2008
|
11 |
6 |
p. A384-
1 p.
|
artikel
|
| 187 |
PCV9 AN ANALYSIS OF THE ANTIHYPERTENSIVE EFFECTIVENESS OF IRBESARTANVS. CANDESARTAN
|
Sharplin, P
|
|
2008
|
11 |
6 |
p. A383-
1 p.
|
artikel
|
| 188 |
PCV56 AN ECONOMIC ANALYSIS OF INDUCTION OF LABOR AND EXPECTANT MANAGEMENT INWOMEN WITH PREGNANCYINDUCED HYPERTENSION OR PREECLAMPSIA AT TERM (HYPITAT TRIAL)
|
Vijgen, SM
|
|
2008
|
11 |
6 |
p. A398-
1 p.
|
artikel
|
| 189 |
PCV81 AN ECONOMIC EVALUATION OF THE ADDITION OF FIXED-DOSE NIACIN EXTENDED-RELEASE AND SIMVASTATIN THERAPY TO THE MANAGED CARE FORMULARY IN TERMS OF OPTIMAL LIPID VALUE ATTAINMENT
|
Balu, S
|
|
2008
|
11 |
6 |
p. A406-
1 p.
|
artikel
|
| 190 |
PCV78 ANEURYSM OCCLUSION IN ELDERLY PATIENTS WITH ANEURYSMAL SUBARACHNOID HAEMORRHAGE: A COST-UTILITY ANALYSIS
|
Koffijberg, H
|
|
2008
|
11 |
6 |
p. A405-
1 p.
|
artikel
|
| 191 |
PCV83 AN EVALUATION OF THE INCREMENTAL CHANGE IN THE INCIDENCE OF CARDIOVASCULAR EVENTS AND RELATED COSTS WITH THE ADDITION OF FIXED-DOSE NIACIN EXTENDED-RELEASE AND SIMVASTATIN THERAPY TO THE MANAGED CARE FORMULARY
|
Balu, S
|
|
2008
|
11 |
6 |
p. A407-
1 p.
|
artikel
|
| 192 |
PCV5 A REALWORLD COMPARISON OF COMBINED LIPID TARGET ATTAINMENT BETWEEN COMBINATION NIACIN EXTENDED-RELEASE+ANY STATIN THERAPY AND FIXED DOSE SIMVASTATIN+EZETIMIBE
|
Simko, RJ
|
|
2008
|
11 |
6 |
p. A382-
1 p.
|
artikel
|
| 193 |
PCV115 ASSESSING THE POTENTIAL BENEFITS OF CHANGING REIMBURSEMENT CRITERIA FOR LIPID LOWERINGTHERAPY IN KOREA
|
Kang, HY
|
|
2008
|
11 |
6 |
p. A417-
1 p.
|
artikel
|
| 194 |
PCV13 ATTAINMENT OF MULTIPLE RECOMMENDED LIPID LEVELS FOLLOWING LIPID MODIFYING TREATMENT IN HIGH RISK PATIENTS. PRIMULA STUDY, SPAIN
|
Suarez, C
|
|
2008
|
11 |
6 |
p. A384-A385
nvt p.
|
artikel
|
| 195 |
PCV25 BUDGET IMPACT ANALYSIS OF THROMBOLYSIS FOR STROKE: A DISCRETE EVENT SIMULATION MODEL
|
Mar, J
|
|
2008
|
11 |
6 |
p. A388-
1 p.
|
artikel
|
| 196 |
PCV24 BUDGET IMPACT OF GUIDELINE ADHERENT THERAPY IN ACUTE CORONARY SYNDROME (ACS) IN GERMANY
|
Neubauer, AS
|
|
2008
|
11 |
6 |
p. A388-
1 p.
|
artikel
|
| 197 |
PCV14 CENTRALISED PAN-EUROPEAN SURVEY ON THE UNDER-TREATMENT OF HYPERCHOLESTEROLEMIA IN PATIENTS USING LIPID LOWERING DRUGS (CEPHEUS-GREECE
|
Elisaf, M
|
|
2008
|
11 |
6 |
p. A385-
1 p.
|
artikel
|
| 198 |
PCV82 CHANGE IN LIPID VALUES, TARGET LIPID VALUE ATTAINMENT, AND ANNUAL HEALTH CARE RESOURCE UTILIZATION AND COSTS AMONG PATIENTS INITIATING COMBINATION STATIN AND EXTENDED-RELEASE NIACIN THERAPY
|
Simko, RJ
|
|
2008
|
11 |
6 |
p. A406-A407
nvt p.
|
artikel
|
| 199 |
PCV8 CLINICAL AND ECONOMIC IMPACT OF DRUG-ELUTING STENT AND BARE METAL STENT IN HONG KONG—A SINGLE CENTRE “REALWORLD” EXPERIENCE
|
Lee, VWY
|
|
2008
|
11 |
6 |
p. A383-
1 p.
|
artikel
|
| 200 |
PCV67 CLINICAL CHARACTERISTICS, MEDICATION AND COSTS IN ACUTE HEART FAILURE PATIENTS IN THE CZECH REPUBLIC
|
Ondrackova, B
|
|
2008
|
11 |
6 |
p. A402-
1 p.
|
artikel
|
| 201 |
PCV7 CLINICAL EFFECTIVENESS OF BOSENTAN, EPOPROSTENOL, ILOPROST, SILDENAFIL AND TREPROSTINIL IN THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION—A SYSTEMATIC REVIEW
|
Becla, L
|
|
2008
|
11 |
6 |
p. A382-A383
nvt p.
|
artikel
|
| 202 |
PCV107 CLOPIDOGREL PATTERNS OF USE IN ACUTE CORONARY SYNDROME PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION IN FIVE EUROPEAN COUNTRIES
|
McCollam, PL
|
|
2008
|
11 |
6 |
p. A415-
1 p.
|
artikel
|
| 203 |
PCV17 COLD AND INACTIVITY: THE ULTIMATE FACTORS FOR HEART ATTACK
|
Horváth, L
|
|
2008
|
11 |
6 |
p. A386-
1 p.
|
artikel
|
| 204 |
PCV63 CO-MORBIDITY AND DIRECT COSTS ACCORDING THE CARDIOVASCULAR RISK LEVEL IN A SPANISH POPULATION SETTING
|
Sicras, A
|
|
2008
|
11 |
6 |
p. A400-A401
nvt p.
|
artikel
|
| 205 |
PCV117 COMPARATIVE ANALYSIS OF HEALTHTECHNOLOGY ASSESSMENTS (HTA) OF DRUG ELUTING STENTS (DES)
|
Hurry, MV
|
|
2008
|
11 |
6 |
p. A418-
1 p.
|
artikel
|
| 206 |
PCV3 COMPARISON OF GOAL ATTAINMENT RATES BETWEEN USERS OF SIMVASTATIN 40 MG AND OTHER STATINS
|
Heintjes, E
|
|
2008
|
11 |
6 |
p. A381-
1 p.
|
artikel
|
| 207 |
PCV86 COMPARISON OF PERSISTENCE AND ADHERENCE BETWEEN PRASUGREL AND CLOPIDOGREL IN THE TREATMENT OF PATIENTS WITH ACUTE CORONARY SYNDROMES AND PERCUTANEOUS CORONARY INTERVENTIONS
|
Bae, JP
|
|
2008
|
11 |
6 |
p. A408-
1 p.
|
artikel
|
| 208 |
PCV4 COMPARISON OF THE CLINICAL AND ECONOMIC EFFECTIVENESS OF SIROLIMUS-ELUTING VERSUS BARE-METAL STENTS IN A SUBGROUP OF PATIENTS WITH AND WITHOUT DIABETES
|
Brüggenjürgen, B
|
|
2008
|
11 |
6 |
p. A381-A382
nvt p.
|
artikel
|
| 209 |
PCV15 CORONS STUDY: EXAMPLE OF STATINS IMPACT ON ALL CAUSE MORTALITY IN THE ELDERLY
|
Kieffer, A
|
|
2008
|
11 |
6 |
p. A385-
1 p.
|
artikel
|
| 210 |
PCV111 COST-ANALYSIS OF DYSLIPOPROTEINAEMIA TREATMENTS WITHIN THE SLOVAK REPUBLIC
|
Tesar, T
|
|
2008
|
11 |
6 |
p. A416-
1 p.
|
artikel
|
| 211 |
PCV30 COST-EFFECTIVENESS ANALYSIS OF ENDOVASCULAR ANEURYSM REPAIR (EVAR) FOR ABDOMINAL AORTIC ANEURYSM (AAA) IN SPAIN
|
Rodriguez Barrios, JM
|
|
2008
|
11 |
6 |
p. A390-
1 p.
|
artikel
|
| 212 |
PCV35 COST-EFFECTIVENESS ANALYSIS OF STROKE REHABILITATION STRATEGIES IN EASTERN CHINA
|
O'Prinsen, AC
|
|
2008
|
11 |
6 |
p. A391-
1 p.
|
artikel
|
| 213 |
PCV36 COST-EFFECTIVENESS AND COST-UTILITY ANALYSIS OF TRITACE COMB (RAMIPRIL/HCTZ) IN TREATMENT OF HYPERTENSION IN POLAND
|
Kawalec, P
|
|
2008
|
11 |
6 |
p. A391-A392
nvt p.
|
artikel
|
| 214 |
PCV44 COST-EFFECTIVENESS MODEL OF IMPLANTABLE CARDIAC MONITORS (ICM) FOR PATIENTS TREATED WITH RADIOFREQUENCY CATHETER ABLATION FOR A TRIAL FIBRILLATION (PAAF) IN SPAIN
|
Tsintzos, S
|
|
2008
|
11 |
6 |
p. A394-
1 p.
|
artikel
|
| 215 |
PCV49 COST-EFFECTIVENESS OF ATORVASTATIN 80 MGVS GENERIC SIMVASTATIN 20 TO 40 MG IN SECONDARY PREVENTION IN SPAIN
|
Sánchez Maestre, C
|
|
2008
|
11 |
6 |
p. A396-
1 p.
|
artikel
|
| 216 |
PCV70 COST-EFFECTIVENESS OF CLOPIDOGREL IN COMBINATION WITH ASPIRIN FOR ACUTE CORONARY SYNDROMES IN AUSTRALIA
|
Liew, D
|
|
2008
|
11 |
6 |
p. A403-
1 p.
|
artikel
|
| 217 |
PCV46 COST-EFFECTIVENESS OF CLOPIDOGREL IN MYOCARDIAL INFARCTION WITH ST-SEGMENT ELEVATION: A SPANISH MODEL BASED ON THE CLARITY AND COMMITTRIALS
|
Brosa, M
|
|
2008
|
11 |
6 |
p. A395-
1 p.
|
artikel
|
| 218 |
PCV74 COST-EFFECTIVENESS OF DABIGATRAN ETEXILATE FOR THE PRIMARY PREVENTION OF VENOUSTHROMBOEMBOLISM IN PATIENTS UNDERGOINGTOTAL HIP ORTOTAL KNEE REPLACEMENT SURGERY
|
Wolowacz, S
|
|
2008
|
11 |
6 |
p. A404-
1 p.
|
artikel
|
| 219 |
PCV45 COST-EFFECTIVENESS OF EPLERENONE IN PATIENTS WITH HEART FAILURE AFTER ACUTE MYOCARDIAL INFARCTION
|
Martí-Sánchez, D
|
|
2008
|
11 |
6 |
p. A394-A395
nvt p.
|
artikel
|
| 220 |
PCV34 COST-EFFECTIVENESS OF GADOFOSVESET-ENHANCED MAGNETIC RESONANCE (MR) ANGIOGRAPHY FOR THE PATIENTS WITH CHRONIC PERIPHERAL ARTERIAL OBSTRUCTIVE DISEASE (PAOD) IN KOREA
|
Choi, SE
|
|
2008
|
11 |
6 |
p. A391-
1 p.
|
artikel
|
| 221 |
PCV77 COST EFFECTIVENESS OF HIGH DOSE ATORVASTATIN IN ACUTE CORONARY SYNDROME PATIENTS IN THE UK
|
Thurston, SJ
|
|
2008
|
11 |
6 |
p. A405-
1 p.
|
artikel
|
| 222 |
PCV41 COST EFFECTIVENESS OF IMPLANTABLE LOOP RECORDER SYSTEM (REVEAL DX®) FROM THE SPANISH NHS PERSPECTIVE
|
Garcia-Baena, I
|
|
2008
|
11 |
6 |
p. A393-
1 p.
|
artikel
|
| 223 |
PCV102 COST-EFFECTIVENESS OF MANAGING ORAL ANTICOUAGULATION (OAC) AFTER CATHETER ABLATION FOR A TRIAL FIBRILLATION (PAAF) WITH IMPLANTABLE CARDIAC MONITORS (ICMS)
|
Tsintzos, S
|
|
2008
|
11 |
6 |
p. A413-
1 p.
|
artikel
|
| 224 |
PCV39 COST-EFFECTIVENESS OF NIASPAN®VERSUS ZETIA® AS ADD-ON TREATMENTTO STATIN THERAPY IN HIGH-RISK PATIENTS
|
Sorensen, SV
|
|
2008
|
11 |
6 |
p. A393-
1 p.
|
artikel
|
| 225 |
PCV42 COST-EFFECTIVENESS OF POPULATION-BASED 'SCREEN-AND-TREAT' STRATEGIES DIRECTED AT ALBUMINURIA
|
Boersma, C
|
|
2008
|
11 |
6 |
p. A393-A394
nvt p.
|
artikel
|
| 226 |
PCV50 COST-EFFECTIVENESS OF RULING OUT DEEPVENOUS THROMBOSIS IN PRIMARY CARE VERSUS CARE AS USUAL
|
Ten Cate - Hoek, AJ
|
|
2008
|
11 |
6 |
p. A396-
1 p.
|
artikel
|
| 227 |
PCV40 COST-EFFECTIVENESS OF TARGETING MULTIPLE LIPID PARAMETERS (LDL-C, HDL-C, TG) WITH NIASPAN®VERSUS A SINGLE LIPID PARAMETER (LDL-C) WITH ZETIA® IN PATIENTS RECEIVING ON-GOING STATIN THERAPY
|
Sorensen, SV
|
|
2008
|
11 |
6 |
p. A393-
1 p.
|
artikel
|
| 228 |
PCV73 COST-EFFECTVENESS OF ENDOVASCULAR ANEURYSM REPAIR VERSUS OPEN SURGICAL REPAIR: ACUTE INFRARENAL ABDOMINAL AORTIC ANEURYSM IN AN EMERGENCY SETTING
|
Hayes, P
|
|
2008
|
11 |
6 |
p. A404-
1 p.
|
artikel
|
| 229 |
PCV69 COST-EFFECTVENESS OF ENDOVASCULAR ANEURYSM REPAIR VERSUS OPEN SURGICAL REPAIR: NON-RUPTURED INFRARENAL ABDOMINAL AORTIC ANEURYSM IN AN ELECTIVE SETTING
|
Hayes, P
|
|
2008
|
11 |
6 |
p. A402-A403
nvt p.
|
artikel
|
| 230 |
PCV33 COST OF OUTPATIENT HYPERTENSION PHARMACOTHERAPY—COMPARATIVE STUDY BETWEEN BULGARIA AND SERBIA
|
Ivanova, AD
|
|
2008
|
11 |
6 |
p. A391-
1 p.
|
artikel
|
| 231 |
PCV66 COST SAVINGS OF CORONARY CT ANGIOGRAPHY VS. CARDIAC CATHETERIZATION TO EVALUATE PATIENTS WITH AN ABNORMAL OR NONDIAGNOSTIC STRESS TEST
|
Sola, S
|
|
2008
|
11 |
6 |
p. A401-A402
nvt p.
|
artikel
|
| 232 |
PCV65 COSTS OF BLEEDS ASSOCIATED WITH TREATING ACUTE CORONARY SYNDROME PATIENTS IN GERMANY
|
Bufe, A
|
|
2008
|
11 |
6 |
p. A401-
1 p.
|
artikel
|
| 233 |
PCV58 COSTS OF CORONARY ARTERY DISEASE (CAD) IN POLAND
|
Banasiak, W
|
|
2008
|
11 |
6 |
p. A399-
1 p.
|
artikel
|
| 234 |
PCV72 COST/UTILITY ANALYSIS (CUA) OF VALSARTAN FOR THE TREATMENT OF CONGESTIVE HEART FAILURE (CHF) IN ITALY BASED ON THE VAL-HEFT TRIAL
|
Pradelli, L
|
|
2008
|
11 |
6 |
p. A403-A404
nvt p.
|
artikel
|
| 235 |
PCV71 COST-UTILITY ANALYSIS IN PATIENTS WITH DRUG REFRACTORY CONCOMITANT A TRIAL FIBRILLATION IN SPAIN
|
López Gude, MJ
|
|
2008
|
11 |
6 |
p. A403-
1 p.
|
artikel
|
| 236 |
PCV52 COST-UTILITY ANALYSIS OF HOMETELEMONITORING IN ELDERLY PATIENTS WITH CHRONIC HEART FAILURE
|
Stafylas, P
|
|
2008
|
11 |
6 |
p. A397-
1 p.
|
artikel
|
| 237 |
PCV53 DECISION ANALYTIC MODEL FOR GENETIC TESTING IN THE MANAGEMENT OF WARFARIN ANTICOAGULATION TREATMENT FOR HOSPITALIZED PATIENTS
|
Moriarty, J
|
|
2008
|
11 |
6 |
p. A397-
1 p.
|
artikel
|
| 238 |
PCV92 DERIVING UTILITY VALUES FOR ACUTE CORONARY SYNDROMES FROM THE GENERAL POPULATION IN AUSTRALIA
|
Cordony, A
|
|
2008
|
11 |
6 |
p. A410-
1 p.
|
artikel
|
| 239 |
PCV47 ECONOMIC EVALUATION OF AN ABDOMINAL AORTIC ANEURYSM SCREENING PROGRAM
|
Giardina, S
|
|
2008
|
11 |
6 |
p. A395-
1 p.
|
artikel
|
| 240 |
PCV32 ECONOMIC EVALUATION OF ATORVASTATIN AND ROSUVASTATIN USING HEAD-TO-HEAD RANDOMIZED CONTROLLED TRIAL WITH UP-TITRATION OF DRUG DOSES TO OBTAIN THERAPEUTIC TARGETS FOR LDL-CHOLESTEROL
|
Beamer, B
|
|
2008
|
11 |
6 |
p. A390-
1 p.
|
artikel
|
| 241 |
PCV79 ECONOMIC EVALUATION OF IRBESARTAN IN GREECE
|
Maniadakis, N
|
|
2008
|
11 |
6 |
p. A405-A406
nvt p.
|
artikel
|
| 242 |
PCV6 EFFECTIVENESS OF CLOPIDOGREL IN ADDITION TO ASPIRIN COMPARED TO ASPIRIN ALONE AFTER ACUTE CORONARY SYNDROME
|
Liew, D
|
|
2008
|
11 |
6 |
p. A382-
1 p.
|
artikel
|
| 243 |
PCV11 EFFECTIVENESS OF DRUG-ELUTING STENTS VS. BARE METAL STENTS UNRESTRICTED USE IN PATIENTS WITH CORONARY HEART DISEASE IN SOCIAL SECURITY MEXICAN INSTITUTE
|
González-Díaz, B
|
|
2008
|
11 |
6 |
p. A384-
1 p.
|
artikel
|
| 244 |
PCV18 EFFECT OF ENVIRONMENTAL TEMPERATURE AND WORKDAYS ON HEART ATTACK FIGURES
|
Vadász, R
|
|
2008
|
11 |
6 |
p. A386-
1 p.
|
artikel
|
| 245 |
PCV21 EFFECT OF WEATHER CONDITIONS ON THE MORTALITY OF HEART ATTACKS IN HUNGARY
|
Kriszbacher, I
|
|
2008
|
11 |
6 |
p. A387-
1 p.
|
artikel
|
| 246 |
PCV48 ENHANCING SYNCOPE DIAGNOSTICS: COST-EFFECTIVENESS ANALYSIS OF AN IMPLANTABLE LOOP RECORDER STRATEGY VERSUS THE STANDARD OF CARE
|
Van Genugten, M
|
|
2008
|
11 |
6 |
p. A395-A396
nvt p.
|
artikel
|
| 247 |
PCV37 ENOXAPARIN IS COST-SAVING AS PROPHYLACTIC THERAPY VERSUS UNFRACTIONATED HEPARIN OR NO PROPHYLAXIS IN HOSPITALISED MEDICAL PATIENTS
|
Feng, J
|
|
2008
|
11 |
6 |
p. A392-
1 p.
|
artikel
|
| 248 |
PCV29 ESTIMATING THE BUDGET IMPACT OF DABIGATRAN ETEXILATE IN THE PRIMARY PREVENTION OF VENOUS THROMBOEMBOLISM FOLLOWINGTOTAL HIP OR KNEE REPLACEMENT SURGERY: AN INTERACTIVE MODEL FOR LOCAL HEALTH ECONOMIES IN THE UK
|
Robinson, P
|
|
2008
|
11 |
6 |
p. A389-
1 p.
|
artikel
|
| 249 |
PCV57 ESTIMATING THE NUMBER AND COST OF CARDIOVASCULAR EVENTS AVOIDED BY TREATING TO ALTERNATIVE LDL-C TARGETS: IS LOWER BETTER?
|
Kingslake, SL
|
|
2008
|
11 |
6 |
p. A398-A399
nvt p.
|
artikel
|
| 250 |
PCV104 EVALUATION OF THE PRESCRIPTION PATTERNS OF STATINS THROUGH APPROPRIATE INDICATORS IN TWO ITALIAN LOCAL HEALTH UNITS IN 2004–2006
|
Lopatriello, S
|
|
2008
|
11 |
6 |
p. A414-
1 p.
|
artikel
|
| 251 |
PCV38 EXTENDED PROPHYLAXIS OF VENOUSTHROMBOEMBOLISM (VTE) IN PATIENTS UNDERGOING MAJOR ORTHOPAEDIC SURGERY IN ITALY: A PHARMACOECONOMIC STUDY
|
Capri, S
|
|
2008
|
11 |
6 |
p. A392-
1 p.
|
artikel
|
| 252 |
PCV93 FACTORS DETERMINING UTILITY MEASURED WITHTHE EQ-5D IN PATIENTS WITH A TRIAL FIBRILLATION
|
Berg, J
|
|
2008
|
11 |
6 |
p. A410-
1 p.
|
artikel
|
| 253 |
PCV120 GLYCOPROTEIN INHIBITOR USE IN ACUTE CORONARY SYNDROME PATIENTS IN 2007: RESULTS FROM THE ANTIPLATELET TREATMENT OBSERVATIONAL STUDY (APTOR)
|
Zeymer, U
|
|
2008
|
11 |
6 |
p. A419-
1 p.
|
artikel
|
| 254 |
PCV84 HEALTH CARE RESOURCES AND QUALITY OF LIFE IN ACUTE CORONARY SYNDROME PATIENTS IN 2007: FRENCH BASELINE RESULTS FROM THE ANTIPLATELET TREATMENT OBSERVATIONAL STUDY (APTOR)
|
Ferrieres, J
|
|
2008
|
11 |
6 |
p. A407-
1 p.
|
artikel
|
| 255 |
PCV91 IMPACT OF CATHETER ABLATION VERSUS ANTIARRHYTHMIC DRUGS ON QUALITY OF LIFE IN PATIENTS WITH A TRIAL FIBRILLATION
|
Bulkova, V
|
|
2008
|
11 |
6 |
p. A410-
1 p.
|
artikel
|
| 256 |
PCV68 IMPACT OF DRUG ELUTING STENTS ON CLINICAL AND ECONOMIC OUTCOMES IN AN UNSELECTED INTERVENTIONAL PRACTICE
|
Rihal, CS
|
|
2008
|
11 |
6 |
p. A402-
1 p.
|
artikel
|
| 257 |
PCV88 IMPACT OF SINGLE-PILL VS. 2-PILL AMLODIPIN/ATORVASTATIN TREATMENT ON COMPLIANCE: A CZECH PILOT PROJECT ON MEDICATION ADHERENCE
|
Cerna, V
|
|
2008
|
11 |
6 |
p. A409-
1 p.
|
artikel
|
| 258 |
PCV64 INDEX, FOLLOW-UP AND TOTAL HOSPITALIZATION COSTS IN PATIENTS WITH ACUTE CORONARY SYNDROMES UNDERGOING PLANNED PERCUTANEOUS CORONARY INTERVENTION TREATED WITH PRASUGREL VS. CLOPIDOGREL IN THE TRITON-TIMI 38 TRIAL
|
Mahoney, EM
|
|
2008
|
11 |
6 |
p. A401-
1 p.
|
artikel
|
| 259 |
PCV61 INFLUENCE THE CO-MORBIDITY AND DIRECT COSTS OF STROKETO POPULATION SETTING AND IN CLINICAL PRACTICE
|
Sicras-Mainar, A
|
|
2008
|
11 |
6 |
p. A400-
1 p.
|
artikel
|
| 260 |
PCV59 INPATIENT RESOURCE USE ASSOCIATED WITHTHE TREATMENT OF SECONDARY A TRIAL FIBRILLATION
|
Spalding, JR
|
|
2008
|
11 |
6 |
p. A399-
1 p.
|
artikel
|
| 261 |
PCV121 LIPID MANAGEMENT OF HIGH RISK PATIENTS IN THE OUTPATIENT SETTING IN GERMANY: RESULTS OF DYSIS-GERMANY
|
Gitt, AK
|
|
2008
|
11 |
6 |
p. A419-
1 p.
|
artikel
|
| 262 |
PCV100 METFORMIN FOR THE TREATMENT OF METABOLIC DISTURBANCES AND CARDIOVASCULAR RISK FACTORS INWOMEN WITH POLYCYSTIC OVARY SYNDROME: A SYSTEMATIC REVIEW AND META-ANALYSIS
|
Bouza, C
|
|
2008
|
11 |
6 |
p. A413-
1 p.
|
artikel
|
| 263 |
PCV43 MODELED COST-EFFECTIVENESS OF ACHIEVING MULTIPLE LIPID TARGETSWHEN FENOFIBRIC ACID IS CO-ADMINISTERED WITH SIMVASTATIN, ROSUVASTATIN, AND ATORVASTATIN
|
Webb, SF
|
|
2008
|
11 |
6 |
p. A394-
1 p.
|
artikel
|
| 264 |
PCV122 MODELING THE EFFECT OF DIFFERENTIAL COMPLIANCE WITH ANTIHYPERTENSIVE DRUGS ON CLINICAL ENDPOINTS
|
Lowy, A
|
|
2008
|
11 |
6 |
p. A420-
1 p.
|
artikel
|
| 265 |
PCV27 MODELING THE FISCAL IMPACT OF USING PERFLUTREN LIPID MICROSPHERES (PLM) FOR FOLLOW-UP ECHOCARDIOGRAPHIC IMAGING
|
Miller, JD
|
|
2008
|
11 |
6 |
p. A389-
1 p.
|
artikel
|
| 266 |
PCV98 MODELLING THE EFFECT OF DIAGNOSTIC STRATEGIES IN PATIENTS WITH SUSPECTED CORONARY ARTERY DISEASE (CAD) ON CAPACITY AND PRODUCTIVITY OF CORONARY DIAGNOSTIC FACILITIES IN THE UNITED KINGDOM
|
Barwell, T
|
|
2008
|
11 |
6 |
p. A412-
1 p.
|
artikel
|
| 267 |
PCV16 MONITORING POTENTIAL DRUG-DRUG INTERACTIONS—AN APPLICATION FOR PRESCRIPTION CLAIMS DATABASES
|
Foley, K
|
|
2008
|
11 |
6 |
p. A385-A386
nvt p.
|
artikel
|
| 268 |
PCV31 ORAL ANTICOAGULATION AFTER MAJOR HIP OR KNEE REPLACEMENT SURGERIES
|
Wilke, T
|
|
2008
|
11 |
6 |
p. A390-
1 p.
|
artikel
|
| 269 |
PCV106 PATIENT OUTCOMES AND HEALTH ECONOMICS ASSOCIATED WITH THE USE OF OCTYLCYANOACROLATE TOPICAL SKIN ADHESIVE IN CABG SURGERY
|
Fraeman, KH
|
|
2008
|
11 |
6 |
p. A414-A415
nvt p.
|
artikel
|
| 270 |
PCV113 PATIENTS WITH ACUTE ST-ELEVATION MYOCARDIAL INFARCTION: WHOARE THE “UNTREATED PATIENTS” IN HOSPITALS WITH CATH LAB?
|
Hamad, B
|
|
2008
|
11 |
6 |
p. A417-
1 p.
|
artikel
|
| 271 |
PCV87 PERSISTENCE WITH AMIODARONE OR SOTALOL AND ITS IMPACT ON A TRIAL FIBRILLATION-RELATED HOSPITALIZATIONS AND CARDIOVERSIONS
|
Ishak, KJ
|
|
2008
|
11 |
6 |
p. A408-
1 p.
|
artikel
|
| 272 |
PCV55 PHARMACOECONOMIC EVALUATION OF TREATMENT WITH PROCORALAN® PREPARATION COMPARED TO INVASIVE TREATMENT
|
Filipiak, KJ
|
|
2008
|
11 |
6 |
p. A398-
1 p.
|
artikel
|
| 273 |
PCV20 PREDICTED CARDIOVASCULAR EVENT REDUCTION WITH THE CO-ADMINISTRATION OF FENOFIBRIC ACID AND STATINS IN A DYSLIPIDEMIA PATIENT COHORT
|
Sorensen, SV
|
|
2008
|
11 |
6 |
p. A386-A387
nvt p.
|
artikel
|
| 274 |
PCV94 PREDICTORS OF HEALTH STATUS CHANGE AMONG PATIENTS TREATED WITH A CALCIUM ANTAGONISTOR AN ATENOLOL-LED HYPERTENSION STRATEGY IN THE INTERNATIONAL VERAPAMIL SR-TRANDOLAPRIL STUDY (INVEST)
|
Ried, LD
|
|
2008
|
11 |
6 |
p. A411-
1 p.
|
artikel
|
| 275 |
PCV109 PRESCRIPTION DRUG INSURANCE AND EX ANTE MORAL HAZARD
|
Khan, N
|
|
2008
|
11 |
6 |
p. A415-A416
nvt p.
|
artikel
|
| 276 |
PCV101 PROSPECTIVE STUDY TO EVALUATE THE IMPACT OF A DISEASE EDUCATION PROGRAM OF CARDIOVASCULAR RISK CONTROL IN HYPERTENSION
|
Galera, J
|
|
2008
|
11 |
6 |
p. A413-
1 p.
|
artikel
|
| 277 |
PCV108 RISK AND COSTS OF THE FIRST HYPERTENSION-ASSOCIATED EVENT, COMPLIANCE AND PERSISTENCE IN NAÏVE HYPERTENSIVE PATIENTS AFTER INITIATING MONOTHERAPY
|
Mathes, J
|
|
2008
|
11 |
6 |
p. A415-
1 p.
|
artikel
|
| 278 |
PCV114 SEARCHING THE OPTIMAL TREATMENT MIX STRATEGY WITH A TREATMENT MIX CHART APPROACH—THE CASE OF CHOLESTEROL LOWERING IN SWEDEN
|
Martikainen, JA
|
|
2008
|
11 |
6 |
p. A417-
1 p.
|
artikel
|
| 279 |
PCV51 SINGLE PILL AMLODIPINE/ATORVASTATIN IS COST-EFFECTIVE FOR THE PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE IN KOREA
|
Liew, D
|
|
2008
|
11 |
6 |
p. A396-A397
nvt p.
|
artikel
|
| 280 |
PCV95 SOCIODEMOGRAPHIC AND CARDIOVASCULAR RISK FACTORS INFLUENCES ON EQ-5D SOCIAL PREFERENCES SCORES AND SELF-REPORTED HEALTH: A GENERAL POPULATION SURVEY IN ARGENTINA
|
Augustovski, FA
|
|
2008
|
11 |
6 |
p. A411-
1 p.
|
artikel
|
| 281 |
PCV105 STATIN PRESCRIBING IN THE CITY OF ZAGREB (2001–2006) AND THEIR ROLE IN SECONDARY PREVENTION OF CARDIOVASCULAR EVENTS
|
ŠTimac, D
|
|
2008
|
11 |
6 |
p. A414-
1 p.
|
artikel
|
| 282 |
PCV112 STATINS USE IN PATIENTS WITH A RECENT ISCHEMIC STROKE: RESULTS FROM THE STROKE ANALYZER DATABASE
|
Nasuti, PI
|
|
2008
|
11 |
6 |
p. A416-A417
nvt p.
|
artikel
|
| 283 |
PCV85 STROKE PATIENT RESOURCE USE AND CAREGIVER BURDEN OUTCOMES BY SEVERITY (RECOVERY) STUDY: METHODS AND RESULTS FROM THE ATHENS STROKE REGISTRY
|
Payne, K
|
|
2008
|
11 |
6 |
p. A407-A408
nvt p.
|
artikel
|
| 284 |
PCV10 SUPERIOR FORGIVENESS WITH ALISKIREN IN THE PRESENCE OF IMPERFECT COMPLIANCE
|
Jung, W
|
|
2008
|
11 |
6 |
p. A383-A384
nvt p.
|
artikel
|
| 285 |
PCV103 TECHNOLOGICAL INNOVATION AND THE DECISION-MAKING PROCESS IN ITALIAN HOSPITALS
|
Bartoli, S
|
|
2008
|
11 |
6 |
p. A413-A414
nvt p.
|
artikel
|
| 286 |
PCV116 THE ANALYSIS OF STATINS USAGE IN CROATIA DURING THE FIVE-YEAR PERIOD
|
Vitezic, D
|
|
2008
|
11 |
6 |
p. A418-
1 p.
|
artikel
|
| 287 |
PCV62 THE BURDEN OF ACUTE CORONARY SYNDROMES IN AUSTRALIA
|
Liew, D
|
|
2008
|
11 |
6 |
p. A400-
1 p.
|
artikel
|
| 288 |
PCV123 THE CARDIOVASCULAR PREVENTION MODEL (CPM), A GENERICALLY APPLICABLE MODEL FOR UNDERTAKING COST-EFFECTIVENESS ANALYSES OF PREVENTIVE INTERVENTIONS
|
Liew, D
|
|
2008
|
11 |
6 |
p. A420-
1 p.
|
artikel
|
| 289 |
PCV90 THE CONTRIBUTION OF THE MEASUREMENT OF TREATMENT ACCEPTABILITY TO UNDERSTAND PATIENTS' ADHERENCE TO LONG-TERM TREATMENTS. RESULTS FROM A FEASIBILITY STUDY CONDUCTED WITH IN FINE PHARMA®: A COMMUNITY-PHARMACY NETWORK DEDICATED TO PHARMACOEPIDEMIOLOGICAL SURVEYS
|
Saussier, C
|
|
2008
|
11 |
6 |
p. A409-
1 p.
|
artikel
|
| 290 |
PCV89 THE COST EFFECTIVENESS OF PERSISTENCE TO ANTIHYPERTENSIVE TREATMENT
|
Jorgensen, E
|
|
2008
|
11 |
6 |
p. A409-
1 p.
|
artikel
|
| 291 |
PCV75 THE IMPACT OF POSTPRANDIAL PEAKS ON CARDIOVASCULAR COMPLICATIONS BEYONDTHE HBA1C LEVEL—A HEALTH ECONOMIC ASSESSMENT
|
Neeser, K
|
|
2008
|
11 |
6 |
p. A404-
1 p.
|
artikel
|
| 292 |
PCV76 THE KOREAN INDIVIDUAL-MICROSIMULATION MODEL FOR CARDIOVASCULAR HEALTH INTERVENTIONS (KIMCHI)
|
Liew, D
|
|
2008
|
11 |
6 |
p. A405-
1 p.
|
artikel
|
| 293 |
PCV110 THE POTENTIAL ECONOMIC IMPACTS OF RECONFIGURING TIA CARE IN THE UK
|
Jackson, D
|
|
2008
|
11 |
6 |
p. A416-
1 p.
|
artikel
|
| 294 |
PCV1 THE ROLE OF LDL-LEVELS IN INITIATING STATIN TREATMENT
|
van der Bij, S
|
|
2008
|
11 |
6 |
p. A381-
1 p.
|
artikel
|
| 295 |
PCV19 THE TIME OF SUNRISE AND HOURS WITH DAYLIGHT MAY HAVE AN EFFECT ON THE SEASONALITY AND DIURNAL VARIATION OF A HEART ATTACK
|
Kriszbacher, I
|
|
2008
|
11 |
6 |
p. A386-
1 p.
|
artikel
|
| 296 |
PCV80 TISSUE ENGINEERING OF VALVEDVENOUS CONDUITS (VVC) VERSUS CONSERVATIVE THERAPY IN PATIENTS WITH CHRONICVENOUS INSUFFICIENCY (CVI). A DECISION ANALYTIC MODEL USING EXPERT ESTIMATED UTILITIES BASED ON DERIVED DATA FROM ANIMAL STUDIES AS A PRE-MARKETINGTECHNOLOGY ASSESSMENT APPROACH WITH GERMAN DATA
|
Dintsios, CM
|
|
2008
|
11 |
6 |
p. A406-
1 p.
|
artikel
|
| 297 |
PCV22 TOLERABILITY OF ROSUVASTATIN 40 MG COMPARED TO 20 MG IN THE TREATMENT OF HYPERCHOLESTEROLAEMIA: EVIDENCE FROM RANDOMISED CONTROLLED TRIALS
|
Edwards, SJ
|
|
2008
|
11 |
6 |
p. A387-
1 p.
|
artikel
|
| 298 |
PCV26 TREATING TO LOWER LDL-C TARGETS: ESTIMATING THE NUMBER AND COST OF CARDIOVASCULAR EVENTS AVOIDED FOR REGIONAL HEALTH ECONOMIES IN ENGLAND, SCOTLAND, WALES AND NORTHERN IRELAND
|
Kingslake, SL
|
|
2008
|
11 |
6 |
p. A388-
1 p.
|
artikel
|
| 299 |
PCV97 TREATMENTS FOR VARICOSE VEIN DISEASE: EXPECTATIONS AND EXPERIENCES OF PATIENTS
|
Spijkers, CJ
|
|
2008
|
11 |
6 |
p. A412-
1 p.
|
artikel
|
| 300 |
PCV60 TWO-YEAR HOSPITALIZATION RATES AND ASSOCIATED COSTS IN PATIENTS FROM GERMANY WITH PERIPHERAL ARTERIAL DISEASE: RESULTS FROMTHE REDUCTION OF AT HEROTHROMBOSIS FOR CONTINUED HEALTH (REACH) REGISTRY
|
Mahoney, EM
|
|
2008
|
11 |
6 |
p. A399-A400
nvt p.
|
artikel
|
| 301 |
PCV2 UNDERUSE OF STATINES AMONG HIGH RISK PATIENTS
|
Heintjes, EM
|
|
2008
|
11 |
6 |
p. A381-
1 p.
|
artikel
|
| 302 |
PDB17 A COMPARISON OF COSTS AMONG PATIENTS WITH TYPE 2 DIABETESWHO INITIATED THERAPY WITH EXENATIDE OR INSULIN GLARGINE
|
Misurski, DA
|
|
2008
|
11 |
6 |
p. A500-A501
nvt p.
|
artikel
|
| 303 |
PDB18 A COMPARISON OF COSTS AMONG PATIENTS WITH TYPE 2 DIABETESWHO INITIATED THERAPY WITH EXENATIDE OR SITAGLIPTIN
|
Lage, MJ
|
|
2008
|
11 |
6 |
p. A501-
1 p.
|
artikel
|
| 304 |
PDB65 A COMPARISON OF DIABETES KNOWLEDGE AMONG RESIDENTS IN BANGKOK AND OTHER CENTRAL PROVINCES OF THAILAND
|
Pongmesa, T
|
|
2008
|
11 |
6 |
p. A517-
1 p.
|
artikel
|
| 305 |
PDB60 A COMPARISON OF THE MANAGEMENT OF SEVERE HYPOGLYCAEMIA IN INSULIN-TREATED DIABETES IN THREE EUROPEAN COUNTRIES: SIMILARITIES, DIFFERENCES AND RESOURCE IMPLICATIONS
|
Lammert, M
|
|
2008
|
11 |
6 |
p. A515-
1 p.
|
artikel
|
| 306 |
PDB24 A COST-EFFECTIVENESS ANALYSIS OF IRBESARTAN IN THE TREATMENT OF HYPERTENSIVE PATIENTS WITH DIABETIC RENAL DISEASE
|
Lee, TJ
|
|
2008
|
11 |
6 |
p. A503-
1 p.
|
artikel
|
| 307 |
PDB43 ADDING INSULIN GLARGINE TO ORALTHERAPY IN PATIENTS WITHTYPE 2 DIABETES RESULTS IN LONGER PERSISTENCE WITH TREATMENT COMPARED TO NPH INSULIN
|
Pfohl, M
|
|
2008
|
11 |
6 |
p. A509-A510
nvt p.
|
artikel
|
| 308 |
PDB52 A SELF-MANAGEMENT PROFILE FOR PATIENTS WITH TYPE-2 DIABETES
|
Patrick, DL
|
|
2008
|
11 |
6 |
p. A512-A513
nvt p.
|
artikel
|
| 309 |
PDB12 ASSOCIATION BETWEEN HYPOGLYCEMIA EPISODES AND CHANGES IN THE SULPHONYLUREA TREATMENT PATTERN IN TYPE 2 DIABETES MELLITUS (T2DM) PATIENTS. RECAP-DM SPANISH COHORT STUDY
|
Caloto, MT
|
|
2008
|
11 |
6 |
p. A499-
1 p.
|
artikel
|
| 310 |
PDB8 BURDEN OF DIABETES AND ASSOCIATED TREATMENT PATTERNS IN EUROPE: A COMPARISON OF SIX COUNTRIES
|
Narayanan, S
|
|
2008
|
11 |
6 |
p. A497-A498
nvt p.
|
artikel
|
| 311 |
PDB61 CHART AUDIT OF THE DOSE AND EFFECTIVENESS OF LONG ACTING INSULIN ANALOGUES IN AUSTRALIAN CLINICAL PRACTICE
|
O'Leary, BA
|
|
2008
|
11 |
6 |
p. A515-A516
nvt p.
|
artikel
|
| 312 |
PDB15 COMPARATIVE COST-UTILITY ANALYSIS OF LONG-ACTING INSULIN ANALOGUE (INSULIN DETEMIR) AND NPH INSULIN FOR THE TREATMENT OF TYPE 1 AND TYPE 2 DIABETES AND THE BUDGET IMPACT ANALYSIS OF INSULIN ANALOGUE REIMBURSEMENT IN POLAND
|
Walczak, J
|
|
2008
|
11 |
6 |
p. A500-
1 p.
|
artikel
|
| 313 |
PDB10 COMPREHENSIVE LIPID PROFILE AMONGTYPE 2 DIABETES MELLITUS (T2DM) POPULATION IN SPAIN. RECAP-DM SPANISH COHORT STUDY
|
Nocea, G
|
|
2008
|
11 |
6 |
p. A498-
1 p.
|
artikel
|
| 314 |
PDB50 CONCEPTUAL DEVELOPMENT OF A PATIENT SELF-ASSESSMENT TOOL TO IMPROVE PATIENT-CLINICIAN COMMUNICATION ON THE DAILY MANAGEMENT OF TYPE 2 DIABETES
|
Arnould, B
|
|
2008
|
11 |
6 |
p. A512-
1 p.
|
artikel
|
| 315 |
PDB33 COST COMPARISON OF INSULIN GLARGINE AND INSULIN DETEMIR IN TYPE 2 DIABETES MELLITUS IN ARGENTINA: A TRIAL-BASED PROBABILISTIC MODEL
|
Pichon-Riviere, A
|
|
2008
|
11 |
6 |
p. A506-
1 p.
|
artikel
|
| 316 |
PDB25 COST EFFECTIVENESS ANALYSIS OF HUMAN PREMIX INSULIN REGIMENS COMPARED WITH A PREMIX ANALOGUE INSULIN IN THE PRIVATE HEALTH CARE SECTOR IN SOUTH AFRICA
|
White, J
|
|
2008
|
11 |
6 |
p. A503-A504
nvt p.
|
artikel
|
| 317 |
PDB22 COST-EFFECTIVENESS OF INSULIN GLARGINE COMPARED TO INSULIN DETEMIR FOR TYPE 1 (T1DM) AND TYPE 2 DIABETES MELLITUS (T2DM) PATIENTS IN THE CANADIAN PAYER SETTING
|
Minshall, ME
|
|
2008
|
11 |
6 |
p. A502-
1 p.
|
artikel
|
| 318 |
PDB21 COST-EFFECTIVENESS OF INSULIN GLARGINE PLUS ORAL ANTIDIABETIC DRUGS (OADS) COMPARED TO PREMIXED INSULIN FOR TYPE 2 DIABETES MELLITUS (T2DM) PATIENTS IN THE CANADIAN PAYER SETTING
|
Minshall, ME
|
|
2008
|
11 |
6 |
p. A502-
1 p.
|
artikel
|
| 319 |
PDB26 COST-EFFECTIVENESS OF ROSIGLITAZONE COMBINATION THERAPY FOR THE TREATMENT OF TYPE 2 DIABETES IN THE CZECH REPUBLIC
|
Doležal, T
|
|
2008
|
11 |
6 |
p. A504-
1 p.
|
artikel
|
| 320 |
PDB23 COST-EFFECTIVENESS OF SOMATROPIN (NORDITROPIN) FOR THE TREATMENT OF GROWTH HORMONE DEFICIENT (GHD) CHILDREN IN A SWEDISH SETTING
|
Bech, PG
|
|
2008
|
11 |
6 |
p. A502-A503
nvt p.
|
artikel
|
| 321 |
PDB41 COST-EFFECTIVENESS OF SOMATROPIN (NORDITROPIN®) FOR THE TREATMENT OF GROWTH HORMONE DEFICIENT (GHD) CHILDREN IN A UK SETTING
|
Christensen, T
|
|
2008
|
11 |
6 |
p. A509-
1 p.
|
artikel
|
| 322 |
PDB36 COST-EFFECTIVENESS OF THE ROUX-EN-Y GASTRIC BYPASS SURGERY COMPARED WITH MEDICAL MANAGEMENT FOR TREATMENT OF TYPE 2 DIABETES MELLITUS (T2DM) PATIENTS IN THE USA
|
Minshall, ME
|
|
2008
|
11 |
6 |
p. A507-
1 p.
|
artikel
|
| 323 |
PDB35 COST-UTILITY ANALYSIS OF BIPHASIC INSULIN ASPART VERSUS HUMAN INSULIN IN TYPE 2 DIABETES MELLITUS PATIENTS TREATED IN TIER III HOSPITALS IN BEIJING, CHINA: A LONGTERM OUTCOMES MODEL EVALUATION FROM THE IMPROVE OBSERVATIONAL STUDY
|
White, J
|
|
2008
|
11 |
6 |
p. A507-
1 p.
|
artikel
|
| 324 |
PDB40 COST-UTILITY OF INSULIN GLARGINE COMPARED TO NPH IN TYPE DM1 FROM A PUBLIC PAYER PERSPECTIVE IN POLAND
|
McEwan, P
|
|
2008
|
11 |
6 |
p. A508-A509
nvt p.
|
artikel
|
| 325 |
PDB42 COST-UTILITY OF INSULIN GLARGINE COMPARED TO PRE MIX IN TYPE 2 FROM PUBLIC PAYER PERSPECTIVE IN POLAND
|
McEwan, P
|
|
2008
|
11 |
6 |
p. A509-
1 p.
|
artikel
|
| 326 |
PDB28 DIABETES MELLITUS BURDEN AND RELATIONSHIP WIHTHE DEGREE OF PATIENTxS GLYCEMIC CONTROL
|
Banegas, JR
|
|
2008
|
11 |
6 |
p. A504-A505
nvt p.
|
artikel
|
| 327 |
PDB46 DIABETES RELATED QUALITY OF LIFE IN PORTUGUESE PATIENTS
|
Mendes, Z
|
|
2008
|
11 |
6 |
p. A510-A511
nvt p.
|
artikel
|
| 328 |
PDB57 EFFECT OF INSULIN GLARGINE OR NPH INSULIN ON TREATMENT SATISFACTION IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
|
Moock, J
|
|
2008
|
11 |
6 |
p. A514-
1 p.
|
artikel
|
| 329 |
PDB64 EFFECTS OF DOSING REGIMEN ON MEDICATION USE BEHAVIOR IN MEDICAID ENROLLED TYPE 2 DIABETES MELLITUS PATIENTS
|
Jayawant, SS
|
|
2008
|
11 |
6 |
p. A516-
1 p.
|
artikel
|
| 330 |
PDB63 EFFECTS OF DOSING REGIMEN ON RESOURCE UTILIZATION AND COSTS IN MEDICAID ENROLLED TYPE 2 DIABETES MELLITUS PATIENTS
|
Jayawant, SS
|
|
2008
|
11 |
6 |
p. A516-
1 p.
|
artikel
|
| 331 |
PDB6 EFFECTS OF PIOGLITAZONE AND ROSIGLITAZONE ON GLUCOSE AND THE CARDIOVASCULAR RISK FACTORS IN PATIENTS WITH TYPE 2 DIABETES: A META-ANALYSIS
|
Lee, JK
|
|
2008
|
11 |
6 |
p. A497-
1 p.
|
artikel
|
| 332 |
PDB9 ESTIMATED INCIDENCE OF TESTOSTERONE DEFICIENCY IN AGING BRAZILIAN MEN AND THE CONSEQUENT COSTS OF NEW CASES OF OSTEOPOROSIS-RELATED HIP FRACTURES
|
Bahia, L
|
|
2008
|
11 |
6 |
p. A498-
1 p.
|
artikel
|
| 333 |
PDB19 ESTIMATING THE COST EFFECTIVENESS IN THE UK OF VILDAGLIPTIN COMPARED TO PIOGLITAZONE AS ADD-ON THERAPY TO METFORMIN USING THE SHEFFIELD TYPE 2 DIABETES MODEL
|
Brennan, A
|
|
2008
|
11 |
6 |
p. A501-
1 p.
|
artikel
|
| 334 |
PDB29 ESTIMATING THE DIRECT COST OF TYPE II DIABETES IN GREECE
|
Athanasakis, K
|
|
2008
|
11 |
6 |
p. A505-
1 p.
|
artikel
|
| 335 |
PDB5 GLYCEMIC CONTROL FOLLOWING INITIATION OF INSULIN GLARGINE OR DETEMIR IN PATIENTS WITH TYPE 2 DIABETES MELLITUS- AN ANALYSIS OF ELECTRONIC MEDICAL RECORDS
|
Levin, P
|
|
2008
|
11 |
6 |
p. A496-A497
nvt p.
|
artikel
|
| 336 |
PDB4 GLYCEMIC CONTROL OF TYP-2 DIABETES IN MAKKAH SECURITY FORCES HEALTH CARE CENTER (MSFHCC), SAUDI ARABIA: A DISCRIPTIVE PILOT STUDY
|
Suliman, MA
|
|
2008
|
11 |
6 |
p. A496-
1 p.
|
artikel
|
| 337 |
PDB49 HEALTH-RELATED QUALITY OF LIFE (HRQOL) AND TREATMENT SATISFACTION (TS) IN DIABETIC PATIENTS ATTENDED IN SPANISH PRIMARY CARE CENTRES
|
De Pablos, PL
|
|
2008
|
11 |
6 |
p. A511-A512
nvt p.
|
artikel
|
| 338 |
PDB56 IDENTIFYING FACTORSTHAT AFFECT PATIENTS' WILLINGNESS TO PAY FOR INHALED INSULIN
|
Pinto, SL
|
|
2008
|
11 |
6 |
p. A514-
1 p.
|
artikel
|
| 339 |
PDB62 IMPACT OF INSURANCE PAYMENT SYSTEMS ON QUALITY OF CARE AND HEALTH CARE SERVICE UTILIZATION IN TYPE 2 DIABETES MEDICAID ENROLLEES
|
Pawaskar, MD
|
|
2008
|
11 |
6 |
p. A516-
1 p.
|
artikel
|
| 340 |
PDB2 IMPROVED GLYCAEMIC CONTROL BY SWITCHING FROM INSULIN NPHTO INSULIN GLARGINE: A RETROSPECTIVE OBSERVATIONAL STUDY
|
Gordon, JP
|
|
2008
|
11 |
6 |
p. A495-A496
nvt p.
|
artikel
|
| 341 |
PDB30 INSTIGATE STUDY (INSULIN TITRATION; GAINING AN UNDERSTANDING OF THE BURDEN OF TYPE 2 DIABETES IN EUROPE): HEALTH CARE RESOURCE UTILIZATION AND COSTS WITHIN THE FIRST 6 MONTHS OF INSULIN THERAPY—FRENCH DATA
|
Fagnani, F
|
|
2008
|
11 |
6 |
p. A505-
1 p.
|
artikel
|
| 342 |
PDB27 INSULIN GLARGINE AND NPH INSULIN-BASED REGIMENS REVEAL COMPARABLE TOTAL DIRECT TREATMENT COSTS IN TYPE 2 DIABETES PATIENTS.THE LONG-ACTING INSULIN GLARGINE VS. NPH INSULIN COST EVALUATION STUDY IN GERMANY (LIVE-DE)
|
Scholten, T
|
|
2008
|
11 |
6 |
p. A504-
1 p.
|
artikel
|
| 343 |
PDB66 INSULIN GLARGINE UTILIZATION IN REAL-LIFE—EFFICACY OF A REGIMEN BASED ON INSULIN GLARGINE IN PATIENTS WITH TYPE 2 DIABETES PREVIOUSLY ON NPH INSULIN IN CLINICAL PRACTICE IN SPAIN
|
Delgado, E
|
|
2008
|
11 |
6 |
p. A517-
1 p.
|
artikel
|
| 344 |
PDB37 IS INSULIN GLARGINE A COST-EFFECTIVE OPTION FOR TREATMENT OF PATIENTS NAÏVE TO INSULIN TREATMENT WITH TYPE 2, BASELINE HBA1C ABOVE 8% AND AGE BELOW 65YEARS IN COMPARISON TO NPH AND PREMIX IN POLAND?
|
McEwan, P
|
|
2008
|
11 |
6 |
p. A507-A508
nvt p.
|
artikel
|
| 345 |
PDB39 IS INSULIN GLARGINE A COST EFFECTIVE OPTION IN TREATMENT OF PATIENTS WITH TYPE DM1 WITH BASELINE HBA1C ABOVE 8% IN COMPARISON TO NPH AND PREMIX IN POLAND?
|
McEwan, P
|
|
2008
|
11 |
6 |
p. A508-
1 p.
|
artikel
|
| 346 |
PDB14 LARGE IMPACT OF ANTIDIABETIC DRUGTREATMENT AND HOSPITALIZATIONS ON ECONOMIC BURDEN OF DIABETES MELLITUS IN THE NETHERLANDS DURING 2000 TO 2004
|
Van der Linden, MW
|
|
2008
|
11 |
6 |
p. A499-A500
nvt p.
|
artikel
|
| 347 |
PDB20 LONG-TERM COST-EFFECTIVENESS OF INSULIN DETEMIR COMPARED TO NEUTRAL PROTAMINE HAGEDORN INSULIN IN PATIENTS WITH TYPE 1 DIABETES USING A BASAL-BOLUS REGIMEN IN BELGIUM, FRANCE, GERMANY, ITALY AND SPAIN
|
Gschwend, MH
|
|
2008
|
11 |
6 |
p. A501-A502
nvt p.
|
artikel
|
| 348 |
PDB68 LONG-TERM COST-EFFECTIVENESS OF INSULIN DETEMIR COMPARED TO NEUTRAL PROTAMINE HAGEDORN INSULIN IN PATIENTS WITH TYPE 1 DIABETES USING A BASAL-BOLUS REGIMEN IN SWEDEN
|
Valentine, WJ
|
|
2008
|
11 |
6 |
p. A503-
1 p.
|
artikel
|
| 349 |
PDB7 LONGTERM HEALTH OUTCOMES IN NEWLY DIAGNOSED TREATMENT NAï VE TYPE 2 DIABETES PATIENTS INITIATED WITH BIPHASIC INSULIN ASPART IN CHINA: DATA FROM THE IMPROVE STUDY
|
White, J
|
|
2008
|
11 |
6 |
p. A497-
1 p.
|
artikel
|
| 350 |
PDB32 MEDICAL COSTS ATTRIBUTABLE TO OBESITY IN PATIENTS WITH DIABETES MELLITUS AMONG U.S.ADULTS
|
Barone, JA
|
|
2008
|
11 |
6 |
p. A506-
1 p.
|
artikel
|
| 351 |
PDB34 MONITORING OF TREATMENT COSTS AFTER REIMBURSEMENT DECISION: SOMATOSTATIN ANALOGUES FOR ACROMEGALY
|
Valentim, J
|
|
2008
|
11 |
6 |
p. A506-A507
nvt p.
|
artikel
|
| 352 |
PDB48 NOT ALL ROADS LEAD TO ROME—A REVIEW OF QUALITY OF LIFE MEASUREMENT IN DIABETES
|
Speight, J
|
|
2008
|
11 |
6 |
p. A511-
1 p.
|
artikel
|
| 353 |
PDB67 PATIENT-CENTERED OUTCOMES IN THE ECONOMIC EVALUATION OF TYPE 2 DIABETES TREATMENT: A SYSTEMATIC REVIEW OF MODELING METHODS
|
Redekop, WK
|
|
2008
|
11 |
6 |
p. A517-
1 p.
|
artikel
|
| 354 |
PDB11 POTENTIAL IMPACT OF LIPID CONTROL AND SUBSEQUENT CARDIOVASCULAR (CV) RISK REDUCTION INT2DM POPULATION TREATED WITH ORAL COMBINATION THERAPY (OCT) RECAP-DM STUDY
|
Nocea, G
|
|
2008
|
11 |
6 |
p. A498-A499
nvt p.
|
artikel
|
| 355 |
PDB58 PREDICTION MODEL FOR BLOOD GLUCOSE OF TYPE 2 DIABETIC PATIENT
|
Auamnoy, T
|
|
2008
|
11 |
6 |
p. A514-A515
nvt p.
|
artikel
|
| 356 |
PDB54 PSYCHOLOGICAL INSULIN RESISTANCE (PIR): PATIENT AND PHYSICIAN BELIEFS IMPACTING DIABETES MANAGEMENT
|
Kongsø, JH
|
|
2008
|
11 |
6 |
p. A513-
1 p.
|
artikel
|
| 357 |
PDB55 PSYCHOMETRIC STRENGTH OF CURRENT TREATMENT SATISFACTION QUESTIONNAIRES IN NON-INSULIN TREATED TYPE 2 DIABETES
|
Howarth, A
|
|
2008
|
11 |
6 |
p. A513-A514
nvt p.
|
artikel
|
| 358 |
PDB13 REMUBURSEMENT OF LONG-ACTING INSULIN ANALOGS IN POLAND: A BUDGT IMPACT ANALYSIS
|
Rys, P
|
|
2008
|
11 |
6 |
p. A499-
1 p.
|
artikel
|
| 359 |
PDB45 SELF-MANAGEMENT AND PATIENT PERCEPTIONS OF CARE IN RELATION TO HEALTH AND COST-RELATED OUTCOMES IN TYPE 2 DIABETES: A SYSTEMATIC REVIEW
|
Cobden, D
|
|
2008
|
11 |
6 |
p. A510-
1 p.
|
artikel
|
| 360 |
PDB3 SWITCHING FROM PREMIXED INSULIN TO INSULIN GLARGINE-BASED REGIMEN IMPROVES GLYCAEMIC CONTROL IN PATIENTS WITH TYPE 1 ORTYPE 2 DIABETES: A RETROSPECTIVE PRIMARY CARE-BASED ANALYSIS
|
McEwan, P
|
|
2008
|
11 |
6 |
p. A496-
1 p.
|
artikel
|
| 361 |
PDB38 THE COST-EFFECTIVENESS OF GROWTH HORMONE REPLACEMENTTHERAPY WITH GENOTROPIN® IN HYPOPITUITARY ADULT PATIENTS
|
Bolin, K
|
|
2008
|
11 |
6 |
p. A508-
1 p.
|
artikel
|
| 362 |
PDB31 THE COST OF TYPE 2 DIABETES MELLITUS IN CZECH REPUBLIC
|
Doležal, T
|
|
2008
|
11 |
6 |
p. A505-A506
nvt p.
|
artikel
|
| 363 |
PDB16 THE COST-UTILITY AND BUDGET IMPACT ANALYSIS OF SITAGLIPTIN (JANUVIA®) IN TYPE 2 DIABETES IN POLAND
|
Walczak, J
|
|
2008
|
11 |
6 |
p. A500-
1 p.
|
artikel
|
| 364 |
PDB1 THE IMPACT OF INSULIN DETEMIR COMPARED TO NEUTRAL PROTAMINE HAGEDORN INSULIN ON LONG-TERM DIABETES-RELATED COMPLICATIONS: A MODELING ANALYSIS IN TYPE 1 DIABETES PATIENTS IN BELGIUM, FRANCE, GERMANY, ITALY AND SPAIN
|
Gschwend, MH
|
|
2008
|
11 |
6 |
p. A495-
1 p.
|
artikel
|
| 365 |
PDB47 THE SUITABILITY OF POLYCYSTIC OVARY SYNDROME-SPECIFIC QUESTIONNAIRES FOR MEASURING THE IMPACT OF PCOS ON QUALITY OF LIFE IN CLINICAL TRIALS
|
Malik-Aslam, A
|
|
2008
|
11 |
6 |
p. A511-
1 p.
|
artikel
|
| 366 |
PDB44 TREATMENT COMPLIANCE AND ILLNESS KNOWLEDGE IN DIABETIC PATIENTS ATTENDED IN SPANISH PRIMARY CARE CENTRES
|
Franch, J
|
|
2008
|
11 |
6 |
p. A510-
1 p.
|
artikel
|
| 367 |
PDB59 TREATMENT PATTERNS AND GOAL ATTAINMENT FOR PATIENTS WITH TYPE 2 DIABETES
|
Wisloff, TF
|
|
2008
|
11 |
6 |
p. A515-
1 p.
|
artikel
|
| 368 |
PDB51 UNDERSTANDING AND ASSESSING THE IMPACT OF DIABETES TREATMENT ACROSS MEDICATION DELIVERY SYSTEMS
|
Brod, M
|
|
2008
|
11 |
6 |
p. A512-
1 p.
|
artikel
|
| 369 |
PDB53 VALIDATION OF THE HUMAN GROWTH HORMONE PREFERENCE AND SATISFACTION QUESTIONNAIRE (HGH-PSQ)
|
Stephens, JM
|
|
2008
|
11 |
6 |
p. A513-
1 p.
|
artikel
|
| 370 |
PG15 A BUDGET IMPACT ANALYSIS FOR DETERMINING THE COSTS OF INCREASED PANTOPRAZOL IV PRESCRIPTION FOR THE MANAGEMENT OF PEPTIC ULCER IN SPAIN
|
Darba, J
|
|
2008
|
11 |
6 |
p. A519-
1 p.
|
artikel
|
| 371 |
PG137 A COMPARISON OF TREATMENT FAILURE RATES BASED ON STARTING ALGINATE THERAPY OBSERVED IN A LARGE REPRESENTATIVE LONGITUDINAL UK DATABASE
|
Connolly, M
|
|
2008
|
11 |
6 |
p. A530-
1 p.
|
artikel
|
| 372 |
PG18 A COST-EFFECTIVENESS EVALUATION—RETREATMENT WITH PEGYLATED INTERFERON ALFA 2B PLUS RIBAVIRIN IN HEPATITIS C PATIENTSWHO HAVE PREVIOUSLY RECEIVED INTERFERON-BASED THERAPY AND FAILED TO ATTAIN A SUSTAINED VIROLOGICAL RESPONSE
|
Gibbons, CJ
|
|
2008
|
11 |
6 |
p. A520-
1 p.
|
artikel
|
| 373 |
PG111 A COST-EFFICACY ANALYSIS MODEL FOR PHYSICIAN ADMINISTERED ANTI-TUMOR NECROSIS FACTOR AGENTS IN CROHN'S DISEASE
|
Waters, H
|
|
2008
|
11 |
6 |
p. A521-
1 p.
|
artikel
|
| 374 |
PG130 A EUROPEAN CROSS-SECTIONAL STUDY TO EVALUATE SYMPTOM BURDEN AND CLINICAL MANAGEMENT OF GASTROESOPHAGEAL REFLUX DISEASE (RANGE-GREECE)
|
Karagiannis, D
|
|
2008
|
11 |
6 |
p. A527-
1 p.
|
artikel
|
| 375 |
PG114 A HYPOTHETICAL ROAD MAPTO REDUCE ACID RELATED DISEASES COSTS MANAGEMENT
|
Cammarota, S
|
|
2008
|
11 |
6 |
p. A522-
1 p.
|
artikel
|
| 376 |
PG139 ALEGRIA, A REAL LIFE EVALUATION OF GERD (GASTROESOPHAGEAL REFLUX DISEASE) IMPACT OF SYMPTOM ASSESSMENT IN LUXEMBOUR
|
Fritz, R
|
|
2008
|
11 |
6 |
p. A530-A531
nvt p.
|
artikel
|
| 377 |
PG17 AN ECONOMIC EVALUATION OF THE TWO LEADING ALGINTE THERAPIES IN THE UK: RESULTS FROM A LARGE LONGITUDINAL DATABASE
|
Connolly, M
|
|
2008
|
11 |
6 |
p. A519-A520
nvt p.
|
artikel
|
| 378 |
PG133 A POPULATION-BASED SURVEY TO ASSESS IMPACT OF TROUBLESOME SYMPTOMS IN GASTROESOPHAGEAL REFLUX DISEASE ON WORK PRODUCTIVITY
|
Reimer, C
|
|
2008
|
11 |
6 |
p. A528-
1 p.
|
artikel
|
| 379 |
PG120 ASSESSING THE COST AND EFFECTIVENESS OF TERLIPRESSIN COMPARED WITH SOMATOSTATIN FOR THE TREATMENT OF BLEEDING OESOPHAGEAL VARICES IN SPAIN
|
Darba, J
|
|
2008
|
11 |
6 |
p. A524-
1 p.
|
artikel
|
| 380 |
PG122 ASSESSING THE PATIENT-REPORTED IMPACT OF USING BOWEL CLEANSING PREPARATIONS
|
Doward, LC
|
|
2008
|
11 |
6 |
p. A524-A525
nvt p.
|
artikel
|
| 381 |
PG14 BUDGET IMPACT OF METHYLNALTREXONE SC ON A PUBLIC DRUG PROGRAM FORMULARY
|
Wang, M
|
|
2008
|
11 |
6 |
p. A519-
1 p.
|
artikel
|
| 382 |
PG132 CORRELATION BETWEENTHE SEVERITY OF UPPER GASTROINTESTINAL (GI) SYMPTOMS AND ENDOSCOPIC FINDINGS IN THE GREEK PRIMARY CARE SETTING
|
Papatheodoridis, G
|
|
2008
|
11 |
6 |
p. A528-
1 p.
|
artikel
|
| 383 |
PG115 COSTS OF CROHN'S DISEASE WITHIN THE GERMAN STATUTORY HEALTH INSURANCE
|
Prenzler, A
|
|
2008
|
11 |
6 |
p. A522-
1 p.
|
artikel
|
| 384 |
PG126 DERIVING PREFERENCE BASED UTILITIES FOR CD AND UC PATIENTS: CONVERTING IBDQ INTO EQ-5D UTILITIES
|
Punekar, YS
|
|
2008
|
11 |
6 |
p. A526-
1 p.
|
artikel
|
| 385 |
PG128 DEVELOPMENT AND PSYCHOMETRIC VALIDATION OF A NEW QUESTIONNAIRE MEASURING THE IMPACT OF CHILD GASTROENTERITIS ON PARENTS
|
Viala-Danten, M
|
|
2008
|
11 |
6 |
p. A526-A527
nvt p.
|
artikel
|
| 386 |
PG118 DIRECT MEDICAL COSTS OF CROHN'S DISEASE IN SPAIN: A MARKOV MODEL
|
Casellas, F
|
|
2008
|
11 |
6 |
p. A523-
1 p.
|
artikel
|
| 387 |
PG116 DIRECT MEDICAL COSTS OF GERD AND ASSOCIATED FACTORS
|
Tafalla, M
|
|
2008
|
11 |
6 |
p. A523-
1 p.
|
artikel
|
| 388 |
PG125 ESTABLISHING THE RELATIONSHIP BETWEENTHE ULCERATIVE COLITIS DISEASE ACTIVITY INSTRUMENT (UCDAI) AND PATIENT HEALTH RELATED QUALITY OF LIFE FROM A LARGE RANDOMISED CONTROLLED TRIAL
|
Poole, CD
|
|
2008
|
11 |
6 |
p. A526-
1 p.
|
artikel
|
| 389 |
PG124 FURTHER VALIDATION OF THE GASTROINTESTINAL SHORT FORM QUESTIONNAIRE (GSFQ) IN THE SPANISH POPULATION
|
Ruiz, MA
|
|
2008
|
11 |
6 |
p. A525-
1 p.
|
artikel
|
| 390 |
PG131 GENDER, AGE AND BODY MASS-RELATED DIFFERENCES IN THE IMPACT OF GASTRO-ESOPHAGEAL REFLUX DISEASE (GERD) SYMPTOMS IN PRIMARY CARE PATIENTS ASSESSED BY THE GASTROINTESTINAL IMPACT SCALE (GIS)
|
Ferrus, J
|
|
2008
|
11 |
6 |
p. A527-A528
nvt p.
|
artikel
|
| 391 |
PG129 INDIVIDUAL AND SOCIETAL PREFERENCE SCORES BOTH IDENTIFY ACTIVE INFLAMMATORY BOWEL DISEASE (IBD) IN GERMANY
|
Stark, R
|
|
2008
|
11 |
6 |
p. A527-
1 p.
|
artikel
|
| 392 |
PG112 MODELING THE LONG-TERM COST-EFFECTIVENESS OF CRONIC HEP. B THERAPIES IN SPAIN
|
Buti, M
|
|
2008
|
11 |
6 |
p. A521-A522
nvt p.
|
artikel
|
| 393 |
PG110 ONCE DAILY MESALAZINE FOR MAINTAINING REMISSION IS COST-SAVING COMPARED TO TWICE DAILY MESALAZINE: AN ECONOMIC EVALUATION BASED ON THE PODIUM RANDOMISED CONTROLLED TRIAL
|
Connolly, M
|
|
2008
|
11 |
6 |
p. A521-
1 p.
|
artikel
|
| 394 |
PG135 PATIENT PREFERENCES FOR CROHN'S DISEASE FLARE-UP THERAPY: A DISCRETE CHOICE EXPERIMENT
|
Darba, J
|
|
2008
|
11 |
6 |
p. A529-
1 p.
|
artikel
|
| 395 |
PG134 PATIENT PREFERENCES FOR CROHN'S DISEASE MAINTENANCE THERAPY: A DISCRETE CHOICE EXPERIMENT
|
Darba, J
|
|
2008
|
11 |
6 |
p. A529-
1 p.
|
artikel
|
| 396 |
PG13 PHARMACOECONOMIC ASSESSMENT OF LANREOTIDE IN THE MANAGEMENT OF POST-OPERATIVE DIGESTIVE FISTULAS
|
De Pouvourville, G
|
|
2008
|
11 |
6 |
p. A522-
1 p.
|
artikel
|
| 397 |
PG140 PROTON PUMP INHIBITORS MARKET IN PRIMARY CARE SETTING
|
Cammarota, S
|
|
2008
|
11 |
6 |
p. A531-
1 p.
|
artikel
|
| 398 |
PG127 PSYCHOMETRIC VALIDATION OF TRANSLATION TO SPANISH OF THE REFLUX DISEASE QUESTIONNAIRE (RDQ) AND GASTROINTESTINAL IMPACT SCALE IN PATIENTS WITH GASTROESOPHAGEAL REFLUX DISEASE (GERD)
|
Tafalla, M
|
|
2008
|
11 |
6 |
p. A526-
1 p.
|
artikel
|
| 399 |
PG123 QUALITY OF LIFE (HEALTH-RELATED UTILITY) IN ADULTS WITH ULCERATIVE COLITIS IN REMISSION VS. MILD/MODERATE AND SEVERE RELAPSE: FINDINGS FROM THE PODIUM STUDY
|
Poole, CD
|
|
2008
|
11 |
6 |
p. A525-
1 p.
|
artikel
|
| 400 |
PG117 REALWORLD DOSING OF ANTI-TUMOR NECROSIS FACTOR THERAPIES IN THE TREATMENT OF ADULTS WITH CROHN'S DISEASE
|
Waters, H
|
|
2008
|
11 |
6 |
p. A523-
1 p.
|
artikel
|
| 401 |
PG121 REDUCTION OF WORK PRODUCTIVITY ASSOCIATED WITH GASTROESOPHAGEAL REFLUX DISEASE (GERD) AND RELATED COSTS
|
Gisbert, JP
|
|
2008
|
11 |
6 |
p. A524-
1 p.
|
artikel
|
| 402 |
PG138 RESULTS OF ALEGRIA, A REAL LIFE EVALUATION OF GERD IMPACT OF SYMPTOM ASSESSMENT IN BELGIUM
|
Louis, E
|
|
2008
|
11 |
6 |
p. A530-
1 p.
|
artikel
|
| 403 |
PG136 SELF-DIAGNOSIS AND HEALTH SEEKING BEHAVIOUR OF WOMEN FOR MINOR BOWL AILMENTS IN A LARGE REPRESENTATIVE UNITED KINGDOM (UK) SAMPLE POPULATION
|
Connolly, M
|
|
2008
|
11 |
6 |
p. A529-A530
nvt p.
|
artikel
|
| 404 |
PG19 THE COST-EFFECTIVENESS OF HIGH-DOSE INTRAVENOUS ESOMEPRAZOLE IN PEPTIC ULCER BLEEDING: A DECISION-TREE MODEL WITH SPANISH COSTS AND NEW CLINICAL DATA
|
Barkun, A
|
|
2008
|
11 |
6 |
p. A520-
1 p.
|
artikel
|
| 405 |
PG119 THE COST-UTILITY OF LIVER DISEASE DIAGNOSIS: ASSESSING GP DECISIONS FOR PATIENTS WITH ABNORMAL LIVER FUNCTION TESTS AND NO OBVIOUS LIVER DISEASE
|
McLernon, DJ
|
|
2008
|
11 |
6 |
p. A524-
1 p.
|
artikel
|
| 406 |
PG11 THE DEVELOPMENT AND PERFORMANCE OF MODELS TO PREDICT RISK OF LIVER DISEASE DIAGNOSIS FOLLOWING LIVER FUNCTION TESTING IN PRIMARY CARE
|
McLernon, DJ
|
|
2008
|
11 |
6 |
p. A518-
1 p.
|
artikel
|
| 407 |
PG16 THE MANAGEMENT OF GASTRO OESOPHAGEAL REFLUX DISEASE IN SPAIN: A BUDGET IMPACT ANALYSIS TO ESTIMATE COSTS DUETO A GREATER PANTOPRAZOL IV PENETRATION
|
Darba, J
|
|
2008
|
11 |
6 |
p. A519-
1 p.
|
artikel
|
| 408 |
PG12 UNCONTROLLED GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD): FINDINGS FROM A UK MULTICENTRE, CROSS-SECTIONAL STUDY
|
Borrill, J
|
|
2008
|
11 |
6 |
p. A518-
1 p.
|
artikel
|
| 409 |
PHC5 A COST-EFFECTIVENESS ANALYSIS OF RHBMP-2 IN SPINE FUSION SURGERY IN THE NETHERLANDS
|
Van Genugten, M
|
|
2008
|
11 |
6 |
p. A532-A533
nvt p.
|
artikel
|
| 410 |
PHC13 CHANGINGTHE SURGICALWOUND CLOSURE MANAGEMENT PATHWAY: TIME AND SUPPLIES WITH PRINEO VS. STANDARD OF CARE FOR ABDOMINOPLASTY SURGERY IN GERMANY
|
De Cock, E
|
|
2008
|
11 |
6 |
p. A535-
1 p.
|
artikel
|
| 411 |
PHC12 COMPARING TIME AND SUPPLIES USAGE ASSOCIATED WITH A NEW SKIN CLOSURE DEVICE VS. STANDARD OF CARE WOUND CLOSURE FOR ABDOMINOPLASTY SURGERY IN THE NETHERLANDS
|
Van Nooten, F
|
|
2008
|
11 |
6 |
p. A535-
1 p.
|
artikel
|
| 412 |
PHC3 COST AND QUALITY IMPROVEMENTS ASSOCIATED WITH MINIMALLY INVASIVE SURGERY (MIS) TOTAL HIP ARTHROPLASTY (THA)
|
Straumann, D
|
|
2008
|
11 |
6 |
p. A532-
1 p.
|
artikel
|
| 413 |
PHC4 COST-EFFECTIVENESS OF HARMONIC SCALPEL USE VERSUS CONVENTIONALTOTAL THYROIDECTOMY
|
Cicchetti, A
|
|
2008
|
11 |
6 |
p. A532-
1 p.
|
artikel
|
| 414 |
PHC7 COST-EFFECTIVENESS OF RIVAROXABANVERSUS ENOXAPARIN FORTHROMBOPROPHYLAXIS AFTER TOTAL HIP REPLACEMENT IN CANADA
|
Diamantopoulos, A
|
|
2008
|
11 |
6 |
p. A533-
1 p.
|
artikel
|
| 415 |
PHC6 COST-EFFECTIVENESS OF RIVAROXABANVERSUS ENOXAPARIN FORTHROMBOPROPHYLAXIS AFTER TOTAL HIP REPLACEMENT IN SPAIN
|
Diamantopoulos, A
|
|
2008
|
11 |
6 |
p. A533-
1 p.
|
artikel
|
| 416 |
PHC9 COST-EFFECTIVENESS OF RIVAROXABANVERSUS ENOXAPARIN FORTHROMBOPROPHYLAXIS AFTER TOTAL HIP REPLACEMENT IN THE UK
|
Diamantopoulos, A
|
|
2008
|
11 |
6 |
p. A534-
1 p.
|
artikel
|
| 417 |
PHC8 COST-EFFECTIVENESS OF RIVAROXABANVERSUS ENOXAPARIN FORTHROMBOPROPHYLAXIS AFTER TOTAL KNEE REPLACEMENT IN THE UK AND SPAIN
|
Diamantopoulos, A
|
|
2008
|
11 |
6 |
p. A533-A534
nvt p.
|
artikel
|
| 418 |
PHC2 IMPACT OF LOCAL HAEMOSTATIC AGENTS IN ABDOMINAL SURGERY ON HOSPITAL BUDGET
|
Krysanov, I
|
|
2008
|
11 |
6 |
p. A531-A532
nvt p.
|
artikel
|
| 419 |
PHC14 ORGAN SHORTAGE IN TRANSPLANTATION MEDICINE: WHOSEVALUES AND ON WHAT BASIS SHOULD ORGAN PROCUREMENT BE ORGANISED?
|
Naujoks, C
|
|
2008
|
11 |
6 |
p. A535-A536
nvt p.
|
artikel
|
| 420 |
PHC10 PROPHYLAXIS WITH RIVAROXABAN AGAINST VENOUS THROMBOEMBOLISM (VTE):A COST-CONSEQUENCE ANALYSIS FROM THE PERSPECTIVE OF THE ITALIAN HEALTH CARE SERVICE
|
Negrini, C
|
|
2008
|
11 |
6 |
p. A534-
1 p.
|
artikel
|
| 421 |
PHC11 THE BURDEN OF ADHESIOLYSIS DURING LAPAROSCOPIC GYNECOLOGICAL SURGERY
|
Crowe, AM
|
|
2008
|
11 |
6 |
p. A534-A535
nvt p.
|
artikel
|
| 422 |
PHC1 TREATMENT OF DISCOGENIC LOW BACK PAIN WITH INTRADISCAL ELECTROTHERMAL THERAPY [IDET], A MINIMALLY INVASIVE, LOW COST ALTERNATIVE TO OPEN SURGERY: A PROSPECTIVE 24-MONTH OUTCOMES STUDY IN 50 CONSECUTIVE PATIENTS
|
Assietti, R
|
|
2008
|
11 |
6 |
p. A531-
1 p.
|
artikel
|
| 423 |
PHP28 A COMPARISON OF HIGH-COST HEALTH CARE PROGRAMS AVAILABLE IN THE BRAZILIAN PUBLIC HEALTH CARE SYSTEM
|
Saggia, MG
|
|
2008
|
11 |
6 |
p. A371-
1 p.
|
artikel
|
| 424 |
PHP8 ADVERSE DRUG REACTIONS IN GERMANY: COST ANALYSIS OF INTERNAL MEDICINE HOSPITALIZATIONS
|
Rottenkolber, D
|
|
2008
|
11 |
6 |
p. A364-A365
nvt p.
|
artikel
|
| 425 |
PHP41 ANALYSIS OF CLINICAL PHARMACISTS' INTERVENTIONS IN A UNIVERSITY TEACHING HOSPITAL IN OMAN
|
Al Zadjali, B
|
|
2008
|
11 |
6 |
p. A374-A375
nvt p.
|
artikel
|
| 426 |
PHP49 ANALYSIS OF FACTORS ASSOCIATED WITH REIMBURSEMENT DECISION MAKING IN HEALTHTECHNOLOGY ASSESSMENT AGENCIES (HTA)
|
Bending, MW
|
|
2008
|
11 |
6 |
p. A377-
1 p.
|
artikel
|
| 427 |
PHP54 ANTIBIOTICS CONSUMPTION IN THE REPUBLIC OF SERBIA IN 2004, 2005, 2006 AND 2007
|
Radonjic, V
|
|
2008
|
11 |
6 |
p. A378-
1 p.
|
artikel
|
| 428 |
PHP47 ASSOCIATION BETWEEN HEALTH-RELATED QUALITY OF LIFE AND HEALTH SERVICE UTILIZATION AMONG PRIMARY CARE PATIENTS
|
Chen, T
|
|
2008
|
11 |
6 |
p. A376-
1 p.
|
artikel
|
| 429 |
PHP46 CATEGORISING RESEARCH: WHERE IS THE FOCUS?
|
Samuels, E
|
|
2008
|
11 |
6 |
p. A376-
1 p.
|
artikel
|
| 430 |
PHP23 CHARACTERISTICS OF UTILIZATION OF PRIMARY CARE OF GENERAL PRACTITIONERS IN COUNTY BARANYA IN HUNGARY
|
Sebestyen, A
|
|
2008
|
11 |
6 |
p. A369-
1 p.
|
artikel
|
| 431 |
PHP55 CHIRALTY AND HOSPITAL FORMULARY: A SECOND LIFE FOR A BLOCKBUSTER
|
Vernaz-Hegi, N
|
|
2008
|
11 |
6 |
p. A379-
1 p.
|
artikel
|
| 432 |
PHP6 CLINICAL AND ECONOMIC OUTCOME OF MECHANICALLY VENTILATED PATIENTS UNDER DRG 483 IN SPAIN: A POPULATION-BASED STUDY
|
Bouza, C
|
|
2008
|
11 |
6 |
p. A364-
1 p.
|
artikel
|
| 433 |
PHP22 COMPARATIVE ANALYSIS OF HOSPITAL BED CAPACITITES OF OLD (EU-15) AND NEW (EU-12) MEMBERSTATES OF THE EUROPEAN UNION
|
Vas, G
|
|
2008
|
11 |
6 |
p. A369-
1 p.
|
artikel
|
| 434 |
PHP7 COMPARING THE ACTUAL HOSPITAL COST OF A PATIENT WITH OESOPHAGEAL CANCERTO NORMATIVE DRG REIMBURSEMENT
|
Varga, S
|
|
2008
|
11 |
6 |
p. A364-
1 p.
|
artikel
|
| 435 |
PHP18 COMPARISON OF COST/QALY RATIO IN DIAGNOSTIC AND THERAPEUTIC DEVICES OR DRUGS
|
Rodríguez Bezos, D
|
|
2008
|
11 |
6 |
p. A367-A368
nvt p.
|
artikel
|
| 436 |
PHP60 COMPARISON OF THE HEALTH ECONOMIC GUIDELINES OF THE CZECH REPUBLIC, HUNGARY, POLAND AND THE SLOVAK REPUBLIC
|
Petríková, A
|
|
2008
|
11 |
6 |
p. A380-
1 p.
|
artikel
|
| 437 |
PHP2 CONSUMERS' PERCEPTIONS OF DRUG EFFECTIVENESS AND PRICES IN GREECE
|
Tsiantou, V
|
|
2008
|
11 |
6 |
p. A362-A363
nvt p.
|
artikel
|
| 438 |
PHP32 COST-BENEFIT ANALYSIS OF PUBLIC HOSPITAL DEVELOPMENT
|
Kalo, Z
|
|
2008
|
11 |
6 |
p. A372-
1 p.
|
artikel
|
| 439 |
PHP30 COST DRIVERS IN THE PHARMACEUTICAL MARKET IN GERMANY IN 2007
|
Häussler, B
|
|
2008
|
11 |
6 |
p. A371-
1 p.
|
artikel
|
| 440 |
PHP38 COST-EFFECTIVENESS OF PREVENTION: OPPORTUNITIES FOR PUBLIC HEALTH POLICY IN THE NETHERLANDS?
|
Van den Berg, M
|
|
2008
|
11 |
6 |
p. A373-A374
nvt p.
|
artikel
|
| 441 |
PHP34 COSTS ASSOCIATED TO ADDITIONAL TEMPORAL SICK LEAVE DAYS IN THE IMSS
|
Contreras-Hernandez, I
|
|
2008
|
11 |
6 |
p. A372-A373
nvt p.
|
artikel
|
| 442 |
PHP9 DELAY OF DECISION-MAKING ON PHARMACEUTICAL REIMBURSEMENT IN NORMAL PROCEDURE IN HUNGARY
|
Nagy, Z
|
|
2008
|
11 |
6 |
p. A365-
1 p.
|
artikel
|
| 443 |
PHP15 DETERMINANTS OF PHARMACEUTICAL CONSUMPTION IN A GENERAL POPULATION
|
Pappa, E
|
|
2008
|
11 |
6 |
p. A366-A367
nvt p.
|
artikel
|
| 444 |
PHP25 EVALUATING AN ONLINE FREEWARE CALCULATOR AND PLOTTER FOR ANALYZING COST EFFECTIVENESS DATA FOR FORMULARY DRUG CLASSES
|
McGhan, WF
|
|
2008
|
11 |
6 |
p. A370-
1 p.
|
artikel
|
| 445 |
PHP58 EVALUATING THE PERFORMANCE OF AN INNOVATIVE PUBLIC HEALTH INSURANCE: THE CASE OF A DECENTRALIZED PROVINCE IN ARGENTINA
|
Maceira, DA
|
|
2008
|
11 |
6 |
p. A380-
1 p.
|
artikel
|
| 446 |
PHP52 EVALUATION OF CURRENT ASSESSMENTS OF WORLDWIDE AGENCIES FOR HEALTHTECHNOLGY ASSESSMENT
|
Wiebinga, C
|
|
2008
|
11 |
6 |
p. A378-
1 p.
|
artikel
|
| 447 |
PHP42 EVALUATION OF THE AFTERNOON OUTPATIENT CLINICS OPERATION AT THE UNIVERSITY HOSPITAL IN LARISA
|
Geitona, M
|
|
2008
|
11 |
6 |
p. A375-
1 p.
|
artikel
|
| 448 |
PHP53 EXPANDINGTHE PHYSICIAN QUALITY REPORTING INITIATIVE (PQRI): MEASURES GROUPS AND REGISTRY-BASED REPORTING
|
Pierce, CA
|
|
2008
|
11 |
6 |
p. A378-
1 p.
|
artikel
|
| 449 |
PHP43 GREEK HOSPITALS' SUPPLY CHAIN MANAGEMENT
|
Perros, G
|
|
2008
|
11 |
6 |
p. A375-
1 p.
|
artikel
|
| 450 |
PHP37 HEALTH EXPENDITURES AND PERFORMANCE.THE ANÁLISIS OF THE FINANCIAL GAPS IN BUENOS AIRES PROVINCE
|
Maceira, DA
|
|
2008
|
11 |
6 |
p. A373-
1 p.
|
artikel
|
| 451 |
PHP5 HEALTH LITERACY—AN ECONOMIC PERSPECTIVE: A SYSTEMATIC REVIEW
|
Eichler, K
|
|
2008
|
11 |
6 |
p. A363-A364
nvt p.
|
artikel
|
| 452 |
PHP56 IMPACT OF ICU SEDATION PRACTICE ON PATIENT MORBIDITY, COST AND HOSPITAL RESOURCE USE: A SYSTEMATIC REVIEW
|
Jackson, D
|
|
2008
|
11 |
6 |
p. A379-
1 p.
|
artikel
|
| 453 |
PHP57 INAPPROPRIATE SEDATION IN ICUS: EVIDENCE FROM THE LITERATURE
|
Jackson, D
|
|
2008
|
11 |
6 |
p. A379-
1 p.
|
artikel
|
| 454 |
PHP44 IN EQUALITIES IN THE FINANCING OF DRUGS AMONG AUTONOMOUS REGIONS IN SPAIN
|
Badia, X
|
|
2008
|
11 |
6 |
p. A375-
1 p.
|
artikel
|
| 455 |
PHP33 INFLUENCE OF MORBIDITY ON THE USE OF RESOURCES IN PRIMARY CARE: RETROSPECTIVE APPLICATION OF ACG AT A SPANISH INTERREGIONAL LEVEL
|
Sicras-Mainar, A
|
|
2008
|
11 |
6 |
p. A372-
1 p.
|
artikel
|
| 456 |
PHP3 INNOVATIVE HEALTHTECHNOLOGIES IN THE “ANTI-AGING-MEDICINE” FIELD: RESULTS FROM A SYSTEMATIC HORIZON SCANNING
|
Storz, P
|
|
2008
|
11 |
6 |
p. A363-
1 p.
|
artikel
|
| 457 |
PHP40 INVESTIGATING THE PROMOTION OF HEALTH BEHAVIOR AND HEALTH-RELATED QUALITY OF LIFE BY APPLYING SELF-DETERMINATION THEORY: USING “EXERCISE” AS AN EXAMPLE
|
Lin, WL
|
|
2008
|
11 |
6 |
p. A374-
1 p.
|
artikel
|
| 458 |
PHP31 IS PATENT PROTECTION CREATING OPPORTUNITY FOR INNOVATION?—THE ALENDRONATE CASE IN BELGIUM
|
Arickx, F
|
|
2008
|
11 |
6 |
p. A371-A372
nvt p.
|
artikel
|
| 459 |
PHP59 LABEL CLAIMS BASED ON PATIENT REPORTED OUTCOMES IN EMEA AND FDA APPROVALS SINCE 2000
|
Scott, J
|
|
2008
|
11 |
6 |
p. A380-
1 p.
|
artikel
|
| 460 |
PHP39 LINKING HOSPITAL ADMISSION DATA INTO PRIMARY CARE RECORDS WITHIN THE GENERAL PRACTICE RESEARCH DATABASE
|
Williams, TJ
|
|
2008
|
11 |
6 |
p. A374-
1 p.
|
artikel
|
| 461 |
PHP13 MARKET AUTHORIZATION (MA) AND REIMBURSEMENT: ANALYSIS OF THE POST-MA TIMELINES AND THE ACCESS TO NEW MEDICINES IN BELGIUM
|
Arickx, F
|
|
2008
|
11 |
6 |
p. A366-
1 p.
|
artikel
|
| 462 |
PHP29 MICROCOSTING STUDY OF THE DAILY ICU COSTS IN THREE COUNTRIES
|
Tan, S
|
|
2008
|
11 |
6 |
p. A371-
1 p.
|
artikel
|
| 463 |
PHP51 OTHER HEALTHTECHNOLOGY ASSESSMENT GROUPS OPERATING IN ENGLAND; ITS NOT JUST NICETHAT NEEDS TO BE TAKEN INTO CONSIDERATION
|
Way, J
|
|
2008
|
11 |
6 |
p. A377-A378
nvt p.
|
artikel
|
| 464 |
PHP16 OUTHOSPITAL DRUG CONSUMPTION IN MONTENEGRO IN 2007
|
Tomic, Z
|
|
2008
|
11 |
6 |
p. A367-
1 p.
|
artikel
|
| 465 |
PHP4 PATIENT PREFERENCES TOWARD HEALTH SERVICES PROVIDED BY THE GENERAL PRACTIONER
|
Pezij, JW
|
|
2008
|
11 |
6 |
p. A363-
1 p.
|
artikel
|
| 466 |
PHP1 PATIENTS' PREFERENCES FOR AND PRICE ELASTICITY OF GENERIC AND BRANDED OVER-THE-COUNTER MEDICINES—AN ADAPTIVE CONJOINT ANALYSIS (ACA) APPROACH
|
Halme, ML
|
|
2008
|
11 |
6 |
p. A362-
1 p.
|
artikel
|
| 467 |
PHP36 PERFORMANCE OF YOUR 5-STAR HOSPITALS
|
Baser, O
|
|
2008
|
11 |
6 |
p. A373-
1 p.
|
artikel
|
| 468 |
PHP35 PHARMACEUTICAL EXPENDITURE IN GREECE 1980–2006
|
Karampli, E
|
|
2008
|
11 |
6 |
p. A373-
1 p.
|
artikel
|
| 469 |
PHP10 PHARMACY AND HOSPITAL MARKET PERFORMANCE INDICATORS IN FINLAND 1995–2007
|
Jormanainen, V
|
|
2008
|
11 |
6 |
p. A365-
1 p.
|
artikel
|
| 470 |
PHP19 REGIONAL MARKET ACCESS IN EQUALITIES FOR NEW ONCOLOGY DRUGS IN SPAIN
|
Vieta, A
|
|
2008
|
11 |
6 |
p. A368-
1 p.
|
artikel
|
| 471 |
PHP17 SOURCES OF INFORMATION ON DRUGS USED BY GENERAL PRACTITIONERS IN POLAND
|
Ulanowski, P
|
|
2008
|
11 |
6 |
p. A367-
1 p.
|
artikel
|
| 472 |
PHP12 THE BELGIAN REIMBURSEMENT PROCEDURE (BRP):ARE ADDED THE RAPEUTIC VALUE (ATV) AND ICER AFFECTING THE DRUG REIMBURSEMENT DECISION (DRD)?
|
Verplanken, P
|
|
2008
|
11 |
6 |
p. A366-
1 p.
|
artikel
|
| 473 |
PHP14 THE COMPETITIVE ACQUISITION PROGRAM (CAP): WHERE IS IT AFTER TWO YEARS?
|
Pierce, CA
|
|
2008
|
11 |
6 |
p. A366-
1 p.
|
artikel
|
| 474 |
PHP20 THE EFFECT OF THE INTRODUCTION OF HOSPITAL DAILY FEE ON THE NUMBER OF ADMISSIONS TO ACUTE CARE HOSPITALWARDS IN HUNGARY
|
Nagy, J
|
|
2008
|
11 |
6 |
p. A368-
1 p.
|
artikel
|
| 475 |
PHP21 THE EFFECT OF THE INTRODUCTION OF VISIT FEE ON THE NUMBER OF PATIENT-VISITS TO OUTPATIENT CARE DEPARTMENTS IN HUNGARY
|
Boncz, I
|
|
2008
|
11 |
6 |
p. A368-A369
nvt p.
|
artikel
|
| 476 |
PHP48 THE EFFECTS OF NICE HTA'S ON PRESCRIPTION VOLUME, AVERAGE RETAIL PRICE AND AVERAGE OUT-OF-POCKET COSTS OF DRUGS DEEMED MEDICALLY NECESSARY FOR MEDICARE PART D REIMBURSEMENT IN THE UNITED STATES
|
Sepulveda, B
|
|
2008
|
11 |
6 |
p. A376-A377
nvt p.
|
artikel
|
| 477 |
PHP45 THE REIMBURSEMENT OF ORPHAN DRUGS ACROSS EUROPE
|
Nixon, F
|
|
2008
|
11 |
6 |
p. A375-A376
nvt p.
|
artikel
|
| 478 |
PHP50 UNIVERSAL STEPS IN PERFORMING EARLY-STAGE MEDICAL TECHNOLOGY ASSESSMENT
|
O'Prinsen, AC
|
|
2008
|
11 |
6 |
p. A377-
1 p.
|
artikel
|
| 479 |
PHP24 USE OF THE AMCP FORMAT IN THE U.S.:A NATIONAL SURVEY OF HEALTH PLANS
|
Neumann, PJ
|
|
2008
|
11 |
6 |
p. A369-
1 p.
|
artikel
|
| 480 |
PIH13 ASSESSING THE INCREASED MATERNAL AND NEONATAL HEALTH CARE COSTS ASSOCIATED WITH PREECLAMPSIA
|
Chawla, A
|
|
2008
|
11 |
6 |
p. A424-
1 p.
|
artikel
|
| 481 |
PIH24 ASSESSMENT OF CURRENT CLINICAL PRACTICE AMONG PHYSICIANS AND SEX THERAPISTS REGARDING ERECTILE DYSFUNCTION (ED) TREATMENT INITIATION WITH PHOSPHODIESTERASE-5 INHIBITORS (PDE5I)
|
Schnetzler, G
|
|
2008
|
11 |
6 |
p. A427-A428
nvt p.
|
artikel
|
| 482 |
PIH1 CHANGES IN PELVIC FLOOR MUSCLE STRENGTH, ITS DURATION AND ITS RELAXATION ABILITY DURING PREGNANCY
|
Hock, M
|
|
2008
|
11 |
6 |
p. A420-A421
nvt p.
|
artikel
|
| 483 |
PIH9 COST-EFFECTIVENESS OF LEVONORGESTREL-RELEASING INTRAUTERINE SYSTEM (LNG-IUS) FOR THE TREATMENT OF DYSFUNCTIONAL UTERINE BLEEDING (DUB) IN SPAIN
|
Lete, I
|
|
2008
|
11 |
6 |
p. A423-
1 p.
|
artikel
|
| 484 |
PIH8 COST-EFFECTIVENESS OF PLANNED CAESAREAN SECTION VERSUS PLANNEDVAGINAL DELIVERY IN BREECH-PRESENTATION PREGNANCIES AT TERM
|
Vijgen, SM
|
|
2008
|
11 |
6 |
p. A423-
1 p.
|
artikel
|
| 485 |
PIH11 COST OF INSOMNIA IN PATIENTS OVER 54 YEARS IN SWEDEN
|
Justo, N
|
|
2008
|
11 |
6 |
p. A423-A424
nvt p.
|
artikel
|
| 486 |
PIH14 COSTS AND OUTCOMES ASSOCIATED WITH IN VITRO FERTILISATION (IVF) OR INTRACYTOPLASMIC SPERM INJECTION (ICSI) USING RECOMBINANT FOLLICLE STIMULATING HORMONE (RFSH)
|
Holman, AJ
|
|
2008
|
11 |
6 |
p. A424-A425
nvt p.
|
artikel
|
| 487 |
PIH7 ECONOMIC ANALYSIS OF TREATMENT WITH IUI-COH VERSUS 6 MONTHS DELAY OF TREATMENT IN COUPLES WITH UNEXPLAINED SUBFERTILITY
|
Mol, B
|
|
2008
|
11 |
6 |
p. A422-
1 p.
|
artikel
|
| 488 |
PIH21 EFFICACY OF TREATMENT AND PATIENT SATISFACTION IN TREATMENT OF CLIMACTERIC DISORDERS WITH SOY ISOFLAVONES: FRENCH APPROCH
|
Mares, P
|
|
2008
|
11 |
6 |
p. A426-A427
nvt p.
|
artikel
|
| 489 |
PIH3 EPIDEMIOLOGICAL SURVEILLANCE OF CONGENITAL MALFORMATIONS IN 52,744 BIRTHS COLOMBIAN BETWEEN APRIL 2001 AND JANUARY 2008
|
Zarante, I
|
|
2008
|
11 |
6 |
p. A421-
1 p.
|
artikel
|
| 490 |
PIH15 HEALTH-RELATED QUALITY OF LIFE IN ADOLESCENTS WITH THE PRADER-WILLI SYNDROME
|
Sintonen, H
|
|
2008
|
11 |
6 |
p. A425-
1 p.
|
artikel
|
| 491 |
PIH5 INCIDENCE OF MAJOR MALFORMATIONS IN INFANTS FOLLOWING ANTIDEPRESSANT EXPOSURE IN PREGNANCY: RESULTS OF A LARGE PROSPECTIVE COHORT STUDY
|
Einarson, A
|
|
2008
|
11 |
6 |
p. A422-
1 p.
|
artikel
|
| 492 |
PIH12 INPATIENT LENGTH OF STAY AND TOTAL COSTS OF ILLNESSES OF PRESSING CONCERN FOR ASIAN-AMERICAN AND PACIFIC ISLANDERWOMEN IN THE UNITED STATES
|
Candrilli, SD
|
|
2008
|
11 |
6 |
p. A424-
1 p.
|
artikel
|
| 493 |
PIH23 MEDICATION COSTS IN ELDERLY PATIENTS
|
Mendes, Z
|
|
2008
|
11 |
6 |
p. A427-
1 p.
|
artikel
|
| 494 |
PIH2 ONE DAY NATIONAL SURVEY ON PREVALENCE OF MALE SEXUAL DYSFUNCTION, AMONG MEN CONSULTING UROLOGISTS
|
Droupy, S
|
|
2008
|
11 |
6 |
p. A421-
1 p.
|
artikel
|
| 495 |
PIH22 PRICE-ELASTICITY OF DEMAND FOR INFERTILITY SERVICES IN GERMANY
|
Connolly, M
|
|
2008
|
11 |
6 |
p. A427-
1 p.
|
artikel
|
| 496 |
PIH16 PSYCHOMETRIC PERFORMANCE OF THE CHILDREN'S DERMATOLOGY QUALITY OF LIFE INDEX
|
Malhan, S
|
|
2008
|
11 |
6 |
p. A425-
1 p.
|
artikel
|
| 497 |
PIH18 RELIABILITY, AND VALIDITY OF THE FATIGUE SYMPTOM INVENTORY
|
Oksuz, E
|
|
2008
|
11 |
6 |
p. A426-
1 p.
|
artikel
|
| 498 |
PIH6 SYSTEMATIC REVIEW OF ECONOMIC EVALUATION STUDIES IN OBSTETRICS, GYNAECOLOGY AND REPRODUCTIVE MEDICINE
|
Vijgen, SM
|
|
2008
|
11 |
6 |
p. A422-
1 p.
|
artikel
|
| 499 |
PIH19 THE ASSOCIATION OF BODY MASS INDEX ON HEALTH RELATED QUALITY OF LIFE IN THE GENERAL ADULT POPULATION IN ENGLAND
|
Søltoft, F
|
|
2008
|
11 |
6 |
p. A426-
1 p.
|
artikel
|
| 500 |
PIH10 THE COST EFFECTIVENESS OF SCHEDULED MAINTENANCE TREATMENT WITH INFLIXIMAB AMONG PAEDIATRIC PATIENTS WITH CROHN'S DISEASE IN SCOTLAND
|
Punekar, YS
|
|
2008
|
11 |
6 |
p. A423-
1 p.
|
artikel
|
| 501 |
PIH17 TURKISH CULTURAL ADAPTATION AND VALIDATION OF THE MENOPAUSE-SPECIFIC QUALITY OF LIFE QUESTIONNAIRE
|
Malhan, S
|
|
2008
|
11 |
6 |
p. A425-
1 p.
|
artikel
|
| 502 |
PIH20 WEIGHT-RELATED MORBIDITY AND FAMILY DISRUPTION FOLLOWING PEDIATRIC EMERGENCY DEPARTMENT TREATMENT (PED) OF ACUTE MINOR INJURY
|
Hainsworth, KR
|
|
2008
|
11 |
6 |
p. A426-
1 p.
|
artikel
|
| 503 |
PIN1 A BAYESIAN META-ANALYSIS OF THE EFFICACY OF SIX ANTIMICROBIAL AGENTS FOR CONFIRMED STAPHYLOCOCCUS AUREUS COMPLICATED SKIN AND SOFT-TISSUE INFECTIONS (CSSTIS)
|
Logman, JFS
|
|
2008
|
11 |
6 |
p. A428-
1 p.
|
artikel
|
| 504 |
PIN54 ADAPTATION & CALIBRATION OF A UK MODEL OF MENINGOCOCCAL DISEASE TO THE US SETTING
|
Aballéa, S
|
|
2008
|
11 |
6 |
p. A445-A446
nvt p.
|
artikel
|
| 505 |
PIN4 A MARKOV MODELTO ESTIMATE THE IMPACT ON MORBIDITY AND MORTALITY IN PATIENTS WITH CHRONIC HEPATITIS C (CHC) AND NORMALTRANSAMINASES (ALT-N) TREATED WITH PEGYLATED BITHERAPY
|
Deuffic-Burban, S
|
|
2008
|
11 |
6 |
p. A429-
1 p.
|
artikel
|
| 506 |
PIN18 ANALYSIS OF COST-EFFECTIVENESS OF ITRACONAZOLE IN THE TREATMENT OF INVASIVE ASPERGILLOSIS IN TURKISH SETTING
|
Kanbur, B
|
|
2008
|
11 |
6 |
p. A433-A434
nvt p.
|
artikel
|
| 507 |
PIN6 AN OBSERVATIONAL HEALTH ECONOMIC ANALYSIS OF THE COMBINED THERAPY WITH PEGINTERFERON ALPHA-2A (PEGASYS®) AND RIBAVIRIN IN PATIENTS WITH CHRONIC C HEPATITIS (CHC) IN A REAL LIFE SETTING
|
Fagnani, F
|
|
2008
|
11 |
6 |
p. A430-
1 p.
|
artikel
|
| 508 |
PIN50 A REVIEW OF THE FACTORS AFFECTING PUBLIC FUNDING OF VACCINES
|
De Abreu, Lourenco R
|
|
2008
|
11 |
6 |
p. A444-
1 p.
|
artikel
|
| 509 |
PIN3 A SIMULATION-BASED APPROACH TO MODELING THE EFFECTS OF INTERVENTION STRATEGIES ON THE SPREAD OF MENINGOCOCCAL MENINGITIS
|
Smolen, HJ
|
|
2008
|
11 |
6 |
p. A428-A429
nvt p.
|
artikel
|
| 510 |
PIN2 ASSESSING ANTIMICROBIAL SUCCESS RATES IN THE TREATMENT OF METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS (MRSA) COMPLICATED SKIN AND SOFT TISSUE INFECTIONS (CSSTI):A BAYESIAN META-ANALYSIS
|
Logman, JFS
|
|
2008
|
11 |
6 |
p. A428-
1 p.
|
artikel
|
| 511 |
PIN9 BUDGET IMPACT ANALYSIS OF INTRODUCING ROUTINE VACCINATION WITH A QUADRIVALENT HPV-VACCINE IN NORWAY
|
Kristensen, FKO
|
|
2008
|
11 |
6 |
p. A431-
1 p.
|
artikel
|
| 512 |
PIN34 COMPARISON OF GENERIC AND BRAND NAME ANTIBIOTIC USAGE IN TURKEY
|
Malhan, S
|
|
2008
|
11 |
6 |
p. A439-
1 p.
|
artikel
|
| 513 |
PIN27 COST-EFFECTIVENESS ANALYSIS OF CASPOFUNGIN VERSUS AMPHOTERICIN B, VORICONAZOLE, AND ANIDULAFUNGIN IN THE TREATMENT OF INVASIVE CANDIDIASIS
|
Verheggen, BG
|
|
2008
|
11 |
6 |
p. A437-
1 p.
|
artikel
|
| 514 |
PIN30 COST-EFFECTIVENESS ANALYSIS OF DROTRECOGIN ALFA (ACTIVATED; DAA) AS A TREATMENT FOR SEVERE SEPSIS WITH MULTIPLE ORGAN FAILURE (MOF) IN POLAND
|
Kuzma, J
|
|
2008
|
11 |
6 |
p. A438-
1 p.
|
artikel
|
| 515 |
PIN22 COST-EFFECTIVENESS ANALYSIS OF VACCINATION AGAINST ROTAVIRUS WITH RIX4414 IN FRANCE
|
Standaert, BA
|
|
2008
|
11 |
6 |
p. A435-
1 p.
|
artikel
|
| 516 |
PIN23 COST-EFFECTIVENESS ANALYSIS OF 7-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN TAIWAN: TRANSMISSION DYNAMIC MODEL-BASED EVALUATIONS
|
Fann, CS
|
|
2008
|
11 |
6 |
p. A435-
1 p.
|
artikel
|
| 517 |
PIN16 COST-EFFECTIVENESS OF A PROPHYLACTIC HUMAN PAPILLOMA VIRUS 16/18 VACCINE FOR 12-YEAR-OLD DUTCH GIRLS
|
Westra, TA
|
|
2008
|
11 |
6 |
p. A433-
1 p.
|
artikel
|
| 518 |
PIN12 COST-EFFECTIVENESS OF CERVARIX™, A PROPHYLACTIC CERVICAL CANCERVACCINE, IN SPAIN
|
Gauthier, A
|
|
2008
|
11 |
6 |
p. A431-A432
nvt p.
|
artikel
|
| 519 |
PIN55 COST-EFFECTIVENESS OF DARUNAVIR/RITONAVIR 600/100MG BID IN TREATMENT-EXPERIENCED, LPV/R-NAÏVE, PI-RESISTANT, HIV-INFECTED ADULTS IN THE UNITED KINGDOM, BELGIUM, ITALY AND SWEDEN
|
Moeremans, K
|
|
2008
|
11 |
6 |
p. A435-A436
nvt p.
|
artikel
|
| 520 |
PIN17 COST-EFFECTIVENESS OF MASS VACCINATION FOR VARICELLA IN FRANCE WITH MMRV VERSUS MMR
|
Littlewood, K
|
|
2008
|
11 |
6 |
p. A433-
1 p.
|
artikel
|
| 521 |
PIN15 COST-EFFECTIVENESS OF PALIVIZUMAB IN THE PROPHYLAXIS OF SEVERE BRONCHIOLITIS CAUSED BY RSV: RESULTS OF A DECISION MODEL WITH LOCAL DATA
|
García-Altés, A
|
|
2008
|
11 |
6 |
p. A432-A433
nvt p.
|
artikel
|
| 522 |
PIN11 COST-EFFECTIVENESS OF QUADRIVALENT HPV VACCINATION IN FINLAND
|
Väänänen, JJP
|
|
2008
|
11 |
6 |
p. A431-
1 p.
|
artikel
|
| 523 |
PIN20 COST-EFFECTIVENESS OF SURGICAL INTERVENTION FOR THERAPY-INDUCED FACIAL LIPOATROPHY IN HIV-INFECTED PATIENTS
|
Massella, M
|
|
2008
|
11 |
6 |
p. A434-
1 p.
|
artikel
|
| 524 |
PIN26 COST-EFFECTIVENESS OF TREATMENT WITH PEGASYS/COPEGUS IN HIV/HCV CO-INFECTED PATIENTS IN PORTUGAL
|
Macedo, A
|
|
2008
|
11 |
6 |
p. A436-A437
nvt p.
|
artikel
|
| 525 |
PIN25 COST-EFFECTIVENESS OF 7-VALENT PNEUMOCOCCAL CONJUGATE VACCINE (PCV) INCLUDING HERD PROTECTION IN TURKEY
|
Türel, Ö
|
|
2008
|
11 |
6 |
p. A436-
1 p.
|
artikel
|
| 526 |
PIN33 COST-MINIMIZATION ANALYSIS OF DAPTOMYCIN FOR MRSA SKIN AND SOFT TISSUES INFECTIONS IN BRAZILIAN PRIVATE SECTOR
|
Bueno, RLP
|
|
2008
|
11 |
6 |
p. A439-
1 p.
|
artikel
|
| 527 |
PIN31 COST-MINIMIZATION ANALYSIS OF ETRAVIRINE AND RALTEGRAVIR, TWO NEW HIV TREATMENTS FOR TREATMENT-EXPERIENCED PATIENTS
|
Martin, SC
|
|
2008
|
11 |
6 |
p. A438-
1 p.
|
artikel
|
| 528 |
PIN32 COSTS OF INTERMITTENT VERSUS CONTINUOUS ANTIRETROVIRAL THERAPY IN PATIENTS WITH CONTROLLED HIV INFECTION.A SUBSTUDY OF THE ANRS 106 WINDOW TRIAL
|
Charreau, I
|
|
2008
|
11 |
6 |
p. A438-A439
nvt p.
|
artikel
|
| 529 |
PIN41 DEVELOPING AN ECONOMIC MODEL OF GRAM+ COMPLICATED SKIN AND SOFT TISSUE INFECTIONS (CSSTI) FOR INPATIENT AND OUTPATIENT TREATMENT SETTINGS
|
Stephens, JM
|
|
2008
|
11 |
6 |
p. A441-
1 p.
|
artikel
|
| 530 |
PIN43 DIFFERENCE IN HEALTH CARE UTILIZATION IN EUROPE BETWEENTREATMENT-NAÏVE PATIENTS WITH CHRONIC HEPATITIS C AND PATIENTSWHO FAILED PRIOR THERAPY
|
Zhang, H
|
|
2008
|
11 |
6 |
p. A442-
1 p.
|
artikel
|
| 531 |
PIN42 DIRECT MEDICAL COSTS AND PRODUCTIVITY LOSS ASSOCIATED WITH VENOUS LEG ULCER
|
Chen, S
|
|
2008
|
11 |
6 |
p. A441-A442
nvt p.
|
artikel
|
| 532 |
PIN21 ECONOMICAL EVALUATION OF ETRAVIRINE IN TREATMENT-EXPERIENCED HIV-1-INFECTED PATIENTS BASED ON DUET TRIALS
|
Avxentyeva, M
|
|
2008
|
11 |
6 |
p. A434-A435
nvt p.
|
artikel
|
| 533 |
PIN13 ECONOMIC ANALYSIS OF MICAFUNGIN VERSUS LIPOSOMAL AMPHOTERICIN B FOR TREATMENT OF CANDIDAEMIA AND INVASIVE CANDIDIASIS IN ITALY
|
Viale, P
|
|
2008
|
11 |
6 |
p. A432-
1 p.
|
artikel
|
| 534 |
PIN24 ECONOMIC AND CLINICAL IMPACT OF IMPLEMENTATION OF AN ACELLULAR PERTUSSIS VACCINE IN CANADA
|
Iskedjian, M
|
|
2008
|
11 |
6 |
p. A436-
1 p.
|
artikel
|
| 535 |
PIN29 EFFECTIVENESS AND COST-EFFECTIVENESS OF HEPATITIS C SCREENING—A SYSTEMATIC REVIEW
|
Sroczynski, G
|
|
2008
|
11 |
6 |
p. A437-A438
nvt p.
|
artikel
|
| 536 |
PIN51 EVALUATION OF SEPSIS MANAGEMENT AND OUTCOMES AT A LARGE INNER-CITY ACADEMIC MEDICAL CENTER IN THE SURVIVING SEPSIS CAMPAIGN ERA
|
Ohuabunwo, CJ
|
|
2008
|
11 |
6 |
p. A444-A445
nvt p.
|
artikel
|
| 537 |
PIN37 GENITAL WARTS IN ITALY: A COST OF ILLNESS ANALYSIS
|
Bamfi, F
|
|
2008
|
11 |
6 |
p. A440-
1 p.
|
artikel
|
| 538 |
PIN35 HEALTH ECONOMIC ASSESSMENT OF A PRE-PANDEMIC INFLUENZA VACCINE FOR GERMANY
|
Postma, MJ
|
|
2008
|
11 |
6 |
p. A439-
1 p.
|
artikel
|
| 539 |
PIN46 HEALTH-RELATED QUALITY OF LIFE AMONG PATIENTS WITH VENOUS LEG ULCER
|
Chen, S
|
|
2008
|
11 |
6 |
p. A443-
1 p.
|
artikel
|
| 540 |
PIN44 IMPACT OF ETRAVIRINE ON HOSPITALIZATIONS AND HOSPITAL RELATED COSTS IN BELGIUM: 48-WEEK FINDINGS FROM POOLED DUETTRIALS
|
Martin, SC
|
|
2008
|
11 |
6 |
p. A442-
1 p.
|
artikel
|
| 541 |
PIN5 IMPACT OF MASS VACCINATION WITH MMRV VERSUS MMR IN FRANCE ON THE EPIDEMIOLOGY OF VARICELLA AND HERPES ZOSTER, USING A DYNAMIC TRANSMISSION MODEL
|
Vissers, D
|
|
2008
|
11 |
6 |
p. A429-
1 p.
|
artikel
|
| 542 |
PIN45 IMPACT OF PATIENT-HEALTH CARE PROVIDER COMMUNICATION: THE HIV/AIDS PATIENTS' PERSPECTIVES
|
Layton, MR
|
|
2008
|
11 |
6 |
p. A442-A443
nvt p.
|
artikel
|
| 543 |
PIN39 INPATIENT COSTS AND OUTCOMES ASSOCIATED WITH HEPATITIS C, HUMAN IMMUNODEFICIENCY VIRUS, AND CO-INFECTION WITH BOTH IN THE UNITED STATES
|
Mitra, D
|
|
2008
|
11 |
6 |
p. A440-A441
nvt p.
|
artikel
|
| 544 |
PIN49 INTERNATIONAL DEVELOPEMENT OF A NEW HEALTH-RELATED QUALITY OF LIFE QUESTIONNAIRE SPECIFIC TO HIV/AIDS—PROQOL HIV STUDY
|
Duracinsky, M
|
|
2008
|
11 |
6 |
p. A444-
1 p.
|
artikel
|
| 545 |
PIN40 MANAGEMENT AND COST ASSOCIATED WITH NON-PERMANENT CATHETER-RELATED BACTERAEMIA CAUSED BY MICROORGANISMS GRAM-POSITIVES IN SPANISH HOSPITALS SETTINGS
|
Ruíz-Antorán, B
|
|
2008
|
11 |
6 |
p. A441-
1 p.
|
artikel
|
| 546 |
PIN8 PATIENT FLOW PATHWAY FOR PATIENTS ADMITTED TO CRITICAL CARE UNITS WITH A SEVERE BACTERIAL INFECTION IN ENGLAND
|
Das, R
|
|
2008
|
11 |
6 |
p. A430-
1 p.
|
artikel
|
| 547 |
PIN19 PHARMACOECONOMIC EVALUATION OF PARENTERAL ITRACONAZOLE USE IN THE PROPHYLAXIS OF INVASIVE FUNGAL INFECTIONS IN TURKISH SETTING
|
Kanbur, B
|
|
2008
|
11 |
6 |
p. A434-
1 p.
|
artikel
|
| 548 |
PIN7 PHARMACOGENOMICS: RELEVANCE AND APPLICABILITY IN POST-GENOMIC ERA (HIV-THERAPY)
|
Chawla, A
|
|
2008
|
11 |
6 |
p. A430-
1 p.
|
artikel
|
| 549 |
PIN53 PHARMACY-IMPLEMENTED GUIDELINES ON SWITCHING FROM INTRAVENOUSTO ORAL ANTIBIOTICS: A PROSPECTIVE STUDY IN A TEACHING HOSPITAL
|
Briquet, C
|
|
2008
|
11 |
6 |
p. A445-
1 p.
|
artikel
|
| 550 |
PIN36 SOCIO-ECONOMIC IMPACT OF AVIAN INFLUENZA IN SOUTH-EAST ASIA AND NEIGHBOURING HIGH RISK COUNTRIES
|
Arora, M
|
|
2008
|
11 |
6 |
p. A439-A440
nvt p.
|
artikel
|
| 551 |
PIN38 THE ECONOMIC BURDEN OF HCV AND HBV CO-INFECTION: EVIDENCE FROM UNITED STATES MANAGED CARE DATA
|
Mitra, D
|
|
2008
|
11 |
6 |
p. A440-
1 p.
|
artikel
|
| 552 |
PIN10 THE ECONOMIC IMPACT OF LOWER HIV PREVALENCE ESTIMATES
|
Ho, J
|
|
2008
|
11 |
6 |
p. A431-
1 p.
|
artikel
|
| 553 |
PIN28 USE OF PEGINTERFERON ALFA-2B IN CHRONIC HEPATITIS C PATIENTS FAILING PRIOR THERAPY: A COSTEFFECTIVENESS ANALYSIS
|
O'Sullivan, AK
|
|
2008
|
11 |
6 |
p. A437-
1 p.
|
artikel
|
| 554 |
PIN14 USING A DECISION SIMULATION MODELTO EVALUATE THE COST-EFFECTIVENESS OF THE TREATMENT OF NUCLEOSIDE-NAÏVE HBE-ANTIGEN NEGATIVE CHB PATIENTS IN ITALY WITH ENTECAVIR AND TEN OF OVIR
|
Zammit, DC
|
|
2008
|
11 |
6 |
p. A432-
1 p.
|
artikel
|
| 555 |
PIN52 UTILIZATION ANALYSIS AND IMPACT OF ANTIBACTERIAL AGENTS IN TWO LEADING UNIVERSITY HOSPITALS IN NEIGHBORING COUNTRIES WITH DIFFERENT GDP AND HEALTH CARE SYSTEM
|
Francetic, I
|
|
2008
|
11 |
6 |
p. A445-
1 p.
|
artikel
|
| 556 |
PIN48 VALIDATION OF THE ACTIVITY IMPAIRMENT ASSESSMENT IN PATIENTS WITH ACUTE BACTERIAL SINUSITIS
|
Lloyd, A
|
|
2008
|
11 |
6 |
p. A443-A444
nvt p.
|
artikel
|
| 557 |
PIN47 VALIDATION OF THE SINONASAL OUTCOMETEST-16 (SNOT-16) IN PATIENTS WITH ACUTE BACTERIAL SINUSITIS
|
Lloyd, A
|
|
2008
|
11 |
6 |
p. A443-
1 p.
|
artikel
|
| 558 |
PMC14 A FRAMEWORK FOR REAL-WORLD ECONOMIC EVALUATION BY INCORPORATING IMPLEMENTATION PARAMETERS
|
Grutters, JP
|
|
2008
|
11 |
6 |
p. A563-
1 p.
|
artikel
|
| 559 |
PMC5 A MISSING DATATHRESHOLD AS APPLIED TO HEALTH OUTCOMES DATA: DIFFERENTIAL IMPLICATIONS FOR COST-UTILITY ANALYSIS BY DIAGNOSIS
|
Bush, S
|
|
2008
|
11 |
6 |
p. A560-
1 p.
|
artikel
|
| 560 |
PMC36 AN INVESTIGATION OF FACTORIAL STRUCTURE OF SF-36V2 IN THE US GENERAL POPULATION—THE APPLICATION OF CONFIRMATORY FACTOR ANALYSIS THROUGH STRUCTURAL EQUATION MODELLING
|
Chuang, LH
|
|
2008
|
11 |
6 |
p. A570-
1 p.
|
artikel
|
| 561 |
PMC21 ASSESSING THE RELATIONSHIP BETWEEN COMPUTATIONAL SPEED AND PRECISION: A CASE STUDY USING A DISCRETE EVENT SIMULATION MODEL IN DIABETES CARE
|
Gordon, JP
|
|
2008
|
11 |
6 |
p. A565-A566
nvt p.
|
artikel
|
| 562 |
PMC47 A STUDY OF THE KEY FACTORS INFLUENCING THE PATIENT SATISFACTION IN INPATIENT AND OUTPATIENT SETTINGS
|
Tsai, SF
|
|
2008
|
11 |
6 |
p. A573-A574
nvt p.
|
artikel
|
| 563 |
PMC37 CHALLENGES OF TRANSLATING AND LINGUISTICALLY VALIDATING PRO MEASURES INTO SLAVIC LANGUAGES
|
Merry, R
|
|
2008
|
11 |
6 |
p. A570-
1 p.
|
artikel
|
| 564 |
PMC1 COLLECTING REAL DATA FROM REAL PATIENTS
|
Wade, AG
|
|
2008
|
11 |
6 |
p. A559-
1 p.
|
artikel
|
| 565 |
PMC49 COMPARISON OF HEALTH LOCUS OF CONTROL BETWEEN PHYSICIANS AND THE GENERAL PUBLIC: MULTI-GROUP STRUCTURAL EQUATION MODELING
|
Tokuda, Y
|
|
2008
|
11 |
6 |
p. A574-
1 p.
|
artikel
|
| 566 |
PMC18 CONCEPTUALISING DISEASE: BUILDING UNIFYING MODELS TO SUPPORT THE DEVELOPMENT OF PROS AND COST-EFFECTIVENESS ANALYSES. A CASE STUDY IN ALZHEIMER—S DISEASE (AD)
|
Wild, D
|
|
2008
|
11 |
6 |
p. A564-A565
nvt p.
|
artikel
|
| 567 |
PMC60 CONSISTENTLY ESTIMATING RISK DIFFERENCE IN A JURISDICTION OF INTEREST: ODDS SOLUTION TO RELATIVE RISK FALLACIES
|
Eckermann, S
|
|
2008
|
11 |
6 |
p. A577-A578
nvt p.
|
artikel
|
| 568 |
PMC19 COST-EFFECTIVENESS ANALYSES OF BEHAVIORAL INTERVENTIONS: TOWARDS A MORE REALISTIC COST-EFFECTIVENESS RATIO BY INCLUDING INTERMEDIATE OUTCOME MEASURES
|
Prenger, R
|
|
2008
|
11 |
6 |
p. A565-
1 p.
|
artikel
|
| 569 |
PMC8 DESIGN AND REPORTING TRENDS IN PIGGY-BACK ECONOMIC TRIALS
|
Ubhadiya, BS
|
|
2008
|
11 |
6 |
p. A561-
1 p.
|
artikel
|
| 570 |
PMC57 DISCONTINUOUS COST MEASUREMENT: HOWTO FILL IN THE GAPS?
|
Hendriks, MRC
|
|
2008
|
11 |
6 |
p. A576-A577
nvt p.
|
artikel
|
| 571 |
PMC9 DISCOUNTING COSTS AND BENEFITS OF HEALTH CARE PROGRAMMES: PROBLEMS OF THE SOCIAL TIME PREFERENCE APPROACH
|
John, J
|
|
2008
|
11 |
6 |
p. A561-A562
nvt p.
|
artikel
|
| 572 |
PMC27 DO LIKERT-TYPE SCALE AND VISUAL ANLOGUE SCALE MEASURE THE SAME QUALITY OF LIFE?
|
Hsiao, YY
|
|
2008
|
11 |
6 |
p. A567-
1 p.
|
artikel
|
| 573 |
PMC13 ESTIMATING COST-OF-ILLNESS USING GENERALIZED LINEAR MODELS: AN ALTERNATIVE TO THE SMEARING APPROACH
|
Exuzides, A
|
|
2008
|
11 |
6 |
p. A563-
1 p.
|
artikel
|
| 574 |
PMC16 EXPENSIVE DRUGS FOR RARE DISORDERS AND THE LOGIC OF COST-EFFECTIVENESS
|
Schlander, M
|
|
2008
|
11 |
6 |
p. A564-
1 p.
|
artikel
|
| 575 |
PMC4 FEASIBILITY OF CONDUCTING BUDGET IMPACT ANALYSIS IN THE SOCIAL SECURITY INSTITUTION OF TURKEY
|
Calgan, Z
|
|
2008
|
11 |
6 |
p. A560-
1 p.
|
artikel
|
| 576 |
PMC2 HASTHE QUALITY OF RANDOMISED CONTROLLED TRIALS INCREASED WITH TIME: AN ANALYSIS OF DATA FROM 5 SYSTEMATIC REVIEWS?
|
Proudfoot, CW
|
|
2008
|
11 |
6 |
p. A559-
1 p.
|
artikel
|
| 577 |
PMC11 IMPROVING PROBABILISTIC SENSITIVITY ANALYSIS (PSA) IN THE TREATMENT OF UNCERTAINTY COSTS USING MCMC
|
Monleon-Getino, A
|
|
2008
|
11 |
6 |
p. A562-
1 p.
|
artikel
|
| 578 |
PMC38 INFLUENCE OF DEMOGRAPHIC AND CULTURAL PREDICTORS ON EQ-5D VALUE SET IN THE POLISH POPULATION
|
Wrona, W
|
|
2008
|
11 |
6 |
p. A570-A571
nvt p.
|
artikel
|
| 579 |
PMC15 IN OR OUT? EMPIRICAL EVIDENCE ON INCOME LOSSES IN HEALTH STATE VALUATIONS AND IMPLICATIONS FOR ECONOMIC EVALUATIONS
|
Tilling, CJ
|
|
2008
|
11 |
6 |
p. A563-A564
nvt p.
|
artikel
|
| 580 |
PMC25 IS THE EQ-5D QUESTIONNAIRE A PREDICTOR OF MORTALITY AND HOSPITALIZATION IN A GENERIC ELDERLY POPULATION?
|
Pacelli, B
|
|
2008
|
11 |
6 |
p. A567-
1 p.
|
artikel
|
| 581 |
PMC53 IS UTILITY A LINEAR FUNCTION OF LIFETIME?
|
Knoph Kvamme, M
|
|
2008
|
11 |
6 |
p. A575-
1 p.
|
artikel
|
| 582 |
PMC52 LINGUISTIC VALIDATION OF THE FRENCH FOR CANADA WORK PRODUCTIVITY AND ACTIVITY IMPAIRMENT QUESTIONNAIRE, GENERAL HEALTHVERSION (WPAI:GH)
|
McKown, S
|
|
2008
|
11 |
6 |
p. A575-
1 p.
|
artikel
|
| 583 |
PMC41 METHODOLOGICAL ISSUES IN THE LITERATURE ON COSTS OF NON-COMPLIANCE IN CHRONIC DISEASES
|
Salas, M
|
|
2008
|
11 |
6 |
p. A571-A572
nvt p.
|
artikel
|
| 584 |
PMC34 METHODOLOGIES FOR ASSESSING AND DEMONSTRATING DATA SATURATION IN QUALITATIVE INQUIRY SUPPORTING PATIENT-REPORTED OUTCOMES RESEARCH
|
Nixon, A
|
|
2008
|
11 |
6 |
p. A569-
1 p.
|
artikel
|
| 585 |
PMC32 METHODS FOR ADDRESSING USE OF PRO INSTRUMENTS IN THE SAME LANGUAGE FOR DIFFERENT COUNTRIES: BEST PRACTICE GUIDELINES FOR DECISION-MAKING AND TRANSLATION OR ADAPTATION
|
Eremenco, S
|
|
2008
|
11 |
6 |
p. A569-
1 p.
|
artikel
|
| 586 |
PMC12 MODELLING THE VALUE FOR MONEY OF CLINICAL PRACTICE CHANGE: A STOCHASTIC APPLICATION IN DIABETES CARE
|
Hoomans, T
|
|
2008
|
11 |
6 |
p. A562-A563
nvt p.
|
artikel
|
| 587 |
PMC3 OVERCOMING THE FINAL HURDLE: COMMUNICATING THE COST EFFECTIVENESS OF A NEW DRUG
|
Shannon, PR
|
|
2008
|
11 |
6 |
p. A559-A560
nvt p.
|
artikel
|
| 588 |
PMC42 PATIENT AND POPULATION HEALTH-STATE VALUES ARE COMPARABLEWHEN DERIVED BY ELEMENTARY MEASUREMENT METHODS
|
Krabbe, PFM
|
|
2008
|
11 |
6 |
p. A572-
1 p.
|
artikel
|
| 589 |
PMC29 PATIENT REPORTED OUTCOMES RESEARCH IN A REAL TIME PRACTICE NETWORK
|
Barr, JT
|
|
2008
|
11 |
6 |
p. A568-
1 p.
|
artikel
|
| 590 |
PMC26 PREDICTING HEALTH SERVICE UTILIZATION WITH THE PCS AND MCS OF THE SF-36
|
Chen, T
|
|
2008
|
11 |
6 |
p. A567-
1 p.
|
artikel
|
| 591 |
PMC10 PREVALENT AND MULTIPLE FUTURE INCIDENT COHORTS IN COST-EFFECTIVENESS ANALYSIS
|
Hoyle, M
|
|
2008
|
11 |
6 |
p. A562-
1 p.
|
artikel
|
| 592 |
PMC20 QUANTITATIVE APPROACH TO DETERMINE THE EFFECT OF SEGMENTATION ON REVENUE GENERATION, POSITIONING AND PRICING OF PHARMACEUTICALS
|
Bolle, M
|
|
2008
|
11 |
6 |
p. A565-
1 p.
|
artikel
|
| 593 |
PMC24 SELF-ASSESSED HEALTH STATUS IN POLAND: EQ-5D FINDINGS FROM POLISH VALUATION STUDY
|
Golicki, D
|
|
2008
|
11 |
6 |
p. A566-A567
nvt p.
|
artikel
|
| 594 |
PMC7 SELF-REPORT VERSUS CAREGIVER REPORT OF HEALTH CARE UTILIZATION: IMPACT ON COST AND COST-EFFECTIVENESS
|
Hoogendoorn, M
|
|
2008
|
11 |
6 |
p. A561-
1 p.
|
artikel
|
| 595 |
PMC46 SHOULDWE BE CONSIDERING COMPONENTS OF SOCIAL COGNITION MODELS TO IMPROVE ADHERENCE TO IMMUNOSUPPRESSION MEDICATION?
|
Reaney, MD
|
|
2008
|
11 |
6 |
p. A573-
1 p.
|
artikel
|
| 596 |
PMC6 SOCIAL DISCOUNTING IN THE ECONOMIC EVALUATION OF HEALTH CARE PROGRAMMES
|
Valentim, J
|
|
2008
|
11 |
6 |
p. A560-A561
nvt p.
|
artikel
|
| 597 |
PMC40 STABILITY OF TREATMENT SATISFACTION WITH MEDICINES QUESTIONNAIRE (SATMED-Q) STRUCTURE IN DIFFERENT PATHOLOGY SAMPLES
|
MÁ, Ruíz
|
|
2008
|
11 |
6 |
p. A571-
1 p.
|
artikel
|
| 598 |
PMC28 STATUS-QUO BIAS IN STATED-CHOICE STUDIES: IS IT REAL?
|
Mohamed, AF
|
|
2008
|
11 |
6 |
p. A567-A568
nvt p.
|
artikel
|
| 599 |
PMC63 SYSTEMATIC REVIEW RELIABILITY: SENSITIVITY AND SPECIFICITY OF ONEVS.TWO REVIEWS
|
Muston, D
|
|
2008
|
11 |
6 |
p. A578-A579
nvt p.
|
artikel
|
| 600 |
PMC55 THE C-STATISTIC AND THE EFFICIENCY OF THE PROPENSITY SCORES MODEL: EVIDENCE FROM SIMULATED DATA
|
Kiri, VA
|
|
2008
|
11 |
6 |
p. A576-
1 p.
|
artikel
|
| 601 |
PMC22 THE IMPACT OF COMORBIDITY BURDEN AND AGE ON PREFERENCE-BASED HRQL IN THE UNITED STATES
|
Sullivan, PW
|
|
2008
|
11 |
6 |
p. A566-
1 p.
|
artikel
|
| 602 |
PMC30 THE IMPACT OF INITIAL DISEASE SEVERITY: AN APPLICATION TO EXISTING HEALTH ECONOMICS MODELS
|
Taylor, MJ
|
|
2008
|
11 |
6 |
p. A568-
1 p.
|
artikel
|
| 603 |
PMC61 THE IMPLICIT VALUE OF STATISTICAL LIFE: ESTIMATES DERIVED FROM PUBLIC INTERVENTIONS IMPLEMENTED IN THE NETHERLANDS
|
Goebbels, AFG
|
|
2008
|
11 |
6 |
p. A578-
1 p.
|
artikel
|
| 604 |
PMC58 THE POTENTIAL PENALTY FOR NOT SAMPLING FROM THE RISK SET IN NESTED CASE-CONTROL DESIGNS: EVIDENCE FROM SIMULATED DATA
|
Kiri, VA
|
|
2008
|
11 |
6 |
p. A577-
1 p.
|
artikel
|
| 605 |
PMC54 THE RIGOUR, FLEXIBILITY AND EASE OF IMPLEMENTATION OF SYSTEMATIC SEARCH STRATEGIES—DOWE NEED AN INDUSTRY STANDARD METHODOLOGY?
|
Reaney, MD
|
|
2008
|
11 |
6 |
p. A575-A576
nvt p.
|
artikel
|
| 606 |
PMC33 THE ROLE OF RANKING DATA IN HEALTHVALUATION
|
Chuang, LH
|
|
2008
|
11 |
6 |
p. A569-
1 p.
|
artikel
|
| 607 |
PMC44 THE SIGNIFICANCE OF PATIENT-REPORTED OUTCOMESTO FACILITATE MARKET ACCESS DURING A PRODUCT LIFECYCLE
|
Rofail, D
|
|
2008
|
11 |
6 |
p. A572-A573
nvt p.
|
artikel
|
| 608 |
PMC50 THE SUITABILITY OF VISUAL ANALOGUE SCALES (VAS) FOR COLLECTING PATIENT-REPORTED OUTCOMES (PRO) DATA FROM INTERNATIONAL SETTINGS
|
Houchin, C
|
|
2008
|
11 |
6 |
p. A574-A575
nvt p.
|
artikel
|
| 609 |
PMC56 THE TRANSFERABILITY OF ECONOMIC EVALUATIONS. VALIDATING THE MODEL OF WELTE
|
Knies, S
|
|
2008
|
11 |
6 |
p. A576-
1 p.
|
artikel
|
| 610 |
PMC62 UNIVERSAL TRANSLATION AND NEUROPSYCHOLOGICAL COMPARISONS OF PATIENTS FROM US-MEXICO BORDER REGION AND SPAIN
|
Herzberg, T
|
|
2008
|
11 |
6 |
p. A578-
1 p.
|
artikel
|
| 611 |
PMC48 UPDATE OF TRENDS IN THE INCLUSION OF PATIENT-REPORTED OUTCOME (PRO) DATA IN APPROVED DRUGS LABELING BY FDA AND EMEA
|
Caron, M
|
|
2008
|
11 |
6 |
p. A574-
1 p.
|
artikel
|
| 612 |
PMC43 USE OF AND COMPLIANCE WITH ELECTRONIC PATIENT REPORTED OUTCOMES WITHIN CLINICAL DRUGTRIALS
|
Wenzel, KW
|
|
2008
|
11 |
6 |
p. A572-
1 p.
|
artikel
|
| 613 |
PMC51 UTILITIES OF THE EQ-5D:TRANSFERABLE OR NOT? INFLUENCE OF THE NATIONAL VALUE SETS OF THE EQ-5D ON THE INCREMENTAL UTILITIES OF TWO HEALTH STATES
|
Knies, S
|
|
2008
|
11 |
6 |
p. A575-
1 p.
|
artikel
|
| 614 |
PMC17 VALIDITY OF ELECTRONIC PRECRIPTION CLAIMS RECORDS: A COMPARISON OF ELECTRONIC PBM CLAIMS RECORDS WITH PHARMACY PROVIDER DERIVED RECORDS
|
Martin, BC
|
|
2008
|
11 |
6 |
p. A564-
1 p.
|
artikel
|
| 615 |
PMC31 VALUING EQ-5D WITH TIME TRADE-OFF FOR THE POLISH POPULATION
|
Golicki, D
|
|
2008
|
11 |
6 |
p. A568-A569
nvt p.
|
artikel
|
| 616 |
PMC39 WHAT DOES ACCEPTABILITY MEAN FOR PATIENTS AND HOW SHOULD IT BE MEASURED? QUALITATIVE STEPS FOR THE DEVELOPMENT OF A NEW MEASUREMENT INSTRUMENT IN PHARMACIES
|
Marant, C
|
|
2008
|
11 |
6 |
p. A571-
1 p.
|
artikel
|
| 617 |
PMC23 WHAT IS POLITICIAN'S AND CLINICIAN'S WILLINGNESS TO PAY (WTP) FOR FUTURE HEALTH BENEFIT BASED ON 15D, EQ-5D AND LIFE-YEARS? A CONTINGENTVALUATION (CV) AMONG 8 DISEASES WITH THE TOTAL OF 1092 CASES
|
Soini, EJ
|
|
2008
|
11 |
6 |
p. A566-
1 p.
|
artikel
|
| 618 |
PMC45 WHAT PROPORTION OF DISEASES ARE QALYS AN IRRELEVANT MEASURE FOR?
|
Proudfoot, CW
|
|
2008
|
11 |
6 |
p. A573-
1 p.
|
artikel
|
| 619 |
PMH45 A COMPARISON OF PATIENT AND PHYSICIAN ATTITUDES TOWARDS THE GOALS FOR THE TREATMENT OF SCHIZOPHRENIA IN GERMANY
|
Rudolph, I
|
|
2008
|
11 |
6 |
p. A594-
1 p.
|
artikel
|
| 620 |
PMH55 A COMPARISON OF PERSISTENCE AND HEALTH CARE COSTS RELATED TO DIFFERENT TREATMENT STRATEGIES AFTER INITIAL ESCITALOPRAM 10MG IN MAJOR DEPRESSIVE DISORDER
|
Sanglier, T
|
|
2008
|
11 |
6 |
p. A597-
1 p.
|
artikel
|
| 621 |
PMH61 ADULTS WITH ATTENTION-DEFICIT/ HYPERACTIVITY DISORDER (ADHD) IN GERMANY—PREVALENCE, COMORBIDITIES AND PHARMACOTHERAPY IN PRACTICE
|
Slawik, L
|
|
2008
|
11 |
6 |
p. A599-
1 p.
|
artikel
|
| 622 |
PMH31 A GPRD-BASED COMPARISON OF SECOND-LINE ANTIDEPRESSANT THERAPY WITH ESCITALOPRAM AND VENLAFAXINE
|
Wade, AG
|
|
2008
|
11 |
6 |
p. A589-
1 p.
|
artikel
|
| 623 |
PMH32 A GPRD STUDY OF HEALTH CARE COST ASSOCIATED WITH DIFFERENT FIRST-LINE ANTIDEPRESSANT TREATMENTS IN SEVERE DEPRESSION
|
Wade, AG
|
|
2008
|
11 |
6 |
p. A589-
1 p.
|
artikel
|
| 624 |
PMH30 ANTIDEPRESSANT THERAPY DURING PREGNANCY: AN INSIGHT ON ITS POTENTIAL HEALTH CARE COSTS
|
Ramos, E
|
|
2008
|
11 |
6 |
p. A589-
1 p.
|
artikel
|
| 625 |
PMH6 A SYSTEMATIC REVIEW ON THE EPIDEMIOLOGY AND SOCIOECONOMIC BURDEN OF BIPOLAR DISORDER IN EUROPE
|
Fajutrao, L
|
|
2008
|
11 |
6 |
p. A580-A581
nvt p.
|
artikel
|
| 626 |
PMH58 BUDGET CONSTRAINTS AS A MAJOR CAUSE FOR UNDERTREATMENT OF PATIENTS SUFFERING FROM ALZHEIMER'S DISEASE IN GERMANY: A COMPARATIVE PANEL SURVEY OF GENERAL PRACTIONERS AND NEUROLOGISTS
|
Gaudig, M
|
|
2008
|
11 |
6 |
p. A598-
1 p.
|
artikel
|
| 627 |
PMH12 BUDGET IMPACT OF GENERIC ANTIPSYCHOTIC SUBSTITUTION—A DATABASE ANALYSIS IN GERMANY
|
Rudolph, I
|
|
2008
|
11 |
6 |
p. A582-A583
nvt p.
|
artikel
|
| 628 |
PMH38 CAN PATIENTS WITH SCHIZOPHRENIA COMPLETE A CONJOINT ANALYSIS? EVIDENCE FROM GERMANY
|
Bridges, JF
|
|
2008
|
11 |
6 |
p. A591-A592
nvt p.
|
artikel
|
| 629 |
PMH5 COMPARISON OF RISK OF UPPER GASTROINTESTINAL HEMORRHAGE AMONG SSRI-USERS WITHIN U.S. MANAGED CARE POPULATION
|
Kreilick, C
|
|
2008
|
11 |
6 |
p. A580-
1 p.
|
artikel
|
| 630 |
PMH35 COST ANALYSIS OF THE TRENDS IN HOSPITALISATION OF PATIENTS WITH SCHIZOPHRENIA IN SPAIN FROM 1980–2004
|
Saz-Parkinson, Z
|
|
2008
|
11 |
6 |
p. A590-A591
nvt p.
|
artikel
|
| 631 |
PMH21 COST-EFFECTIVENESS-ANALYSIS OF RISPERIDONE LONG-ACTING INJECTION IN SCHIZOPHRENIA: 12 MONTH DATA FROM CZECH REPUBLIC
|
Skoupá, J
|
|
2008
|
11 |
6 |
p. A585-
1 p.
|
artikel
|
| 632 |
PMH15 COST-EFFECTIVENESS OF QUETIAPINE IN COMBINATION WITH LITHIUM/DIVALPROEX IN MAINTENANCE TREATMENT OF BIPOLAR I DISORDER
|
Fajutrao, L
|
|
2008
|
11 |
6 |
p. A583-
1 p.
|
artikel
|
| 633 |
PMH33 COST-UTILITY ANALYSIS OF DULOXETINE VERSUS VENLAFAXINE IN THE MANAGEMENT OF MAJOR DEPRESSION IN PORTUGAL
|
Pinto, CG
|
|
2008
|
11 |
6 |
p. A590-
1 p.
|
artikel
|
| 634 |
PMH13 COST-UTILITY AND BUDGET IMPACT OF SERTINDOLE IN THE TREATMENT OF SCHIZOPHRENIA IN POLAND
|
Walczak, J
|
|
2008
|
11 |
6 |
p. A583-
1 p.
|
artikel
|
| 635 |
PMH51 DECLINE IN DEPRESSION TREATMENT PERSISTS AFTER FDA ANTIDEPRESSANTWARNINGS
|
Libby, AM
|
|
2008
|
11 |
6 |
p. A596-
1 p.
|
artikel
|
| 636 |
PMH60 DETERMINANTS OF PRESCRIPTION IN PRIMARY CARE: PROFILE OF PATIENTS PRESCRIBED NEWER ANTIDEPRESSANTS IN THE UNITED KINGDOM
|
Saragoussi, D
|
|
2008
|
11 |
6 |
p. A599-
1 p.
|
artikel
|
| 637 |
PMH2 DIRECT AND INDIRECT TREATMENT EFFECTS ON SLEEP DISTURBANCE IN GENERALIZED ANXIETY DISORDER: A STATISTICAL MEDIATION MODEL ANALYSIS
|
Bollu, V
|
|
2008
|
11 |
6 |
p. A579-
1 p.
|
artikel
|
| 638 |
PMH24 DIRECT COSTS OF UNTREATED COMORBID-INSOMNIA IN AN ADULT DEPRESSED MANAGED CARE POPULATION
|
Camacho, F
|
|
2008
|
11 |
6 |
p. A587-
1 p.
|
artikel
|
| 639 |
PMH25 DIRECT COSTS OF UNTREATED COMORBID-INSOMNIA IN AN ELDERLY DEPRESSED MANAGED CARE POPULATION
|
Camacho, F
|
|
2008
|
11 |
6 |
p. A587-
1 p.
|
artikel
|
| 640 |
PMH11 DRUG-RELATED PUBLIC EXPENDITURE IN EUROPE: THE BUDGET IMPACT OF ILLEGAL DRUGS
|
Prieto, L
|
|
2008
|
11 |
6 |
p. A582-
1 p.
|
artikel
|
| 641 |
PMH20 ECONOMIC EVALUATION OF PALIPERIDONE ER FOR THE TREATMENT OF SCHIZOPHRENIA IN THE CONTEXT OF BRAZILIAN PUBLIC HEALTH CARE SYSTEM
|
Araujo, D
|
|
2008
|
11 |
6 |
p. A585-
1 p.
|
artikel
|
| 642 |
PMH62 ECONOMIC OUTCOMES OF CO-TREATMENT OF INSOMNIA AND MAJOR DEPRESSIVE DISORDER (MDD) WITH ESZOPICLONE AND FLUOXETINE VERSUS FLUOXETINE TREATMENT ALONE
|
Snedecor, SS
|
|
2008
|
11 |
6 |
p. A586-
1 p.
|
artikel
|
| 643 |
PMH4 EFFICACY AND SAFETY OF ORAL A TYPICAL ANTIPSYCHOTICS FOR SCHIZOPHRENIA: A META-ANALYSIS INCLUDING PALIPERIDONE EXTENDED-RELEASE
|
Jones, MP
|
|
2008
|
11 |
6 |
p. A580-
1 p.
|
artikel
|
| 644 |
PMH29 HEALTH CARE RESOURCE UTILIZATION AND COSTS OF MILD, MODERATE, AND SEVERE DEPRESSION IN THE UNITED STATES
|
Birnbaum, HG
|
|
2008
|
11 |
6 |
p. A588-A589
nvt p.
|
artikel
|
| 645 |
PMH42 HEALTH-RELATED QUALITY OF LIFE OF MARRIED, WORKING WOMEN WITH CHILDREN (SUPERWOMAN SYNDROME) IN KOREA
|
Kim, S
|
|
2008
|
11 |
6 |
p. A593-
1 p.
|
artikel
|
| 646 |
PMH27 HEALTH SERVICE EXPENDITURES FOR PATIENTS WITH A DIAGNOSIS OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD) IN GERMANY—AN AGE AND GENDER SPECIFIC ANALYSIS
|
Schlander, M
|
|
2008
|
11 |
6 |
p. A588-
1 p.
|
artikel
|
| 647 |
PMH22 IMPACT ON SCHIZOPHRENIA INPATIENT RESOURCE USE FOLLOWING SWITCHTO LONG-ACTING RISPERIDONE IN FINLAND
|
Seppälä, N
|
|
2008
|
11 |
6 |
p. A586-
1 p.
|
artikel
|
| 648 |
PMH54 INDICATION SPECTRUM OF SNRI APPLIED FOR THE TREATMENT OF DEPRESSION—A PHARMACOEPIDEMIOLOGICAL ANALYSIS OF CLAIMS DATA OF A GERMAN SICKNESS FUND
|
Gothe, H
|
|
2008
|
11 |
6 |
p. A597-
1 p.
|
artikel
|
| 649 |
PMH49 INTERNATIONAL INVESTIGATION INTO DEPRESSION BASED ON THE STRUCTURED INTERVIEW GUIDE FOR THE HAMILTON DEPRESSION RATING SCALE (SIGH-D) AND THE CLINICIAN RATED INVENTORY OF DEPRESSIVE SYMPTOMATOLOGY (IDS-C)
|
Caire, P
|
|
2008
|
11 |
6 |
p. A595-
1 p.
|
artikel
|
| 650 |
PMH44 LINGUISTIC VALIDATION, SENSITIVITY AND SPECIFICITY OF THE SCALE “DEPRESSION IN THE MEDICALLY ILL-18”
|
Las Hayas, C
|
|
2008
|
11 |
6 |
p. A593-A594
nvt p.
|
artikel
|
| 651 |
PMH59 MODELLING THE ANTIDEPRESSANTS MARKET BEHAVIOUR AFTER PATENT EXPIRIES
|
Pechlivanoglou, P
|
|
2008
|
11 |
6 |
p. A598-A599
nvt p.
|
artikel
|
| 652 |
PMH26 ONE YEAR PROSPECTIVE HEALTH CARE AND NON-HEALTH CARE RESOURCES USE AND COST STUDY IN PATIENTS WITH DEMENTIA OF ALZHEIMER TYPE: A SPANISH PERSPECTIVE
|
Coduras, A
|
|
2008
|
11 |
6 |
p. A587-A588
nvt p.
|
artikel
|
| 653 |
PMH46 PATIENT PREFERENCES IN ADHD—DISCRETE CHOICE EXPERIMENT
|
Mühlbacher, AC
|
|
2008
|
11 |
6 |
p. A594-
1 p.
|
artikel
|
| 654 |
PMH40 PATIENTS WITH ATTENTION DEFICIT/HYPERACTIVITY DISORDER 2-YEAR ASSESSMENT OF IMPACT ON QUALITY OF LIFE AND CLINICAL SEVERITY: RESULTS FROM ADORE STUDY IN FRANCE
|
Le Heuzey, MF
|
|
2008
|
11 |
6 |
p. A592-
1 p.
|
artikel
|
| 655 |
PMH56 PATTERNS OF FIRST VISITS TO PSYCHIATRIC CLINICS IN TAIWAN: A NATIONWIDE STUDY, 2006
|
Chou, LF
|
|
2008
|
11 |
6 |
p. A597-A598
nvt p.
|
artikel
|
| 656 |
PMH19 PHARMACOECONOMIC POSITIONING OF SERTINDOLE AMONG ANTIPSYCHOTICS IN THE MANAGEMENT OF SCHIZOPHRENIA IN NORWAY
|
Mehlum, E
|
|
2008
|
11 |
6 |
p. A585-
1 p.
|
artikel
|
| 657 |
PMH52 PILOT SURVEY OF ADVERSE EVENT MANAGEMENT ASSOCIATED WITH ANTIPSYCHOTIC USE: THE NEGLECTED DIMENSION IN RESOURCE USE IMPLICATIONS (A UK PERSPECTIVE)
|
Meier, G
|
|
2008
|
11 |
6 |
p. A596-
1 p.
|
artikel
|
| 658 |
PMH53 PREDICTIVE FACTORS OF RECURRENCE AND BIPOLAR DISORDER MANAGEMENT IN SPAIN: A PROSPECTIVE COHORT STUDY BASELINE ASSESSMENT
|
Tafalla, M
|
|
2008
|
11 |
6 |
p. A596-A597
nvt p.
|
artikel
|
| 659 |
PMH7 PREVALENCE OF POTENTIAL MEDICATION INTERACTIONS WITH ANTIPSYCHOTICS VIA CYTOCHROME P450 IN PATIENTS WITH SCHIZOPHRENIA IN GERMANY
|
Mehnert, A
|
|
2008
|
11 |
6 |
p. A581-
1 p.
|
artikel
|
| 660 |
PMH1 PREVALENCE OF TIC DISORDERS AND COEXISTENCE WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD) IN A GERMAN COMMUNITY SAMPLE
|
Schlander, M
|
|
2008
|
11 |
6 |
p. A579-
1 p.
|
artikel
|
| 661 |
PMH47 QUANTIFYING UNMET NEEDS AMONG PATIENTS WITH DEPRESSION USING AN SSRI OR SNRI ACROSS FIVE EUROPEAN COUNTRIES USING PATIENT-REPORTED SURVEY DATA
|
Wagner, S
|
|
2008
|
11 |
6 |
p. A594-A595
nvt p.
|
artikel
|
| 662 |
PMH39 RELATIONSHIP BETWEEN CLINICAL OUTCOMES AND PATIENTS' REPORTED OUTCOMES IN SCHIZOPHRENIA: THE CONTRIBUTION OF THE EQ-5D
|
Scalone, L
|
|
2008
|
11 |
6 |
p. A592-
1 p.
|
artikel
|
| 663 |
PMH3 RISPERIDONE LONG-ACTING INJECTION (RLAI) IN THE TREATMENT OF SCHIZOPHRENIA: 3 MONTH PRELIMINARY RESULTS FROM THE ELECTRONIC SCHIZOPHRENIA TREATMENT ADHERENCE REGISTRY (E-STAR) IN RUSSIA
|
Lyubov, E
|
|
2008
|
11 |
6 |
p. A579-A580
nvt p.
|
artikel
|
| 664 |
PMH41 SAD BLUE DEPRESSED DAYS, HEALTH–RELATED QUALITY OF LIFE, AND HEALTH BEHAVIORS AMONGWOMEN IN A UNIVERSITY COMMUNITY
|
Bastardo, YM
|
|
2008
|
11 |
6 |
p. A592-A593
nvt p.
|
artikel
|
| 665 |
PMH57 SECOND GENERATION ANTIPSYCHOTICS AND HOSPITALIZATION IN BIPOLAR DISORDER: A CLAIMS DATA ANALYSIS
|
Pikalov, A
|
|
2008
|
11 |
6 |
p. A598-
1 p.
|
artikel
|
| 666 |
PMH37 SWITCHING OF ANTIPSYCHOTICS FROM THE PATIENTS POINT OF VIEW: RESULTS OF A QUANTITATIVE PATIENT SURVEY
|
Schmeding, A
|
|
2008
|
11 |
6 |
p. A591-
1 p.
|
artikel
|
| 667 |
PMH48 TELEPHONE HOTLINE AS AN ADJUNCT TO CONTINUING CARE FOR ADOLESCENTS TREATED FOR PSYCHOACTIVE SUBSTANCE USE DISORDER
|
Ciesla, JR
|
|
2008
|
11 |
6 |
p. A595-
1 p.
|
artikel
|
| 668 |
PMH16 THE COST-EFFECTIVENESS OF PALIPERIDONE ER IN ACUTE PHASE OF SCHIZOPHRENIA IN TURKEY
|
Kanbur, B
|
|
2008
|
11 |
6 |
p. A584-
1 p.
|
artikel
|
| 669 |
PMH18 THE COST-EFFECTIVENESS OF PALIPERIDONE ER IN LONG-TERM TREATMENT OF SCHIZOPHRENIA IN TURKEY
|
Sarioz, F
|
|
2008
|
11 |
6 |
p. A584-
1 p.
|
artikel
|
| 670 |
PMH14 THE COST-EFFECTIVENESS OF QUETIAPINE EXTENDED-RELEASE VERSUS OLANZAPINE FOLLOWING GENERIC RISPERIDONE IN PATIENTS WITH FIRST EPISODE SCHIZOPHRENIA
|
Meier, G
|
|
2008
|
11 |
6 |
p. A583-
1 p.
|
artikel
|
| 671 |
PMH23 THE ECONOMIC EFFECTS OF FASTER TITRATION AND LOWER RELAPSE RATE OF QUETIAPINE XR COMPARED TO QUETIAPINE IR—THE ECONOMICVALUE OF A NEW DRUG FORMULATION
|
Laine, J
|
|
2008
|
11 |
6 |
p. A586-
1 p.
|
artikel
|
| 672 |
PMH28 THE ECONOMICS OF SCHIZOPHRENIA IN GERMANY AND THE POTENTIAL OF LONG ACTING SECOND GENERATION DEPOT TREATMENT
|
Bergman, A
|
|
2008
|
11 |
6 |
p. A588-
1 p.
|
artikel
|
| 673 |
PMH50 THE ROLE OF PRE-TREATMENT EXPECTANCY ON THE OUTCOME OF PRIMARY CARE TREATMENTS FOR DEPRESSION
|
Gerhards, SAH
|
|
2008
|
11 |
6 |
p. A595-A596
nvt p.
|
artikel
|
| 674 |
PMH43 THE SPANISH VERSION OF THE TOOL QUESTIONNAIRE: A USEFUL MEASURE FOR EVALUATING THE HRQOL AND UTILITIES FROM SCHIZOPHRENIC AND BIPOLAR PATIENTS
|
Maurino, J
|
|
2008
|
11 |
6 |
p. A593-
1 p.
|
artikel
|
| 675 |
PMH9 TOLERABILITY OF A TYPICAL ANTIPSYCHOTICS IN THE TREATMENT OF SCHIZOPHRENIA AND BIPOLAR DISORDER: A SYSTEMATIC REVIEW OF RANDOMISED CONTROLLED TRIALS
|
Edwards, SJ
|
|
2008
|
11 |
6 |
p. A581-A582
nvt p.
|
artikel
|
| 676 |
PMH10 TOLERABILITY OF ONCE-DAILY EXTENDED RELEASE QUETIAPINE COMPARED TO QUETIAPINE IMMEDIATE RELEASE: A META-ANALYSIS OF RANDOMISED CONTROLLED TRIALS IN SCHIZOPHRENIA
|
Edwards, SJ
|
|
2008
|
11 |
6 |
p. A582-
1 p.
|
artikel
|
| 677 |
PMH8 TOLERABILITY OF ONCE-DAILY EXTENDED RELEASE QUETIAPINE COMPARED TO QUETIAPINE IMMEDIATE RELEASE IN THE TREATMENT OF ACUTE BIPOLAR DISORDER: AN ADJUSTED INDIRECT COMPARISON
|
Edwards, SJ
|
|
2008
|
11 |
6 |
p. A581-
1 p.
|
artikel
|
| 678 |
PMH17 TREATMENT OF OPIATE DEPENDENT PATIENTS INWALES WITH BUPRENORPHINE/NALOXONE—A COST-EFFECTIVENESS EVALUATION
|
Gibbons, CJ
|
|
2008
|
11 |
6 |
p. A584-
1 p.
|
artikel
|
| 679 |
PMH36 WHAT DO PATIENTS WITH SCHIZOPHRENIAWANT OUT OF THEIR MEDICATION? IDENTIFYING PATIENT REPORTED “PROCESSES” IN MENTAL HEALTH
|
Schmeding, A
|
|
2008
|
11 |
6 |
p. A591-
1 p.
|
artikel
|
| 680 |
PMH34 WORKPLACE BURDEN OF MILD, MODERATE, AND SEVERE DEPRESSION IN THE UNITED STATES
|
Birnbaum, HG
|
|
2008
|
11 |
6 |
p. A590-
1 p.
|
artikel
|
| 681 |
PMS3 A COMPARISON OF CLINICAL EFFICACY OF LEFLUNOMIDE VS OTHER THERAPUETIC OPTIONS IN THE TREATEMENT OF RHEUMATOID ARTHRITIS
|
Rys, P
|
|
2008
|
11 |
6 |
p. A537-
1 p.
|
artikel
|
| 682 |
PMS71 A COST-EFFECTIVENESS ASSESSMENT OF ABATACEPT FOR THE TREATMENT OF RHEUMATOID ARTHRITIS IN HUNGARY
|
Brodszky, V
|
|
2008
|
11 |
6 |
p. A549-A550
nvt p.
|
artikel
|
| 683 |
PMS16 ADALIMUMAB, ETANERCEPT AND INFLIXIMAB FOR THE TREATMENT OF ANKYLOSING SPONDYLITIS-BUDGET IMPACT ANALYSIS ON POLISH NATIONAL HEALTH FUND
|
Macioch, T
|
|
2008
|
11 |
6 |
p. A541-
1 p.
|
artikel
|
| 684 |
PMS22 ADALIMUMAB, ETANERCEPT AND INFLIXIMAB IN THE TREATMENT OF ANKYLOSING SPONDYLITIS-COST EFFECTIVENESS ANALYSIS IN POLISH SETTINGS
|
Macioch, T
|
|
2008
|
11 |
6 |
p. A543-
1 p.
|
artikel
|
| 685 |
PMS37 A MICROSIMULATION-BASED COST-UTILITY ANALYSIS OF RITUXIMAB (MABTHERA ®) IN PATIENTS WITH RHEUMATIC ARTHRITIS IN SPAIN
|
Fernández, I
|
|
2008
|
11 |
6 |
p. A548-
1 p.
|
artikel
|
| 686 |
PMS68 ANTI-TUMOUR NECROSIS FACTOR-α INHIBITOR DOSE CHANGES IN RHEUMATOID ARTHRITIS PATIENTS IN A PROSPECTIVE PATIENT REGISTRY SETTING
|
Kievit, W
|
|
2008
|
11 |
6 |
p. A558-
1 p.
|
artikel
|
| 687 |
PMS1 COGNITIVE IMPAIRMENT IN PATIENTS WITH FIBROMYALGIA SYNDROME AS ASSESSED BY THE MINIMENTAL STATE EXAMINATION
|
Rodríguez-Andreu, J
|
|
2008
|
11 |
6 |
p. A536-
1 p.
|
artikel
|
| 688 |
PMS27 COST CONSEQUENCE ANALYSIS OF RITUXIMAB TREATMENT FOR RHEUMATOID ARTHRITIS IN ISRAEL
|
Hammerman, A
|
|
2008
|
11 |
6 |
p. A544-A545
nvt p.
|
artikel
|
| 689 |
PMS40 COST-EFFECTIVENESS ANALYSIS OF ANNUAL DOSE OF ZOLEDRONIC ACID VERSUS ORALLY ADMINISTERED BISPHOSPHONATES IN PREVENTION OF OSTEOPOROTIC FRACTURES IN CZECH POST-MENOPAUSALWOMEN
|
Tichopad, A
|
|
2008
|
11 |
6 |
p. A549-
1 p.
|
artikel
|
| 690 |
PMS4 COST-EFFECTIVENESS ANALYSIS OF LEFLUNOMIDE AS A TREATMENT FOR RHEUMATOID ARTHRITIS IN MEXICO
|
Carlos-Rivera, F
|
|
2008
|
11 |
6 |
p. A537-
1 p.
|
artikel
|
| 691 |
PMS26 COST-EFFECTIVENESS ANALYSIS OF RHBMP-2 IN THE TREATMENT OF OPENTIBIA FRACTURES IN THE NETHERLANDS
|
Van Genugten, M
|
|
2008
|
11 |
6 |
p. A544-
1 p.
|
artikel
|
| 692 |
PMS41 COST-EFFECTIVENESS OF CELECOXIB COMPARED TO CONVENTIONAL NSAIDS AND NSAID+PPI COMBINATION THERAPY IN RHEUMATOID ARTHRITIS
|
Inotai, A
|
|
2008
|
11 |
6 |
p. A549-
1 p.
|
artikel
|
| 693 |
PMS70 COST-EFFECTIVENESS OF ETANERCEPT VS. RITUXIMAB IN THE TREATMENT OF ACTIVE RHEUMATOID ARTHRITIS IN COLOMBIA
|
Gao, X
|
|
2008
|
11 |
6 |
p. A543-
1 p.
|
artikel
|
| 694 |
PMS38 COST-EFFECTIVENESS OF RITUXIMAB AS SECOND-LINE BIOLOGICAL TREATMENT COMPARED TO REGISTRY DATA
|
Kobelt, G
|
|
2008
|
11 |
6 |
p. A548-
1 p.
|
artikel
|
| 695 |
PMS25 COST-EFFECTIVENESS OF RITUXIMAB (MABTHERA) COMPARED WITH TNF INHIBITORS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS (RA) IN POLAND
|
Plisko, R
|
|
2008
|
11 |
6 |
p. A544-
1 p.
|
artikel
|
| 696 |
PMS19 COST-EFFECTIVENESS OF USING ETANERCEPT AS FIRST LINE IN SEVERE AND HIGHLY ACTIVE RHEUMATOID ARTHRITIS (RA)
|
Miadi-Fargier, H
|
|
2008
|
11 |
6 |
p. A541-A542
nvt p.
|
artikel
|
| 697 |
PMS21 COST-EFFECTIVENESS SIMULATION MODEL OF ABATACEPT VERSUS RITUXIMAB IN RHEUMATOID ARTHRITIS IN FRANCE
|
Gossec, L
|
|
2008
|
11 |
6 |
p. A542-A543
nvt p.
|
artikel
|
| 698 |
PMS28 COST OF RHEUMATOID ARTHRITIS MODEL PER LEVEL OF DISEASE ACTIVITY IN FRANCE
|
Beresniak, A
|
|
2008
|
11 |
6 |
p. A545-
1 p.
|
artikel
|
| 699 |
PMS36 COST OF THERAPY OF TUMOR NECROSIS FACTOR BLOCKING AGENTS IN PATIENTS WITH RHEUMATOID ARTHRITIS IN ITALY
|
Fiocco, U
|
|
2008
|
11 |
6 |
p. A547-
1 p.
|
artikel
|
| 700 |
PMS30 COSTS AVOIDED BY DIAGNOSING FIBROMYALGIA IN FRENCH PATIENTS
|
Lamotte, M
|
|
2008
|
11 |
6 |
p. A545-A546
nvt p.
|
artikel
|
| 701 |
PMS29 COSTS AVOIDED BY DIAGNOSING FIBROMYALGIA IN SPANISH PATIENTS
|
Lamotte, M
|
|
2008
|
11 |
6 |
p. A545-
1 p.
|
artikel
|
| 702 |
PMS18 COSTS OF TREATMENT OF RHEUMATOID ARTHRITIS WITH BIOLOGICAL DRUGS
|
Rasmussen, C
|
|
2008
|
11 |
6 |
p. A541-
1 p.
|
artikel
|
| 703 |
PMS42 COST-UTILITY EVALUATION OF THE TREATMENT OF PATIENTS WITH OSTEOARTHRITIS WITH IN SAPONIFICATES OF AVOCADO AND SOY (PIASCLEDINE ®)
|
Ayala, C
|
|
2008
|
11 |
6 |
p. A549-
1 p.
|
artikel
|
| 704 |
PMS39 COST-UTILITY OF ABATACEPT IN RHEUMATOID ARTHRITIS PATIENTS WITH AN INSUFFICIENT RESPONSE OR INTOLERANCE TO ANTI-TNF THERAPY IN ITALY: A PROBABILISTIC SENSITIVITY ANALYSIS
|
Mantovani, LG
|
|
2008
|
11 |
6 |
p. A548-
1 p.
|
artikel
|
| 705 |
PMS46 DEVELOPMENT OF A SPECIFIC TOOL TO EVALUATE WOMEN'S ADHERENCE TO OSTEOPOROSIS TREATMENT
|
Roborel de Climens, A
|
|
2008
|
11 |
6 |
p. A551-
1 p.
|
artikel
|
| 706 |
PMS2 DIAGNOSIS OF OSTEOPOROSIS BY DUAL X-RAY AND LASER (DXL) DENSITOMETRY—A HEALTH TECHNOLOGY ASSESSMENT
|
Beh, JS
|
|
2008
|
11 |
6 |
p. A536-A537
nvt p.
|
artikel
|
| 707 |
PMS64 DIFFERENCES IN QUALITY OF LIFE ACCORDING TO THE REPLACED JOINT
|
Escobar, A
|
|
2008
|
11 |
6 |
p. A557-
1 p.
|
artikel
|
| 708 |
PMS62 DISCONTINUATION RATE OF THE IST AND IIND ANTI-TUMOR NECROSIS FACTORTHERAPIES IN PATIENTS WITH RHEUMATOID ARTHRITIS IN ITALY
|
Punzi, L
|
|
2008
|
11 |
6 |
p. A556-
1 p.
|
artikel
|
| 709 |
PMS55 EURO QOL (EQ-5D) BASED QOL (QUALITY OF LIFE) IN 5,023 JAPANESE PATIENTS WITH RHEUMATOID ARTHRITIS (RA) PATIENTS IN AN OBSERVATIONAL COHORT IORRA
|
Hoshi, D
|
|
2008
|
11 |
6 |
p. A554-
1 p.
|
artikel
|
| 710 |
PMS58 FIBROMYALGIA MOLDOFSKY QUESTIONNAIRE (FMQ): USE OF A TOOL TO AID DIAGNOSIS
|
Le Lay, K
|
|
2008
|
11 |
6 |
p. A555-
1 p.
|
artikel
|
| 711 |
PMS56 FIBROMYALGIA MOLDOFSKY QUESTIONNAIRE (FMQ): VALIDATION OF A TOOL TO AID DIAGNOSIS
|
Le Lay, K
|
|
2008
|
11 |
6 |
p. A554-
1 p.
|
artikel
|
| 712 |
PMS50 FRACTURE INCIDENCE AND CHANGES IN QUALITY OF LIFE AND BACK PAIN INWOMEN WITH OSTEOPOROSIS TREATED WITH TERIPARATIDE: EUROPEAN FORSTEO OBSERVATIONAL STUDY (EFOS) 18 MONTH RESULTS FROM PATIENTS ENROLLED IN FRANCE
|
Rajzbaum, G
|
|
2008
|
11 |
6 |
p. A552-
1 p.
|
artikel
|
| 713 |
PMS65 GOLIMUMAB, A HUMAN ANTI-TNF-ALPHA MONOCLONAL ANTIBODY, SIGNIFICANTLY IMPROVES SELF-REPORTED PRODUCTIVITY IN PATIENTS WITH RHEUMATOID ARTHRITIS: RESULTS FROMTHREE PHASE 3 STUDIES
|
Buchanan, J
|
|
2008
|
11 |
6 |
p. A557-
1 p.
|
artikel
|
| 714 |
PMS43 GOLIMUMAB, A HUMAN ANTI-TNF-ALPHA MONOCLONAL ANTIBODY, SIGNIFICANTLY REDUCES TIME LOST FROM WORK FOR PATIENTS WITH RHEUMATOID ARTHRITIS: POOLED RESULTS FROMTHREE PHASE 3 STUDIES
|
Buchanan, J
|
|
2008
|
11 |
6 |
p. A550-
1 p.
|
artikel
|
| 715 |
PMS34 HEALTH ECONOMIC EVALUATION OF OUTPATIENT MANAGEMENT OF FIBROMYALGIA IN FRANCE
|
Lamotte, M
|
|
2008
|
11 |
6 |
p. A547-
1 p.
|
artikel
|
| 716 |
PMS33 HEALTH ECONOMIC EVALUATION OF OUTPATIENT MANAGEMENT OF FIBROMYALGIA IN SPAIN
|
Lamotte, M
|
|
2008
|
11 |
6 |
p. A546-
1 p.
|
artikel
|
| 717 |
PMS67 HEALTH GAINS FOREGONE DUETO THE SUSTAINED DELAY OF ADEQUATE UTILIZATION OF EVIDENCE BASED TREATMENTS: THE CASE OF BISPHOSPHONATES FOR THE TREATMENT OF OSTEOPOROSIS
|
Storz, P
|
|
2008
|
11 |
6 |
p. A558-
1 p.
|
artikel
|
| 718 |
PMS49 HEALTH-RELATED QUALITY OF LIFE (HRQL) OF MODERATE TO SEVERE RHEUMATOID ARTHRITIS (RA) PATIENTS IN GREECE: PRELIMINARY RESULTS FROM THE HEOR STUDY
|
Papagiannopoulou, V
|
|
2008
|
11 |
6 |
p. A552-
1 p.
|
artikel
|
| 719 |
PMS20 IMPACT OF MEDICATION NON-COMPLIANCE AND NON-PERSISTENCE ON PHARMACOECONOMIC EVALUATIONS IN OSTEOPOROSIS
|
Hiligsmann, M
|
|
2008
|
11 |
6 |
p. A542-
1 p.
|
artikel
|
| 720 |
PMS13 IMPACT OFVIOXX WITHDRAWAL ON VOLUME OF TOTAL HIP AND KNEE REPLACEMENTS
|
Huse, D
|
|
2008
|
11 |
6 |
p. A540-
1 p.
|
artikel
|
| 721 |
PMS23 INITIAL COMBINATION THERAPY WITH INFLIXIMAB VERSUS SEQUENTIAL DMARD MONOTHERAPY: A COST-EFFECTIVENESS MODEL BASED ON THE BEST STUDY
|
Ganz, ML
|
|
2008
|
11 |
6 |
p. A543-
1 p.
|
artikel
|
| 722 |
PMS15 LEFLUNOMIDE IN THE TREATMENT OF RHEUMATOID ARTHRITIS IN POLAND—A BUDGET IMPACT ANALYSIS
|
Golicki, D
|
|
2008
|
11 |
6 |
p. A540-
1 p.
|
artikel
|
| 723 |
PMS51 MAJOR DETERMINANTS OF EUROQOL (EQ-5D) IN PATIENTS WITH RHEUMATOID ARTHRITIS BASED ON A LARGE JAPANESE COHORT IORRA
|
Igarashi, A
|
|
2008
|
11 |
6 |
p. A552-A553
nvt p.
|
artikel
|
| 724 |
PMS14 NEW STRATEGIES IN THE TREATMENT OF RHEUMATOID ARTHRITIS PATIENTS IN ITALY: A BUDGET IMPACT ANALYSIS
|
Iannazzo, S
|
|
2008
|
11 |
6 |
p. A540-
1 p.
|
artikel
|
| 725 |
PMS31 OSTEOARTHRITIS AND JOB ABSENTEEISM COSTS: EVIDENCE FROM U.S. NATIONAL SURVEY DATA
|
Kotlarz, H
|
|
2008
|
11 |
6 |
p. A546-
1 p.
|
artikel
|
| 726 |
PMS45 OUTPATIENT MEDICAL MANAGEMENT OF FIBROMYALGIA IN FRANCE COMPARED TO THE UNITED KINGDOM
|
Maugars, Y
|
|
2008
|
11 |
6 |
p. A550-A551
nvt p.
|
artikel
|
| 727 |
PMS44 PARAMEDICAL OR ALTERNATIVE TREATMENTS AND ASSOCIATED COSTS FOR THE MANAGEMENT OF FIBROMYALGIA IN FRANCE
|
Maugars, Y
|
|
2008
|
11 |
6 |
p. A550-
1 p.
|
artikel
|
| 728 |
PMS48 PATIENT EXPECTATIONS IN HEALTH RELATED QUALITY OF LIFE OUTCOMES IN TOTAL JOINT REPLACEMENT
|
González, M
|
|
2008
|
11 |
6 |
p. A551-A552
nvt p.
|
artikel
|
| 729 |
PMS63 PATIENT REPORTED OUTCOMES OF DIFFERENT SURGICAL PROCEDURES IN PATIENTS WITH CARTILAGE DEFECTS OF THE KNEE AFTER 1 TO 5YEARS
|
Brüggenjürgen, B
|
|
2008
|
11 |
6 |
p. A556-A557
nvt p.
|
artikel
|
| 730 |
PMS69 PATTERNS OF MORBIDITY AND DIRECT COSTS ASSOCIATED IN THE OSTEOPOROSIS SPANISH POPULATION SETTING
|
Sicras, A
|
|
2008
|
11 |
6 |
p. A558-A559
nvt p.
|
artikel
|
| 731 |
PMS7 PREVALENCE OF FIBROMYALGIA: A LARGE-SCALE EUROPEAN SURVEY: EARLY RESULTS IN UNITED-KINGDOM
|
Le Lay, K
|
|
2008
|
11 |
6 |
p. A538-
1 p.
|
artikel
|
| 732 |
PMS6 PREVALENCE OF FIBROMYALGIA IN FRANCE
|
Le Lay, K
|
|
2008
|
11 |
6 |
p. A538-
1 p.
|
artikel
|
| 733 |
PMS5 PREVALENCE OF FIBROMYALGIA IN GERMANY
|
Le Lay, K
|
|
2008
|
11 |
6 |
p. A537-A538
nvt p.
|
artikel
|
| 734 |
PMS8 PREVALENCE OF FIBROMYALGIA IN ITALY
|
Le Lay, K
|
|
2008
|
11 |
6 |
p. A538-
1 p.
|
artikel
|
| 735 |
PMS9 PREVALENCE OF FIBROMYALGIA IN PORTUGAL
|
Le Lay, K
|
|
2008
|
11 |
6 |
p. A538-A539
nvt p.
|
artikel
|
| 736 |
PMS11 PREVALENCE OF FIBROMYALGIA IN RUSSIA: EARLY RESULTS
|
Le Lay, K
|
|
2008
|
11 |
6 |
p. A539-
1 p.
|
artikel
|
| 737 |
PMS10 PREVALENCE OF FIBROMYALGIA IN SPAIN
|
Le Lay, K
|
|
2008
|
11 |
6 |
p. A539-
1 p.
|
artikel
|
| 738 |
PMS53 PUBLIC HEALTH OBJECTIVE: THE QUALITY OF LIFE OF SUFFERERS OF OSTEOARTHRITIS FINALLY TAKEN INTO CONSIDERATION
|
Taieb, C
|
|
2008
|
11 |
6 |
p. A553-
1 p.
|
artikel
|
| 739 |
PMS60 QUALITATIVE STEPS FOR THE DEVELOPMENT OF A QUESTIONNAIRE ASSESSING THE BURDEN OF FIBROMYALGIA ON PATIENTS' DAILY LIVES
|
Arnould, B
|
|
2008
|
11 |
6 |
p. A555-A556
nvt p.
|
artikel
|
| 740 |
PMS54 RELIEF OF PAIN AND SYMPTOMS IN KNEE CARTILAGE DEFECT IS ASSOCIATED WITH HIGHER SF-36 UTILITY SCORES: DATA FROM A PROSPECTIVE RANDOMIZED TRIAL OF CHONDROCELECT®
|
Gerlier, L
|
|
2008
|
11 |
6 |
p. A553-A554
nvt p.
|
artikel
|
| 741 |
PMS59 RESTORATIVE EFFECT OF SLEEP: VALIDATION OF THE SQA (SLEEP QUALITY ASSESSMENT)
|
Le Lay, K
|
|
2008
|
11 |
6 |
p. A555-
1 p.
|
artikel
|
| 742 |
PMS35 RHEUMATOID ARTHRITIS COST STUDY RESULTS IN POLAND
|
Lacki, J
|
|
2008
|
11 |
6 |
p. A547-
1 p.
|
artikel
|
| 743 |
PMS61 SHORT-TERM OUTCOMES AND HRQOL AFTER PEDIATRIC EMERGENCY DEPARTMENT (PED) TREATMENT OF MINOR INJURY: A PILOT STUDY
|
Stevens, MW
|
|
2008
|
11 |
6 |
p. A556-
1 p.
|
artikel
|
| 744 |
PMS24 THE COST-EFFECTIVENESS OF SEQUENTIAL USE OF ANTI-TUMOR NECROSIS FACTOR AGENTS IN THE TREATMENT OF RHEUMATOID ARTHRITIS
|
Taylor, MJ
|
|
2008
|
11 |
6 |
p. A544-
1 p.
|
artikel
|
| 745 |
PMS32 THE DIRECT HEALTH CARE COSTS OF OSTEOARTHRITIS: EVIDENCE FROM US NATIONAL SURVEY DATA
|
Kotlarz, H
|
|
2008
|
11 |
6 |
p. A546-
1 p.
|
artikel
|
| 746 |
PMS17 THE ECONOMIC IMPLICATIONS OF ACHIEVING TREATMENT RESPONSE IN PATIENTS WITH RHEUMATOID ARTHRITIS
|
Taylor, MJ
|
|
2008
|
11 |
6 |
p. A541-
1 p.
|
artikel
|
| 747 |
PMS52 THE QUALITY OF LIFE OF SUFFERERS OF OSTEOARTHRITIS: THE IMPACT OF TREATMENT
|
Taieb, C
|
|
2008
|
11 |
6 |
p. A553-
1 p.
|
artikel
|
| 748 |
PMS12 THE ROLE OF DIFFERENT CO-MORBIDITIES IN THE EVALUATION OF CORRELATION BETWEEN CERTAIN RISK FACTORS AND THE ONE YEAR MORTALITY FOLLOWING FEMORAL NECK FRACTURE
|
Sebestyen, A
|
|
2008
|
11 |
6 |
p. A539-A540
nvt p.
|
artikel
|
| 749 |
PMS47 USING HAQTO ESTIMATE HUI3 AND EQ-5D UTILITY VALUES IN SPANISH RHEUMATOID ARTHRITIS PATIENTS
|
Fernández, I
|
|
2008
|
11 |
6 |
p. A551-
1 p.
|
artikel
|
| 750 |
PMS57 VALIDITY AND RESPONSIVENESS OF THE WORK PRODUCTIVITY SURVEY: A NOVEL DISEASE-SPECIFIC INSTRUMENT ASSESSINGWORK PRODUCTIVITY WITHIN AND OUTSIDE THE HOME IN SUBJECTS WITH RHEUMATOID ARTHRITIS
|
Osterhaus, J
|
|
2008
|
11 |
6 |
p. A554-A555
nvt p.
|
artikel
|
| 751 |
PMS66 WILLINGNESS TO PAY VS. QUALITY ADJUSTEDWAGES AS ALTERNATIVE WAYS TO MEASURE THE BURDEN OF DISEASE IN SPAIN: AN APPLICATION TO BALLOON KYPHOPLASTY
|
Anton, E
|
|
2008
|
11 |
6 |
p. A557-A558
nvt p.
|
artikel
|
| 752 |
PND13 ALZHEIMER'S DISEASE PRESCRIPTION MEDICATION COSTS: 2004–2005
|
Anderson, K
|
|
2008
|
11 |
6 |
p. A603-
1 p.
|
artikel
|
| 753 |
PND3 ANTI-EPILEPTIC MEDICATION DRUG FORMULATION CHANGES AND THEIR RELATIONSHIP TO OUTCOMES (AMBULANCE, EMERGENCY DEPARTMENT AND INPATIENT EVENTS)
|
Mann, TA
|
|
2008
|
11 |
6 |
p. A600-
1 p.
|
artikel
|
| 754 |
PND26 ARE THERE DIFFERENCES IN PATIENT SATISFACTION WITH INSOMNIA MEDICATIONS? PILOT RESULTS FROM A NOVEL REGISTRY
|
Bharmal, M
|
|
2008
|
11 |
6 |
p. A607-A608
nvt p.
|
artikel
|
| 755 |
PND19 AT ALIZUMAB REDUCES RELAPSE-ASSOCIATED COSTS HOSPITALIZATIONS IN PATIENTS WITH RELAPSING MULTIPLE SCLEROSIS
|
O'Day, K
|
|
2008
|
11 |
6 |
p. A605-
1 p.
|
artikel
|
| 756 |
PND10 BURDEN OF DISEASE IN MODERATE ALZHEIMER DISEASE PATIENTS WITH DEPRESSION IN SPAIN (IDEAL STUDY)
|
Collar, JM
|
|
2008
|
11 |
6 |
p. A602-
1 p.
|
artikel
|
| 757 |
PND24 CANTHE CHQ-PF50 BE USED TO MONITOR CHANGES IN BEHAVIORAL AND EMOTIONAL FUNCTIONING IN CHILDREN TREATED FOR EPILEPSY?
|
de La Loge, C
|
|
2008
|
11 |
6 |
p. A607-
1 p.
|
artikel
|
| 758 |
PND8 COST-EFFECTIVENESS ANALYSIS OF REBIF IN FIRST-LINE RELAPSING REMITTING MULTIPLE SCLEROSIS IN GERMANY
|
Nuijten, MJ
|
|
2008
|
11 |
6 |
p. A602-
1 p.
|
artikel
|
| 759 |
PND7 COST-EFFECTIVENESS OF A LIDOCAINE PLASTER RELATIVE TO PREGABALIN IN THE TREATMENT OF POST-HERPETIC NEURALGIA IN THE NETHERLANDS
|
Nuijten, MJ
|
|
2008
|
11 |
6 |
p. A601-
1 p.
|
artikel
|
| 760 |
PND12 COSTS OF HERPES ZOSTER AND POST-HERPETIC NEURALGIA IN FRANCE
|
Bénard, S
|
|
2008
|
11 |
6 |
p. A603-
1 p.
|
artikel
|
| 761 |
PND31 DESCRIPTIVE STUDY OF THE PHARMACOLOGICAL TREATMENTS USED IN PATIENTS WITH DEPRESSION IN PARKINSON'S DISEASE (PD)
|
Sunderland, TJ
|
|
2008
|
11 |
6 |
p. A609-
1 p.
|
artikel
|
| 762 |
PND29 EFFICIENCY PROFILE IN THE NEUROLOGICAL REFERRALS EFFECTUATE REFERENCE SPECIALISTS: USE CASE-MIX SYSTEM ADJUSTED CLINICAL GROUPS
|
Sicras-Mainar, A
|
|
2008
|
11 |
6 |
p. A608-A609
nvt p.
|
artikel
|
| 763 |
PND22 ELICITING UTILITY SCORES FOR HEALTH STATES ASSOCIATED WITH LENNOX-GASTAUT SYNDROME
|
Yi, Y
|
|
2008
|
11 |
6 |
p. A606-
1 p.
|
artikel
|
| 764 |
PND11 EPILEPSY COST OF ILLNESS IN THE U.S. PRIVATELY INSURED
|
Birnbaum, HG
|
|
2008
|
11 |
6 |
p. A602-A603
nvt p.
|
artikel
|
| 765 |
PND25 EVALUATION OF A BRIEF DEMENTIA SCREENING TEST FOR PARKINSON'S DISEASE (PD-BDST) IN A CLINICAL PRACTICE SETTING
|
Andrés, I
|
|
2008
|
11 |
6 |
p. A607-
1 p.
|
artikel
|
| 766 |
PND6 GLATIRAMER ACETATE VERSUS INTERFERON BETA-1A FOR INTRAMUSCULAR ADMINISTRATION: A COMPARISON OF OUTCOMES AMONG MULTIPLE SCLEROSIS PATIENTS
|
Castelli-Haley, J
|
|
2008
|
11 |
6 |
p. A601-
1 p.
|
artikel
|
| 767 |
PND4 GLATIRAMER ACETATE VERSUS INTERFERON BETA-1B FOR SUBCUTANEOUS ADMINISTRATION: A COMPARISON OF OUTCOMES AMONG MULTIPLE SCLEROSIS PATIENTS
|
Castelli-Haley, J
|
|
2008
|
11 |
6 |
p. A600-
1 p.
|
artikel
|
| 768 |
PND2 HUNTINGTON'S DISEASE: WHERE HAVEWE BEEN?
|
Samuels, E
|
|
2008
|
11 |
6 |
p. A600-
1 p.
|
artikel
|
| 769 |
PND1 INCIDENCE OF INJURY AND COST OF CARE FOR PATIENTS SEEKING EMERGENT CARE FOR EPILEPSY IN A UNITED STATES MANAGED CARE SETTING
|
Zachry III, WM
|
|
2008
|
11 |
6 |
p. A599-A600
nvt p.
|
artikel
|
| 770 |
PND16 INDIRECT COSTS OF ALZHEIMER'S DISEASE IN THE UNITED STATES
|
Anderson, K
|
|
2008
|
11 |
6 |
p. A604-
1 p.
|
artikel
|
| 771 |
PND20 MEASURING THE IMPACT OF NARCOLEPSY ON QUALITY OF LIFE: A SYSTEMATIC REVIEW
|
Khagram, L
|
|
2008
|
11 |
6 |
p. A605-A606
nvt p.
|
artikel
|
| 772 |
PND14 MEDICATION COSTS OF PATIENTS WITH CYSTIC FIBROSIS (CF) IN GERMANY
|
Eidt, D
|
|
2008
|
11 |
6 |
p. A603-A604
nvt p.
|
artikel
|
| 773 |
PND30 NATIONAL GUIDELINE FOR MULTIPLE SCLEROSIS TREATMENT IN BRAZILIAN PUBLIC HEALTH: AN ANALYSIS OF TREATMENT PATTERNS AND BUDGET IMPACT
|
Bueno, RLP
|
|
2008
|
11 |
6 |
p. A609-
1 p.
|
artikel
|
| 774 |
PND17 ONE-YEAR EXPENSES FOR THE PHARMACOLOGICAL MANAGEMENT OF EPILEPSY WITHIN OUTPATIENT SETTING OF MONTENEGRO: RATIONAL OR NOT?
|
Duborija-Kovacevic, N
|
|
2008
|
11 |
6 |
p. A604-A605
nvt p.
|
artikel
|
| 775 |
PND23 RELATIONSHIP BETWEEN CHANGES IN EQ-5D DERIVED UTILITY SCORES AND CHANGES IN IRLS SUM SCORES FROM A MAPPING EXERCISE IN TWO PHASE III CLINICAL TRIALS
|
Tan, SC
|
|
2008
|
11 |
6 |
p. A606-A607
nvt p.
|
artikel
|
| 776 |
PND18 RUFINAMIDE IN THE ADJUNCTIVE TREATMETN OF LENNOX-GASTAUT SYNDROME (LGS): A COST EFFECTIVENESS ANALYSIS
|
Yi, Y
|
|
2008
|
11 |
6 |
p. A605-
1 p.
|
artikel
|
| 777 |
PND21 SYMPTOM SEVERITY IN PARKINSON'S DISEASE SCALE (SSPDS): A NEW PATIENT-REPORTED OUTCOME MEASURE OF PARKINSON'S DISEASE SEVERITY
|
Schröder, S
|
|
2008
|
11 |
6 |
p. A606-
1 p.
|
artikel
|
| 778 |
PND15 THE INDIRECT COST BURDEN OF EPILEPSY IN THE UNITED STATES
|
Birnbaum, HG
|
|
2008
|
11 |
6 |
p. A604-
1 p.
|
artikel
|
| 779 |
PND28 TRENDS IN RESEARCH INTO CENTRAL NERVOUS SYSTEM DISORDERS: THE INFLUENCE OF AN AGING POPULATION
|
Lock, K
|
|
2008
|
11 |
6 |
p. A608-
1 p.
|
artikel
|
| 780 |
PND27 UTILIZATION PATTERNS OF ANTIEPILEPTIC DRUGS: AN ITALIAN PRESCRIPTION DATABASE ANALYSIS
|
Menditto, E
|
|
2008
|
11 |
6 |
p. A608-
1 p.
|
artikel
|
| 781 |
PND9 WITHIN-TRIAL COST EFFECTIVENESS ANALYSIS OF ARIPIPRAZOLE COMPARED TO STANDARD-OF-CARE IN THE SCHIZOPHRENIA TRIAL OF ARIPIPRAZOLE (STAR)
|
King, D
|
|
2008
|
11 |
6 |
p. A602-
1 p.
|
artikel
|
| 782 |
PRS22 ARE THE MEASUREMENT PROPERTIES OF THE ASTHMA QUALITY OF LIFE QUESTIONNAIRE (AQLQ) CONSISTENT ACROSS LANGUAGES?
|
Juniper, E
|
|
2008
|
11 |
6 |
p. A452-A453
nvt p.
|
artikel
|
| 783 |
PRS31 A SURVEY OF THE BURDEN OF ALLERGIC RHINITIS IN EUROPE
|
Gueron, B
|
|
2008
|
11 |
6 |
p. A455-
1 p.
|
artikel
|
| 784 |
PRS21 CAN ASTHMA QUALITY OF LIFE QUESTIONNAIRE (AQLQ) DATA FROM DIFFERENT COUNTRIES BE COMBINED FOR ANALYSES?
|
Williams, AE
|
|
2008
|
11 |
6 |
p. A452-
1 p.
|
artikel
|
| 785 |
PRS35 CHALLENGING ASTHMA MANAGEMENT WITH THE USE OF LABA/ICS COMBINATION VIA ATURBUHALER DEVICE, BOTH FOR MAINTENANCE AS WELL AS RELIEF, AND IT'S INFLUENCE ON ASTHMA CONTROL AND PATIENTS' WELL-BEING IN GREECE
|
Rasidakis, A
|
|
2008
|
11 |
6 |
p. A456-A457
nvt p.
|
artikel
|
| 786 |
PRS17 COMPARISON OF OUTPATIENT AND INPATIENT COSTS OF MODERATE AND SEVERE EXACERBATIONS OF COPD IN POLAND IN 2007
|
Jahnz-Rózyk, K
|
|
2008
|
11 |
6 |
p. A451-
1 p.
|
artikel
|
| 787 |
PRS12 COST-EFFECTIVENESS ANALYSIS OF SYMBICORT SMART® VERSUS FIXED COMBINATION TREATMENTS IN FINLAND
|
Tamminen, K
|
|
2008
|
11 |
6 |
p. A449-
1 p.
|
artikel
|
| 788 |
PRS9 COST-EFFECTIVENESS MODEL OF MOXIFLOXACIN IN ACUTE EXACERBATIONS OF CHRONIC BRONCHITIS (AECB) IN GERMANY INCLUDING THE EFFECTS OF RESISTANCE
|
Cure, S
|
|
2008
|
11 |
6 |
p. A448-A449
nvt p.
|
artikel
|
| 789 |
PRS11 COST-EFFECTIVENESS OF INCREASING MAINTENANCE DOSES WITH BUDESONIDE/FORMOTEROL MAINTENANCE + RELIEVER THERAPY
|
Kuna, P
|
|
2008
|
11 |
6 |
p. A449-
1 p.
|
artikel
|
| 790 |
PRS14 COST OF ALLERGIC RHINITIS IN PEDIATRIC PATIENTS IN MEXICO
|
Del-Rio Navarro, B
|
|
2008
|
11 |
6 |
p. A450-
1 p.
|
artikel
|
| 791 |
PRS40 DECISION-MAKING IN HEALTH CARE USING COST-EFFECTIVENESS EVIDENCE—SMOKING CESSATION COMPARED TO TREATMENT OF SMOKING-RELATED DISEASES
|
Poulsen, PB
|
|
2008
|
11 |
6 |
p. A458-
1 p.
|
artikel
|
| 792 |
PRS38 DEVELOPMENT OF EXPLICIT APPROPRIATENESS CRITERIA FOR THE INDICATION OF ADMISSION FROM PATIENTS WITH ACUTE COPD EXACERBATION
|
Quintana, JM
|
|
2008
|
11 |
6 |
p. A457-
1 p.
|
artikel
|
| 793 |
PRS18 DIFFERENCES IN TREATMENT COSTS AND RESOURCE UTILIZATION AMONG COPD PATIENTS TREATED WITH ALBUTEROL MDI OR LEVALBUTEROL MDI
|
Ohsfeldt, R
|
|
2008
|
11 |
6 |
p. A451-
1 p.
|
artikel
|
| 794 |
PRS5 ESTABLISHING THE INCIDENCE AND PREVALENCE OF MULTIPLE A TOPIC CONDITIONS IN UK: COHORT STUDY USING THE GENERAL PRACTICE RESEARCH DATABASE
|
Punekar, YS
|
|
2008
|
11 |
6 |
p. A447-
1 p.
|
artikel
|
| 795 |
PRS15 ESTIMATING EXCESS COSTS OF POPULATION-BASED CASES WITH MILD COPD—RESULTS FROM THE KORA F3 STUDY
|
Menn, P
|
|
2008
|
11 |
6 |
p. A450-
1 p.
|
artikel
|
| 796 |
PRS33 FACTORS AFFECTING QUALITY OF LIFE OF ASTHMATIC AND COPD PATIENTS
|
Meszaros, A
|
|
2008
|
11 |
6 |
p. A456-
1 p.
|
artikel
|
| 797 |
PRS39 GIVING-UP SMOKING: PREDICTIVE FACTORS OF SMOKING CESSATION AND ATTEMPTS TO STOP IN A FRENCH COHORT
|
Thomas, D
|
|
2008
|
11 |
6 |
p. A458-
1 p.
|
artikel
|
| 798 |
PRS28 HAS ASTHMA CONTROL IMPROVED SINCE AIRE? RESULTS OF A SURVEY IN 5 EUROPEAN COUNTRIES
|
Gueron, B
|
|
2008
|
11 |
6 |
p. A454-
1 p.
|
artikel
|
| 799 |
PRS30 HOW CONGRUENT ARE PATIENT AND CLINICIAN MODELS OF ASTHMA CONTROL?—PRELIMINARY FINDINGS FROM A QUALITATIVE STUDY
|
Ruedell, K
|
|
2008
|
11 |
6 |
p. A455-
1 p.
|
artikel
|
| 800 |
PRS27 INTERPRETING SCORES ON THREE PATIENT-REPORTED OUTCOME MEASURES FOR ASTHMA
|
Meads, DM
|
|
2008
|
11 |
6 |
p. A454-
1 p.
|
artikel
|
| 801 |
PRS23 IS THE EQ-5D RESPONSIVE TO RECOVERY FROM A MODERATE COPD EXACERBATION?
|
Goossens, L
|
|
2008
|
11 |
6 |
p. A453-
1 p.
|
artikel
|
| 802 |
PRS3 PREVALENCE OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE FROM ADMINISTRATIVE HEATH SERVICES DATABASES
|
Citarella, A
|
|
2008
|
11 |
6 |
p. A446-A447
nvt p.
|
artikel
|
| 803 |
PRS34 QUALITY OF LIFE DURING ACUTE EXACERBATIONS OF COPD: COMPARING EQ-5D, SF-12 AND SGRQ
|
Menn, P
|
|
2008
|
11 |
6 |
p. A456-
1 p.
|
artikel
|
| 804 |
PRS24 QUALITY OF LIFE RESULTS USING THE EUROQOL QUESTIONNAIRES AND DIRECT MEDICAL COSTS IN ASTHMATIC PATIENTS. CHAS STUDY
|
Tafalla, M
|
|
2008
|
11 |
6 |
p. A453-
1 p.
|
artikel
|
| 805 |
PRS37 RACIAL DISPARITIES IN UTILIZATION OF ASTHMA CONTROLLER DRUGTHERAPY
|
Vaidya, V
|
|
2008
|
11 |
6 |
p. A457-
1 p.
|
artikel
|
| 806 |
PRS19 RATES OF DISCONTINUATION AMONG COMMONLY PRESCRIBED MEDICATIONS IN THE US
|
Vanelli, MR
|
|
2008
|
11 |
6 |
p. A451-A452
nvt p.
|
artikel
|
| 807 |
PRS2 RELATIVE EFFECTIVENESS OF INHALED CORTICOSTEROIDS AND LEUKOTRIENE-RECEPTOR ANTAGONISTS TO PREVENT MODERATE-TO-SEVERE EXACERBATIONS AMONG ASTHMATIC CHILDREN
|
Blais, L
|
|
2008
|
11 |
6 |
p. A446-
1 p.
|
artikel
|
| 808 |
PRS1 SMOKING, ASTHMA AND COPD IN ADULTS: A TOO FREQUENT RELATION
|
Sicras, A
|
|
2008
|
11 |
6 |
p. A446-
1 p.
|
artikel
|
| 809 |
PRS42 SMOKING-CESSATION ACROSS BORDERS: TRANSFERABILITY OF COST-EFFECTIVENESS RESULTS
|
Vemer, P
|
|
2008
|
11 |
6 |
p. A459-
1 p.
|
artikel
|
| 810 |
PRS29 SOCIOECONOMIC ANALYSIS OF SMOKER'S PROFILE WHO INTENDS TO QUIT
|
Ramón, JM
|
|
2008
|
11 |
6 |
p. A454-A455
nvt p.
|
artikel
|
| 811 |
PRS4 SUB-ACUTE LACK OF ASTHMA CONTROL AS A PREDICTOR OF ASTHMA EXACERBATION IN A MANAGED CARE POPULATION
|
Stephenson, JJ
|
|
2008
|
11 |
6 |
p. A447-
1 p.
|
artikel
|
| 812 |
PRS32 SYMPTOMS AND IMPACT OF SYMPTOMS AS REPORTED BY ASTHMA PATIENTS
|
Williams, AE
|
|
2008
|
11 |
6 |
p. A455-A456
nvt p.
|
artikel
|
| 813 |
PRS20 SYSTEMATIC REVIEW OF FIXED-DOSE COMBINATIONS AND UNIT-OF-USE PACKAGING IN PATIENTS WITH HYPERTENSION, DYSLIPIDEMIA, AIDS, ASTHMA AND DIABETES TYPE 2
|
Paladio, N
|
|
2008
|
11 |
6 |
p. A452-
1 p.
|
artikel
|
| 814 |
PRS13 THE COST-EFFECTIVENESS OF VARENICLINE IN SMOKING CESSATION IN DENMARK
|
Poulsen, PB
|
|
2008
|
11 |
6 |
p. A450-
1 p.
|
artikel
|
| 815 |
PRS26 THE EXACT-PRO INITIATIVE: DEVELOPMENT AND VALIDATION OF A SINGLE PATIENT-REPORTED OUTCOME MEASURE FOR EVALUATING EXACERBATIONS OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE
|
Leidy, NK
|
|
2008
|
11 |
6 |
p. A454-
1 p.
|
artikel
|
| 816 |
PRS16 THE HOSPITALIZATION COST OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) IN THE UNIVERSITY HOSPITAL OF ALEXANDROUPOLIS, GREECE
|
Hatzikou, M
|
|
2008
|
11 |
6 |
p. A450-A451
nvt p.
|
artikel
|
| 817 |
PRS25 THE PUBLIC'S WILLINGNESS TO PAY FOR A QALY IN THAILAND
|
Thavorncharoensap, M
|
|
2008
|
11 |
6 |
p. A453-
1 p.
|
artikel
|
| 818 |
PRS7 THE TREATMENT OF MODERATE TO SEVERE PERSISTENT ASTHMA IN SELECTED AUTONOMOUS COMMUNITIES IN SPAIN: AN ECOMIC MODELTO ESTIMATE BUDGET IMPACT CONSEQUENCES OF INTRODUCING BECLOMETHASONE/FORMOTEROL
|
Darba, J
|
|
2008
|
11 |
6 |
p. A448-
1 p.
|
artikel
|
| 819 |
PRS8 TOTAL COSTS OF TOBACCO FOR SOCIETY—WHAT ARE THE RETURNS ON INVESTMENTS FOR DIFFERENT GOVERNMENTAL INTERVENTIONS?
|
Reissell, E
|
|
2008
|
11 |
6 |
p. A448-
1 p.
|
artikel
|
| 820 |
PRS41 USE OF AN ELECTRONIC DIARY IN 55 COUNTIRES: WHAT ARE THE CHALLENGES?
|
Muller, S
|
|
2008
|
11 |
6 |
p. A458-
1 p.
|
artikel
|
| 821 |
PRS36 WILLINGNESS TO PAY FOR CAREGIVERS OF PEDIATRIC ASTHMATIC PATIENTS IN KOREA
|
Park, D
|
|
2008
|
11 |
6 |
p. A457-
1 p.
|
artikel
|
| 822 |
PSS31 ACUTE OTITIS MEDIA: A MAJOR SOURCE OF PRODUCTIVITY LOSS
|
Stolk, E
|
|
2008
|
11 |
6 |
p. A618-A619
nvt p.
|
artikel
|
| 823 |
PSS49 A DISEASE MODEL ILLUSTRATING THE IMPACT OF PSORIASIS ON PATIENTS' LIVES
|
Marant, C
|
|
2008
|
11 |
6 |
p. A624-
1 p.
|
artikel
|
| 824 |
PSS21 ADMINISTRATIVE PREVALENCE OF PSORIASIS IN GERMANY
|
Schlander, M
|
|
2008
|
11 |
6 |
p. A615-A616
nvt p.
|
artikel
|
| 825 |
PSS7 A MIXED TREATMENT COMPARISON OF TOPICAL OCULAR HYPOTENSIVES FOR THE TREATMENT OF GLAUCOMA AND OCULAR HYPERTENSION
|
Orme, M
|
|
2008
|
11 |
6 |
p. A611-A612
nvt p.
|
artikel
|
| 826 |
PSS58 A SCORING SYSTEM FOR QUALITY OF CARE EVALUATION. A COMMUNITY-BASED STUDY OF CHRONIC LEG ULCERS IN NORTH GERMANY
|
Augustin, M
|
|
2008
|
11 |
6 |
p. A627-
1 p.
|
artikel
|
| 827 |
PSS45 A TOPICAL DERMATITIS: EVALUATION OF SELF-PERCEIVED STRESS AND QUALITY OF LIFE
|
Boussetta, S
|
|
2008
|
11 |
6 |
p. A623-
1 p.
|
artikel
|
| 828 |
PSS47 A TOPIC DERMATITIS AND THERMAL THERAPY: EVALUATION IN CHILDREN UNDER 15
|
Boussetta, S
|
|
2008
|
11 |
6 |
p. A623-A624
nvt p.
|
artikel
|
| 829 |
PSS43 A TOPIC DERMATITIS AND THERMAL THERAPY: EVALUATION OF MEDICAL SERVICE
|
Boussetta, S
|
|
2008
|
11 |
6 |
p. A622-
1 p.
|
artikel
|
| 830 |
PSS8 A TOPIC DERMATITIS IN CHILDHOOD: WHAT “DERMATOLOGICAL FUTURE” FOR THESE CHILDREN?
|
Misery, L
|
|
2008
|
11 |
6 |
p. A612-
1 p.
|
artikel
|
| 831 |
PSS53 A TOPIC DERMATITIS IN PAEDIATRIC PATIENTS: COMMON CAREGIVER BEHAVIOURWHEN FACING THE DIFFERENT DISEASE PRESENTATIONS OR LESION SEVERITY. ELIBROT STUDY
|
Lahoz, R
|
|
2008
|
11 |
6 |
p. A625-A626
nvt p.
|
artikel
|
| 832 |
PSS44 A TOPIC DERMATITIS & PSORIASIS: CROSS-EVALUATION OF QUALITY OF LIFE
|
Boussetta, S
|
|
2008
|
11 |
6 |
p. A622-A623
nvt p.
|
artikel
|
| 833 |
PSS32 COST-EFFECTIVENESS ANALYSIS OF THE FIXED COMBINATION GLAUCOMA MEDICATIONS BRIMONIDINE/TIMOLOL AND DORZOLAMIDE/TIMOLOL IN 10 EUROPEAN COUNTRIES
|
Hommer, AB
|
|
2008
|
11 |
6 |
p. A619-
1 p.
|
artikel
|
| 834 |
PSS25 COST-EFFECTIVENESS OF ETANERCEPT AND EFALIZUMAB IN THE MANAGEMENT OF MODERATE AND SEVERE PLAQUE PSORIASIS
|
Ortonne, JP
|
|
2008
|
11 |
6 |
p. A617-
1 p.
|
artikel
|
| 835 |
PSS27 COST-EFFECTIVENESS OF THREE INTRA-OCULAR LENSES AFTER CATARACT SURGERY IN THE NETHERLANDS: RESTOR®, ARRAY-SA40® AND A MONOFOCAL
|
De vries, N
|
|
2008
|
11 |
6 |
p. A617-A618
nvt p.
|
artikel
|
| 836 |
PSS30 COST OF SPECTACLES AFTER CATARACT SURGERY IN THE NETHERLANDS
|
De vries, N
|
|
2008
|
11 |
6 |
p. A618-
1 p.
|
artikel
|
| 837 |
PSS35 COST UTILITY OF BILATERAL COCHLEAR IMPLANT
|
Callejo, D
|
|
2008
|
11 |
6 |
p. A620-
1 p.
|
artikel
|
| 838 |
PSS60 DERMATOLOGY LIFE QUALITY INDEX IS MORE SENSITIVE THAN PSORIASIS AREA AND SEVERITY INDEX TO MEASURE TREATMENT EFFECT IN PATIENTS WITH PSORIASIS: FINDINGS FROM THE PHOENIX I TRIAL
|
Lebwohl, M
|
|
2008
|
11 |
6 |
p. A628-
1 p.
|
artikel
|
| 839 |
PSS50 DEVELOPMENT OF AN INSTRUMENT FOR ASSESSING HEALTH RELATED QUALITY OF LIFE IN PATIENTS WITH CHRONIC URTICARIA
|
Garcia, A
|
|
2008
|
11 |
6 |
p. A624-A625
nvt p.
|
artikel
|
| 840 |
PSS14 DRY SKIN: AN EPIDEMIOLOGICAL APPROACH
|
Boussetta, S
|
|
2008
|
11 |
6 |
p. A613-
1 p.
|
artikel
|
| 841 |
PSS6 EFFECTIVENESS OF MOXIFLOXACIN IN THE TREATMENT OF BACTERIAL CONJUNCTIVITIS IN ADULTS
|
Lafuma, A
|
|
2008
|
11 |
6 |
p. A611-
1 p.
|
artikel
|
| 842 |
PSS2 EFFECTIVENESS OF THE RESTOR MULTIFOCAL INTRAOCULAR LENS (IOL) IN CATARACT AND PRESBYOPIA SURGERIES IN TWO EUROPEAN COUNTRIES
|
Berdeaux, G
|
|
2008
|
11 |
6 |
p. A610-
1 p.
|
artikel
|
| 843 |
PSS54 EVALUATION OF TREATMENT SATISFACTION WITH ETANERCEPT VERSUS ALTERNATIVE TREATMENTS FOR PSORIASIS: A PATIENT SURVEY ACROSS NINE EUROPEAN COUNTRIES
|
Conway, P
|
|
2008
|
11 |
6 |
p. A626-
1 p.
|
artikel
|
| 844 |
PSS22 FINAL EVALUATION OF THE PERSISTENCE DEGREE OF PATIENTS IN FIRST-LINE MONOTHERAPY ANTIGLAUCOMATOUS TREATMENT IN SPAIN
|
Arias, A
|
|
2008
|
11 |
6 |
p. A616-
1 p.
|
artikel
|
| 845 |
PSS13 HAIR LOSS: AN EPIDEMIOLOGICAL APPROACH
|
Misery, L
|
|
2008
|
11 |
6 |
p. A613-
1 p.
|
artikel
|
| 846 |
PSS48 HOSPITAL DERMATOLOGY CONSULTATION TYPES: A FRENCH ASSESSMENT
|
Bousetta, S
|
|
2008
|
11 |
6 |
p. A624-
1 p.
|
artikel
|
| 847 |
PSS37 IDENTIFYING NON COMPLIANT GLAUCOMA PATIENTS USING THE EDSQ, A QUESTIONNAIRE MEASURING SATISFACTION AND COMPLIANCE OF GLAUCOMA TREATMENT
|
Regnault, A
|
|
2008
|
11 |
6 |
p. A620-A621
nvt p.
|
artikel
|
| 848 |
PSS5 IMPACT OF COMPLIANCE ON INTRA-OCULAR PRESSURE (IOP) CONTROL IN GLAUCOMA PATIENTS
|
Lafuma, A
|
|
2008
|
11 |
6 |
p. A611-
1 p.
|
artikel
|
| 849 |
PSS59 IMPACT OF HEALTH CARE REGULATION ON PROSTAGLANDIN ANALOGUE PRESCRIBING IN 5 EUROPEAN COUNTRIES
|
De Natale, R
|
|
2008
|
11 |
6 |
p. A627-A628
nvt p.
|
artikel
|
| 850 |
PSS46 MELANOTIC TUMOURS: EVALUATION OF SELF-PERCEIVED STRESS AND QUALITY OF LIFE
|
Boussetta, S
|
|
2008
|
11 |
6 |
p. A623-
1 p.
|
artikel
|
| 851 |
PSS34 MODELLING THE LONG-TERM CLINICAL OUTCOMES OF MEDICAL MANAGEMENT OF PRIMARY OPEN ANGLE GLAUCOMA AND OCULAR HYPERTENSION
|
Orme, M
|
|
2008
|
11 |
6 |
p. A619-A620
nvt p.
|
artikel
|
| 852 |
PSS26 PHARMACOECONOMIC EVALUATION OF RANIBIZUMAB IN THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION IN AUSTRIA
|
Walter, E
|
|
2008
|
11 |
6 |
p. A617-
1 p.
|
artikel
|
| 853 |
PSS56 PRESCRIPTION REFILLS AND HEALTH CARE COSTS ASSOCIATED WITH TOPICAL METRONIDAZOLE IN MEDICAID ENROLLED PATIENTS WITH ROSACEA
|
Jayawant, SS
|
|
2008
|
11 |
6 |
p. A626-A627
nvt p.
|
artikel
|
| 854 |
PSS42 PSORIASIS AND THERMAL THERAPY: EVALUATION OF MEDICAL SERVICE
|
Boussetta, S
|
|
2008
|
11 |
6 |
p. A622-
1 p.
|
artikel
|
| 855 |
PSS39 QUALITY OF LIFE IN MODERATE TO SEVERE PSORIASIS PATIENTS IN SPAIN
|
Puig, L
|
|
2008
|
11 |
6 |
p. A621-
1 p.
|
artikel
|
| 856 |
PSS38 RELATION BETWEEN SELF REPORTED GLAUCOMA SYMPTOMS AND COMPLIANCE
|
Ruiz, MA
|
|
2008
|
11 |
6 |
p. A621-
1 p.
|
artikel
|
| 857 |
PSS40 RESPONSE SHIFT IN A RANDOMIZED CONTROLLED TRIAL OF LOWVISION CARE FOR PATIENTS WITH AGE-RELATED MACULOPATHY
|
Shimozuma, K
|
|
2008
|
11 |
6 |
p. A621-A622
nvt p.
|
artikel
|
| 858 |
PSS4 RESTOR® VERSUS ACRILISA® ND-YAG LASER INCIDENCE RATE COMPARISON ONE YEAR AFTER SURGERY
|
Gauthier, L
|
|
2008
|
11 |
6 |
p. A610-A611
nvt p.
|
artikel
|
| 859 |
PSS57 RETROSPECTIVE CHART REVIEW TO ASSESS IMPLEMENTATION OF NICE GUIDANCE ON THE USE OF BIOLOGICAL THERAPIES IN PATIENTS WITH CHRONIC PLAQUE PSORIASIS
|
Chauhan, D
|
|
2008
|
11 |
6 |
p. A627-
1 p.
|
artikel
|
| 860 |
PSS1 RISK OF PSYCHIATRIC DISORDERS AND HEALTH CARE EXPENDITURES AMONG PATIENTS WITH MODERATE TO SEVERE PSORIASIS
|
Han, C
|
|
2008
|
11 |
6 |
p. A609-A610
nvt p.
|
artikel
|
| 861 |
PSS52 SCORING AND PSYCHOMETRIC PROPERTIES OF THE EYE-DROP SATISFACTION QUESTIONNAIRE (EDSQ)
|
Regnault, A
|
|
2008
|
11 |
6 |
p. A625-
1 p.
|
artikel
|
| 862 |
PSS51 SCORING AND PSYCHOMETRIC VALIDATION OF THE FREEDOM FROM GLASSES VALUE SCALE (FGVS)
|
Meunier, J
|
|
2008
|
11 |
6 |
p. A625-
1 p.
|
artikel
|
| 863 |
PSS9 SENSITIVE SCALP: AN EPIDEMIOLOGICAL APPROACH
|
Misery, L
|
|
2008
|
11 |
6 |
p. A612-
1 p.
|
artikel
|
| 864 |
PSS10 SENSITIVE SKIN IN EUROPE: AN EPIDEMIOLOGICAL APPROACH
|
Misery, L
|
|
2008
|
11 |
6 |
p. A612-
1 p.
|
artikel
|
| 865 |
PSS17 SENSITIVE SKINS IN BELGIUM: AN EPIDEMIOLOGICAL APPROACH
|
Boussetta, S
|
|
2008
|
11 |
6 |
p. A614-
1 p.
|
artikel
|
| 866 |
PSS11 SENSITIVE SKINS IN FRANCE: AN EPIDEMIOLOGICAL APPROACH
|
Boussetta, S
|
|
2008
|
11 |
6 |
p. A612-A613
nvt p.
|
artikel
|
| 867 |
PSS16 SENSITIVE SKINS IN GERMANY: AN EPIDEMIOLOGICAL APPROACH
|
Boussetta, S
|
|
2008
|
11 |
6 |
p. A614-
1 p.
|
artikel
|
| 868 |
PSS19 SENSITIVE SKINS IN GREECE: AN EPIDEMIOLOGICAL APPROACH
|
Boussetta, S
|
|
2008
|
11 |
6 |
p. A615-
1 p.
|
artikel
|
| 869 |
PSS20 SENSITIVE SKINS IN ITALY: AN EPIDEMIOLOGICAL APPROACH
|
Boussetta, S
|
|
2008
|
11 |
6 |
p. A615-
1 p.
|
artikel
|
| 870 |
PSS12 SENSITIVE SKINS IN PORTUGAL: AN EPIDEMIOLOGICAL APPROACH
|
Boussetta, S
|
|
2008
|
11 |
6 |
p. A613-
1 p.
|
artikel
|
| 871 |
PSS15 SENSITIVE SKINS IN SPAIN: AN EPIDEMIOLOGICAL APPROACH
|
Boussetta, S
|
|
2008
|
11 |
6 |
p. A614-
1 p.
|
artikel
|
| 872 |
PSS18 SENSITIVE SKINS IN SWITZERLAND: AN EPIDEMIOLOGICAL APPROACH
|
Boussetta, S
|
|
2008
|
11 |
6 |
p. A614-A615
nvt p.
|
artikel
|
| 873 |
PSS29 SOCIETAL COSTS OF SEVERE CHRONIC HAND ECZEMA (CHE) IN GERMANY
|
Hieke, K
|
|
2008
|
11 |
6 |
p. A618-
1 p.
|
artikel
|
| 874 |
PSS24 SYSTEMATIC REVIEW AND META-ANALYSIS OF RCTS REGARDING THE COMPARATIVE INCIDENCE OF HYPERAEMIA OF PROSTAGLANDIN TOPICAL GLAUCOMA MEDICATIONS
|
Lee, CW
|
|
2008
|
11 |
6 |
p. A616-A617
nvt p.
|
artikel
|
| 875 |
PSS33 THE COST OF UVEITIS TREATMENT IN FRANCE: A ONE-YEAR RETROSPECTIVE ANALYSIS
|
Kobelt, G
|
|
2008
|
11 |
6 |
p. A619-
1 p.
|
artikel
|
| 876 |
PSS36 THE DESCRIPTIVE EPIDEMIOLOGY AND OUTCOME OF HOSPITALISATIONS FOR PSORIASIS IN THE UNITED KINGDOM
|
Conway, P
|
|
2008
|
11 |
6 |
p. A620-
1 p.
|
artikel
|
| 877 |
PSS23 TOPICAL TACROLIMUS FOR THE TREATMENT OF A TOPIC DERMATITIS: A SYSTEMATIC REVIEW WITH META-ANALYSES
|
Â, Svensson
|
|
2008
|
11 |
6 |
p. A616-
1 p.
|
artikel
|
| 878 |
PSS55 USTEKINUMAB REDUCESWORK LIMITATIONS, INCREASES WORK PRODUCTIVITY AND DECREASESWORKDAYS MISSED DUETO PSORIASIS IN PATIENTS WITH MODERATE TO SEVERE PSORIASIS
|
Reich, K
|
|
2008
|
11 |
6 |
p. A626-
1 p.
|
artikel
|
| 879 |
PSS41 USTEKINUMAB SIGNIFICANTLY IMPROVES HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH MODERATE TO SEVERE PSORIASIS
|
Lebwohl, M
|
|
2008
|
11 |
6 |
p. A622-
1 p.
|
artikel
|
| 880 |
PSS28 VENOUS LEG ULCER. COSTS-OF-ILLNESS OF IN GERMANY. A NATIONAL CROSS-SECTIONAL STUDY
|
Purwins, S
|
|
2008
|
11 |
6 |
p. A618-
1 p.
|
artikel
|
| 881 |
PSS3 VISION WITH RESTOR®, ARRAY® SA40 AND A MONOFOCAL INTRA-OCULAR LENS (IOL) AFTER CATARACT SURGERY
|
De vries, N
|
|
2008
|
11 |
6 |
p. A610-
1 p.
|
artikel
|
| 882 |
PSY62 A NATURAL EXPERIMENT TO ESTIMATE THE IMPACT OF A PREFERRED DRUG LIST POLICY FOR LONG ACTING NARCOTIC ANALGESICS ON COSTS AND UTILIZATION
|
Flannagin, K
|
|
2008
|
11 |
6 |
p. A648-A649
nvt p.
|
artikel
|
| 883 |
PSY59 A POPULATION STUDY ON THE AGE-SPECIFIC RELATIONSHIP BETWEEN BODY MASS INDEX, METABOLIC DISORDERS, AND UTILIZATION OF AMBULATORY SERVICES
|
Chang, HY
|
|
2008
|
11 |
6 |
p. A648-
1 p.
|
artikel
|
| 884 |
PSY50 ASSESSING THE VALUE OF 24-HOUR CHRONIC PAIN CONTROL FROM THE PATIENT PERSPECTIVE: DO EXISTING PATIENT-REPORTED OUTCOMES INSTRUMENTS ADEQUATELY COVER THE RELEVANT CONCEPTS RELATED TO 24-HOUR CHRONIC PAIN CONTROL?
|
Guillemin, I
|
|
2008
|
11 |
6 |
p. A645-
1 p.
|
artikel
|
| 885 |
PSY1 A SYSTEMATIC REVIEW OF THE EFFICACY OF RECOMBINANT ACTIVATED FACTORVII (RFVIIA) AND ACTIVATED PROTHROMBIN COMPLEX CONCENTRATE (APCC) IN THE ON-DEMANDTREATMENT OF MINOR TO MODERATE BLEEDING EPISODES FOR HAEMOPHILIA PATIENTS WITH INHIBITORS
|
Knight, C
|
|
2008
|
11 |
6 |
p. A628-
1 p.
|
artikel
|
| 886 |
PSY8 BUDGET IMPACT ANALYSIS OF DEFERASIROX FOR THE TREATMENT OF CHRONIC IRON OVERLOAD IN PATIENTS WITH BETATHALASSAEMIA IN VENETO REGION, ITALY
|
Venturini, F
|
|
2008
|
11 |
6 |
p. A630-A631
nvt p.
|
artikel
|
| 887 |
PSY9 BUDGET IMPACT OF THE USE OF OROS® HYDROMORPHONE ONCE DAILY IN SEVERE CHRONIC PAIN PATIENTS IN THE GERMAN HEALTH CARE SYSTEM
|
Fleischmann, J
|
|
2008
|
11 |
6 |
p. A631-
1 p.
|
artikel
|
| 888 |
PSY40 BURDEN OF FIBROMYALGIA TO THE UK NATIONAL HEALTH SERVICE (NHS)
|
Lister, S
|
|
2008
|
11 |
6 |
p. A641-
1 p.
|
artikel
|
| 889 |
PSY33 CLINICAL AND ECONOMIC OUTCOMES ASSOCIATED WITH BLOODTRANSFUSION DURING INPATIENT HOSPITALIZATION: AN ANALYSIS OF THE 2004 HEALTH CARE COST AND UTILIZATION PROJECT NATIONWIDEINPATIENT SAMPLE DATABASE
|
Patel, ST
|
|
2008
|
11 |
6 |
p. A639-
1 p.
|
artikel
|
| 890 |
PSY2 CONTRIBUTIONS OF THE FABRY OUTCOME SURVEY (FOS) TO ADVANCING THE MANAGEMENT OF FABRY DISEASE
|
Clarke, J
|
|
2008
|
11 |
6 |
p. A628-A629
nvt p.
|
artikel
|
| 891 |
PSY35 COST-EFFECTIVENESS ANALYSIS OF THE EPOETIN TREATMENT IN PATIENTS WITH ANEMIA INDUCED BY CHEMOTHERAPY, EPICOST STUDY PRELIMINARY RESULTS (ONVIDA GROUP)
|
Camps, C
|
|
2008
|
11 |
6 |
p. A640-
1 p.
|
artikel
|
| 892 |
PSY14 COST-EFFECTIVENESS (CE) EVALUATION OF THE USE OF RITUXIMAB-CHOP VS. CHOP SCHEMES FOR THE TREATMENT OF AGGRESSIVE NON-HODGKIN LYMPHOMA (NHL) STAGES III AND IV: TREATMENT IMPACT OVER RELAPSE AND SURVIVAL, AT THE MEXICAN-NATIONAL CANCER INSTITUTE (MEX-INCAN)
|
Cervera-Ceballos, E
|
|
2008
|
11 |
6 |
p. A632-A633
nvt p.
|
artikel
|
| 893 |
PSY18 COST-EFFECTIVENESS OF FENTANYL ITS (IONSYSTM) IN POST-OPERATIVE PAIN MANAGEMENT: A FINNISH HOSPITAL PERSPECTIVE ANALYSIS
|
Van den Steen, D
|
|
2008
|
11 |
6 |
p. A634-
1 p.
|
artikel
|
| 894 |
PSY12 COST-EFFECTIVENESS OF FOOD FOR SPECIAL MEDICAL PURPOSES RELATIVE TO STANDARD CARE IN PATIENTS UNDERGOING ABDOMINAL SURGERY
|
Nuijten, MJ
|
|
2008
|
11 |
6 |
p. A632-
1 p.
|
artikel
|
| 895 |
PSY21 COST-MINIMIZATION ANALYSIS OF ORALVS. INTRAVENOUS FLUDARABINE (BENEFLUR®) IN SPAIN
|
Delgado, J
|
|
2008
|
11 |
6 |
p. A635-
1 p.
|
artikel
|
| 896 |
PSY26 COST OF TYROSINAEMIA TYPE ONE IN POLAND IN 2006
|
Chrzanowski, M
|
|
2008
|
11 |
6 |
p. A637-
1 p.
|
artikel
|
| 897 |
PSY34 COSTS AND PATIENT-REPORTED OUTCOMES (PRO) IN GERMAN PATIENTS WITH CHRONIC KNEE AND HIP PAIN
|
Breitscheidel, L
|
|
2008
|
11 |
6 |
p. A639-
1 p.
|
artikel
|
| 898 |
PSY32 COSTS OF A BLOODTRANSFUSION IN HEMATO-ONCOLOGIC PATIENTS IN A PORTUGUESE HOSPITAL
|
Brilhante, D
|
|
2008
|
11 |
6 |
p. A639-
1 p.
|
artikel
|
| 899 |
PSY31 ECONOMIC IMPACT OF THE FABRY-ANDERSON DISEASE TREATMENT
|
De Portu, S
|
|
2008
|
11 |
6 |
p. A638-
1 p.
|
artikel
|
| 900 |
PSY15 ECONOMIC IMPLICATIONS OF IRON CHELATION IN PATIENTS WITH REFRACTORY ANEMIA RELATED TO MYELODYSPLASTIC SYNDROME
|
Migliaccio-Walle, K
|
|
2008
|
11 |
6 |
p. A633-
1 p.
|
artikel
|
| 901 |
PSY42 E-DIARY COMPLIANCE IN ACUTE PAIN STUDIES
|
Marino, B
|
|
2008
|
11 |
6 |
p. A642-
1 p.
|
artikel
|
| 902 |
PSY11 EONOMIC EVALUATION OF ETANERCEPT COMPARED TO NO SYSTEMIC THERAPY IN THE MANAGEMENT OF LESS SEVERE CHRONIC PLAQUE PSORIASIS IN THE UK
|
Webber, JM
|
|
2008
|
11 |
6 |
p. A631-A632
nvt p.
|
artikel
|
| 903 |
PSY48 EPIDEMIOLOGY OF HEREDITARY COAGULOPATHIES IN RUSSIA: PATIENT-REPORTED DATA. INTERMEDIATE RESULTS. PART 2
|
Vorobyev, P
|
|
2008
|
11 |
6 |
p. A644-
1 p.
|
artikel
|
| 904 |
PSY4 EPIDEMIOLOGY OF IDIOPATHICTHROMBOCYTOPENIC PURPURA IN BELGIUM ASSESSED USING HOSPITAL RECORDS
|
Gerlier, L
|
|
2008
|
11 |
6 |
p. A629-
1 p.
|
artikel
|
| 905 |
PSY10 ESTIMATION OF THE COSTS FOR A HEREDITARY HEMOCHROMATOSIS GENETIC SCREENING PROGRAMME PER 100.000 INDIVIDUALS UNDER 30YEARS OF AGE IN SPAIN
|
Saz-Parkinson, Z
|
|
2008
|
11 |
6 |
p. A631-
1 p.
|
artikel
|
| 906 |
PSY36 EUROPEAN ECONOMIC EVALUATION OF OROS® HYDROMORPHONE IN THE MANAGEMENT OF SEVERE CHRONIC CANCER AND NON-CANCER PAIN
|
Hauber, AB
|
|
2008
|
11 |
6 |
p. A640-
1 p.
|
artikel
|
| 907 |
PSY5 FACTORS ASSOCIATED WITH SYSTEMIC LUPUS ERYTHEMATOSUS DISEASE ACTIVITY
|
Thaipanich, A
|
|
2008
|
11 |
6 |
p. A629-A630
nvt p.
|
artikel
|
| 908 |
PSY37 HEALTH AND ECONOMIC CONSEQUENCES OF PATHOGEN TRANSMISSION RISK IN THE TREATMENT OF HAEMOPHILIA A WITH FACTOR VIII
|
Asukai, Y
|
|
2008
|
11 |
6 |
p. A640-A641
nvt p.
|
artikel
|
| 909 |
PSY28 HEALTH CARE AND NON-HEALTH CARE RESOURCES UTILIZATION AND RELATED COSTS IN SUBJECTS WITH REFRACTORY PAIN ASSOCIATED TO LOW BACK PAIN: A POST-HOC ANALYSIS OF THE EFFECT OF PREGABALIN IN A 12-WEEK PROSPECTIVE STUDY UNDER ROUTINE MEDICAL PRACTICE CONDITIONS
|
Rejas, J
|
|
2008
|
11 |
6 |
p. A637-
1 p.
|
artikel
|
| 910 |
PSY27 HEALTH CARE AND NON-HEALTH CARE RESOURCES UTILIZATION AND RELATED COSTS IN SUBJECTS WITH REFRACTORY PAIN ASSOCIATED TO NECK PAIN: A POST-HOC ANALYSIS OF THE EFFECT OF PREGABALIN IN A 12-WEEK PROSPECTIVE STUDY UNDER ROUTINE MEDICAL PRACTICE CONDITIONS
|
Morera Domínguez, C
|
|
2008
|
11 |
6 |
p. A637-
1 p.
|
artikel
|
| 911 |
PSY30 HEALTH CARE RESOURCE USE AND COSTS AMONG PATIENTS WITH DIABETIC NEUROPATHIC PAIN IN THE ONE-YEAR FOLLOWING DULOXETINE THERAPY: IS INITIAL DOSING A SIGNIFICANT FACTOR?
|
Zhao, Y
|
|
2008
|
11 |
6 |
p. A638-
1 p.
|
artikel
|
| 912 |
PSY56 HEALTH-RELATED QUALITY OF LIFE AND PRODUCTIVITY AMONG HEMOPHILIA PATIENTS WITH INHIBITORS
|
Brown, TM
|
|
2008
|
11 |
6 |
p. A647-
1 p.
|
artikel
|
| 913 |
PSY39 IMPACT OF HIGHWAIST CIRCUMFERENCE ON PRODUCTIVITY IN US AND GERMAN OVERWEIGHT/OBESE SUBJECTS
|
Caterson, I
|
|
2008
|
11 |
6 |
p. A641-
1 p.
|
artikel
|
| 914 |
PSY38 IMPACT OF TENSION HEADACHE ON WORK PRODUCTIVITY LOSS AND ACTIVITY IMPAIRMENT
|
Bolge, SC
|
|
2008
|
11 |
6 |
p. A641-
1 p.
|
artikel
|
| 915 |
PSY61 INCREMENTAL SAVINGS ASSOCIATED WITH A DECREASE IN ANTIDEPRESSANT MEDICATIONS FOLLOWING BARIATRIC SURGERY IN WESTERN NEWYORK
|
Purdy, CH
|
|
2008
|
11 |
6 |
p. A648-
1 p.
|
artikel
|
| 916 |
PSY24 MANAGEMENT OF HERPES ZOSTER (HZ) AND POST-HERPETIC NEURALGIA (PHN) IN BELGIUM: A COST OF ILLNESS STUDY
|
Caekelbergh, K
|
|
2008
|
11 |
6 |
p. A636-
1 p.
|
artikel
|
| 917 |
PSY19 MEDICAL AND COST EFFECTIVENESS OF BARIATRIC SURGERY IN OBESITY. RESULTS OF AN HTA COMMISIONED BY THE GERMAN AGENY FOR HEALTHTECHNOLOGY ASSESSMENT
|
Vauth, C
|
|
2008
|
11 |
6 |
p. A634-A635
nvt p.
|
artikel
|
| 918 |
PSY55 PAIN MANAGEMENT IN THAILAND: IMPLICATION FOR BETTER PATIENT EDUCATION
|
Layton, MR
|
|
2008
|
11 |
6 |
p. A646-A647
nvt p.
|
artikel
|
| 919 |
PSY45 PATIENT ACCEPTABLE SYMPTOM STATE (PASS) IN EUROPEAN PATIENTS WITH MODERATE-SEVERE PLAQUE PSORIASIS
|
Molta, CT
|
|
2008
|
11 |
6 |
p. A643-
1 p.
|
artikel
|
| 920 |
PSY49 PATIENT-REPORTED OUTCOMES, HEALTH CARE RESOURCES UTILIZATION, WORK PRODUCTIVITY AND THEIR ASSOCIATED COSTS IN PATIENTS WITH NEUROPATHIC PAIN: A CASE CONTROL COMPARISON OF TREATMENT WITH PREGABALIN VERSUS GABAPENTIN IN ROUTINE MEDICAL PRACTICE
|
Pérez, C
|
|
2008
|
11 |
6 |
p. A644-A645
nvt p.
|
artikel
|
| 921 |
PSY46 PATIENT-REPORTED OUTCOMES (PRO) AND ECONOMICS OF MIGRAINE IN GERMANY
|
Breitscheidel, L
|
|
2008
|
11 |
6 |
p. A643-
1 p.
|
artikel
|
| 922 |
PSY51 PATIENT-REPORTED OUTCOMES (PRO) IN SUBJECTS WITH REFRACTORY PAIN ASSOCIATED TO LOW BACK PAIN: A POST-HOC ANALYSIS OF THE EFFECT OF PREGABALIN IN A 12-WEEK PROSPECTIVE STUDY UNDER ROUTINE MEDICAL PRACTICE CONDITIONS
|
Ceberio Balda, F
|
|
2008
|
11 |
6 |
p. A645-
1 p.
|
artikel
|
| 923 |
PSY47 PATIENT-REPORTED OUTCOMES (PRO) IN SUBJECTS WITH REFRACTORY PAIN ASSOCIATED TO NECK PAIN: A POST-HOC ANALYSIS OF THE EFFECT OF PREGABALIN IN A 12-WEEK PROSPECTIVE STUDY UNDER ROUTINE MEDICAL PRACTICE CONDITIONS
|
Flórez García, M
|
|
2008
|
11 |
6 |
p. A644-
1 p.
|
artikel
|
| 924 |
PSY64 PATIENT-REPORTED OUTCOMES (PRO'S) AND ECONOMICS IN PATIENTS WITH BACK PAIN IN GERMANY
|
Breitscheidel, L
|
|
2008
|
11 |
6 |
p. A649-
1 p.
|
artikel
|
| 925 |
PSY63 PATIENT-REPORTED OUTCOMES (PRO'S) AND ECONOMICS OF NEUROPATHIC PAIN IN GERMANY
|
Breitscheidel, L
|
|
2008
|
11 |
6 |
p. A649-
1 p.
|
artikel
|
| 926 |
PSY17 PRECISE STUDY: BASELINE ANALYSIS OF A COST EFFECTIVENESS STUDY ON FAILED BACK SURGERY SYNDROME
|
Beccagutti, G
|
|
2008
|
11 |
6 |
p. A633-A634
nvt p.
|
artikel
|
| 927 |
PSY60 PREDICTING FACTORS FOR METABOLIC SYNDROME AMONG US ADOLESCENTS 12–17YEARS OF AGE
|
Sias, S
|
|
2008
|
11 |
6 |
p. A648-
1 p.
|
artikel
|
| 928 |
PSY6 PREDICTING FACTORS FOR METABOLIC SYNDROME FOR US ADOLESCENTS AGE 12–17
|
Sias, S
|
|
2008
|
11 |
6 |
p. A630-
1 p.
|
artikel
|
| 929 |
PSY3 PREVALENCE OF METABOLIC ABNORMALITIES AMONG OBESE ADULTS IN KOREA
|
Lee, SY
|
|
2008
|
11 |
6 |
p. A629-
1 p.
|
artikel
|
| 930 |
PSY22 PROCESS STUDY: A 6-MONTHS COST-CONSEQUENCE ANALYSIS IN CHRONIC PAIN FROM THE SPANISH PERSPECTIVE
|
Molet, J
|
|
2008
|
11 |
6 |
p. A635-A636
nvt p.
|
artikel
|
| 931 |
PSY52 QUALITY OF LIFE IN RUSSIAN PATIENTS WITH HEREDITARY COAGULOPATHIES. INTERMEDIATE RESULTS
|
Vorobyev, P
|
|
2008
|
11 |
6 |
p. A645-A646
nvt p.
|
artikel
|
| 932 |
PSY58 RETROSPECTIVE ANALYSIS OF FACTORVIII UTILIZATION IN MATCHED HEMOPHILIA A PATIENTS TREATED WITH EITHER RECOMBINANT B DOMAIN-DELETED OR FULL-LENGTH FACTOR VIII
|
Epstein, JD
|
|
2008
|
11 |
6 |
p. A647-A648
nvt p.
|
artikel
|
| 933 |
PSY41 REVIEW OF HOME READINESS INSTRUMENTS TO ASSESS RECOVERY POST-SURGERY
|
Asmussen, M
|
|
2008
|
11 |
6 |
p. A642-
1 p.
|
artikel
|
| 934 |
PSY53 SATISFACTION WITH IRON CHELATION THERAPY IS ASSOCIATED WITH IMPROVED QUALITY OF LIFE IN PATIENTS WITH IRON OVERLOAD
|
Rofail, D
|
|
2008
|
11 |
6 |
p. A646-
1 p.
|
artikel
|
| 935 |
PSY25 SYSTEMATIC REVIEW OF THE COST OF ILLNESS OF SYSTEMIC LUPUS ERYTHEMATOSUS
|
Richard, L
|
|
2008
|
11 |
6 |
p. A636-
1 p.
|
artikel
|
| 936 |
PSY7 THE BUDGETARY IMPACT OF INCLUDING LAPAROSCOPIC ADJUSTABLE GASTRIC BANDING AS A COVERED SURGICAL TREATMENT FOR MORBIDLY OBESE ADULTS IN A MANAGED CARE POPULATION
|
Campbell, J
|
|
2008
|
11 |
6 |
p. A630-
1 p.
|
artikel
|
| 937 |
PSY20 THE COST EFFECTIVENESS OF DULOXETINE IN THE TREATMENT OF FIBROMYALGIA IN THE NHS IN SCOTLAND
|
Beard, S
|
|
2008
|
11 |
6 |
p. A635-
1 p.
|
artikel
|
| 938 |
PSY16 THE ECONOMIC IMPACT OF DIFFERENT STRATEGIES OF MANAGING RARE DISEASES WITH HIGH TREATMENT COSTS: THE CASE OF USING ACTIVATED RECOMBINANT FACTORVII IN SEVERE BLEEDS IN ACQUIRED HAEMOPHILIA PATIENTS
|
Odeyemi, IA
|
|
2008
|
11 |
6 |
p. A633-
1 p.
|
artikel
|
| 939 |
PSY43 THE IMPACT OF ROMIPLOSTIM ON PATIENT-REPORTED OUTCOMES MEASURED BY THE EUROQOL (EQ-5D)
|
Sanz, M
|
|
2008
|
11 |
6 |
p. A642-
1 p.
|
artikel
|
| 940 |
PSY29 TREATMENT COST OF FEBRILE NEUTROPENIA (FN) IN PATIENTS WITH ACUTE LEUKEMIA (AL) OR IN AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) RECIPIENTS FROM THE GERMAN HOSPITALS PERSPECTIVE
|
Ehlken, B
|
|
2008
|
11 |
6 |
p. A638-
1 p.
|
artikel
|
| 941 |
PSY44 UNDERSTANDING AND ASSESSING THE IMPACT OF PRESCRIPTION WEIGHT LOSS MEDICATION; CONCEPTUAL, GENDER AND CULTURAL ISSUES
|
Brod, M
|
|
2008
|
11 |
6 |
p. A642-A643
nvt p.
|
artikel
|
| 942 |
PSY54 UNDERSTANDING PATIENT PERCEPTION OF THE BIOENTERICS INTRAGASTRIC SYSTEM FOR WEIGHT REDUCTION
|
Hale, B
|
|
2008
|
11 |
6 |
p. A646-
1 p.
|
artikel
|
| 943 |
PSY57 USE OF AN ADMINISTRATIVE DATABASE TO ESTIMATE THE NUMBER OF HOSPITAL ADMISSIONS FOR IMMUNE THROMBOCYTOPENIC PURPURA AND ITS ECONOMIC BURDEN IN FRANCE
|
Vainchtock, A
|
|
2008
|
11 |
6 |
p. A647-
1 p.
|
artikel
|
| 944 |
PUK12 A COST-UTILITY ANALYSIS OF SOLIFENACIN 5 MG AND 10 MGVERSUS FESOTERODINE 4 MG AND 8 MG IN THE PHARMACOLOGICAL TREATMENT OF PATIENTS WITH OVERACTIVE BLADDER (OAB) IN THE UK NHS
|
Cardozo, L
|
|
2008
|
11 |
6 |
p. A653-
1 p.
|
artikel
|
| 945 |
PUK11 A COST-UTILITY ANALYSIS OF SOLIFENACIN 5 MG AND SOLIFENACIN 10 MGVERSUS TOLTERODINE ER 4 MG IN THE PHARMACOLOGICAL TREATMENT OF PATIENTS WITH OVERACTIVE BLADDER (OAB)
|
Cardozo, L
|
|
2008
|
11 |
6 |
p. A653-
1 p.
|
artikel
|
| 946 |
PUK14 A HEALTH ECONOMIC EVALUATION OF THE USE OF ERYTHROPOIESIS-STIMULATING AGENTS (ESA) IN PATIENTS WITH RENAL FAILURE TREATED WITH HAEMODIALYSIS
|
Van Bellinghen, LA
|
|
2008
|
11 |
6 |
p. A654-
1 p.
|
artikel
|
| 947 |
PUK15 ASSESSMENT OF THE BENEFITS OF TIME SAVINGS ACHIEVED BY ONCE MONTHLY INJECTION OF ERYTHROPOIETIN STIMULATING AGENTS (ESA) ON ANAEMIA MANAGEMENT IN HAEMODIALYSIS CENTRES
|
Allard, B
|
|
2008
|
11 |
6 |
p. A654-
1 p.
|
artikel
|
| 948 |
PUK7 A TEN-YEAR HORIZON COST-EFFECTIVENESS ANALYSIS OF THE SPANISH INTEGRATED RENAL REPLACEMENT THERAPY PROGRAM
|
Villa, G
|
|
2008
|
11 |
6 |
p. A651-A652
nvt p.
|
artikel
|
| 949 |
PUK1 CLINICAL ATTITUDES ON CHRONIC GRAFT DYSFUNCTION: THE ICEBERG STUDY
|
Font, B
|
|
2008
|
11 |
6 |
p. A649-A650
nvt p.
|
artikel
|
| 950 |
PUK21 CONTENTVALIDITY OF THE SUBJECT'S ASSESSMENT OF CONDITION, SUBJECT'S ASSESSMENT OF TREATMENT SATISFACTION, KING'S HEALTH QUESTIONNAIRE, AND INTERNATIONAL CONSULTATION ON INCONTINENCE QUESTIONNAIRE—SHORT FORM IN PATIENTS WITH OAB
|
Margolis, MK
|
|
2008
|
11 |
6 |
p. A656-
1 p.
|
artikel
|
| 951 |
PUK5 COST-BENEFITS ANALYSIS OF DIET VERSUS DIALYSIS IN ELDERLY CKD5 PATIENTS
|
Borghetti, F
|
|
2008
|
11 |
6 |
p. A651-
1 p.
|
artikel
|
| 952 |
PUK6 COST-EFFECTIVENESS ANALYSIS OF SACRAL NEUROMODULATION (SNM) FOR PATIENTS WITH OVERACTIVE BLADDER (OAB) IN THE NETHERLANDS
|
Van Genugten, M
|
|
2008
|
11 |
6 |
p. A651-
1 p.
|
artikel
|
| 953 |
PUK9 COST OF OVERACTIVE BLADDER IN THE UNITED STATES
|
Ganz, ML
|
|
2008
|
11 |
6 |
p. A652-
1 p.
|
artikel
|
| 954 |
PUK10 ECONOMIC IMPACT OF A LOW-PROTEIN DIET AIMING TO DELAY THE HAEMODIALYSIS TREATMENT IN PATIENTS WITH CHRONIC-RENAL-FAILURE
|
de Portu, S
|
|
2008
|
11 |
6 |
p. A652-A653
nvt p.
|
artikel
|
| 955 |
PUK17 ESTIMATING THE QUALITY OF LIFE IMPACTS OF TOLTERODINE AND TAMSULOSIN TREATMENT IN MEN WITH LOWER URINARY TRACT SYMPTOMS AND OVERACTIVE BLADDER
|
Verheggen, BG
|
|
2008
|
11 |
6 |
p. A655-
1 p.
|
artikel
|
| 956 |
PUK13 EXPANDED CRITERIA DONORS IN RENAL TRANSPLANTATION: RESULTS OF ECONOMIC EVALUATION
|
Ortega, T
|
|
2008
|
11 |
6 |
p. A653-A654
nvt p.
|
artikel
|
| 957 |
PUK16 EXPLORING THE IMPACT OF CHANGES IN NEUROGENIC URINARY INCONTINENCE FREQUENCY AND CONDITION SPECIFIC QUALITY OF LIFE ON PREFERENCE-BASED OUTCOMES
|
Hollingworth, W
|
|
2008
|
11 |
6 |
p. A654-A655
nvt p.
|
artikel
|
| 958 |
PUK22 FACTORS ASSOCIATED WITH PERCEIVED SATISFACTION IN HEMODYALISIS PATIENTS
|
Valdes, C
|
|
2008
|
11 |
6 |
p. A656-A657
nvt p.
|
artikel
|
| 959 |
PUK8 FESOTERODINE IS COST-EFFECTIVE FOR THE TREATMENT OF OVERACTIVE BLADDER: RESULTS OF AN ECONOMIC MODEL
|
Kelleher, C
|
|
2008
|
11 |
6 |
p. A652-
1 p.
|
artikel
|
| 960 |
PUK2 IN GREECE, INCREASING THE UTILIZATION OF PERITONEAL DIALYSIS THERAPY MAY REDUCE OVERALL DIALYSIS EXPENDITURES
|
Walker, DR
|
|
2008
|
11 |
6 |
p. A650-
1 p.
|
artikel
|
| 961 |
PUK4 PHARMACOECONOMIC EVALUATION OF SOLIFENACIN IN THE TREATMENT OF OVERACTIVE BLADDER SYNDROME IN ITALY
|
Pradelli, L
|
|
2008
|
11 |
6 |
p. A650-A651
nvt p.
|
artikel
|
| 962 |
PUK19 PSYCHOMETRIC EVALUATION OF THE KHQ IN TEN LANGUAGES
|
Coyne, KS
|
|
2008
|
11 |
6 |
p. A655-A656
nvt p.
|
artikel
|
| 963 |
PUK3 THE COST ADVANTAGE OF INCREASING THE USE OF PERITONEAL DIALYSIS IN TURKEY
|
Bademlioglu, C
|
|
2008
|
11 |
6 |
p. A650-
1 p.
|
artikel
|
| 964 |
PUK20 VALIDATION OF THE SPANISH VERSION OF THE PELVIC ORGAN PROLAPSE/URINARY INCONTINENCE SEXUAL QUESTIONNAIRE-SHORT FORM (PISQ-12)
|
Rebollo, P
|
|
2008
|
11 |
6 |
p. A656-
1 p.
|
artikel
|
| 965 |
PUK18 VALIDATION OF THE URINARY SENSATION SCALE (USS)
|
Coyne, KS
|
|
2008
|
11 |
6 |
p. A655-
1 p.
|
artikel
|
| 966 |
QL3 ACCESS TO HEALTH-RELATED QUALITY OF LIFE (HRQL) INSTRUMENTS AND THEIR TRANSLATIONS IN THE LIGHT OF EMEA RECOMMENDATIONS
|
Anfray, C
|
|
2008
|
11 |
6 |
p. A341-
1 p.
|
artikel
|
| 967 |
QL1 AGGREGATION OF DATA FROM MULTIPLE LANGUAGES AND CULTURES: REPORT FROM THE ISPOR TASK FORCE ON TRANSLATION AND LINGUISTIC VALIDATION
|
Wild, D
|
|
2008
|
11 |
6 |
p. A340-
1 p.
|
artikel
|
| 968 |
QL8 COMPARISON OF CANCER-RELATED FATIGUE USING A ONE- VERSUS FOUR-WEEK RECALL PERIOD
|
Lai, JS
|
|
2008
|
11 |
6 |
p. A348-
1 p.
|
artikel
|
| 969 |
QL5 COMPARISON OF EQ-5D AND HUI3 IN PATIENTS WITH TINNITUS
|
Maes, IH
|
|
2008
|
11 |
6 |
p. A347-
1 p.
|
artikel
|
| 970 |
QL9 DEVELOPMENT AND VALIDATION OF AN ELETRONIC VERSION OF THE HEALTH ASSESSMENT QUESTIONNAIRE DISABILITY INDEX (HAQ-DI)
|
Tiplady, B
|
|
2008
|
11 |
6 |
p. A354-
1 p.
|
artikel
|
| 971 |
QL10 DEVELOPMENT AND VALIDATION OF THE SATISFACTION WITH MEDICATION QUESTIONNAIRE (SAT-Q) IN PATIENTS WITH CHRONIC DISEASE
|
Cuervo, J
|
|
2008
|
11 |
6 |
p. A354-A355
nvt p.
|
artikel
|
| 972 |
QL11 FATIGUE REDUCTION AND PHYSICAL FUNCTION IMPROVEMENTS ASSOCIATED WITH INCREASED PRODUCTIVITY AT WORK AND AT HOME IN RHEUMATOID ARTHRITIS PATIENTS
|
Hazes, M
|
|
2008
|
11 |
6 |
p. A355-
1 p.
|
artikel
|
| 973 |
QL12 FRENCH NORMATIVE REFERENCE DATA FOR THE QUALITY OF LIFE ASSESSMENT OF GROWTH HORMONE DEFICIENCY IN ADULTS (QOL-AGHDA) QUESTIONNAIRE
|
Chachuat, A
|
|
2008
|
11 |
6 |
p. A355-
1 p.
|
artikel
|
| 974 |
QL7 INTERPRETING SCORES ON THREE COPD PATIENT-REPORTED OUTCOME MEASURES
|
McKenna, SP
|
|
2008
|
11 |
6 |
p. A348-
1 p.
|
artikel
|
| 975 |
QL4 PREDICTING EQ-5D, SF-6D AND 15D UTILITIES FROM EORTC QLQ-C30 DATA
|
Kontodimopoulos, N
|
|
2008
|
11 |
6 |
p. A341-
1 p.
|
artikel
|
| 976 |
QL6 ROLE OF DISEASE SPECIFIC INSTRUMENTS IN THE MEASUREMENT OF HEALTH-RELATED QUALITY OF LIFE IN CANCER CLINICAL TRIALS
|
Narvilkar, P
|
|
2008
|
11 |
6 |
p. A347-
1 p.
|
artikel
|
| 977 |
QL2 TRANSLATION OF THE COLUMBIA SUICIDE SEVERITY RATING SCALE (C-SSRS) FOR USE IN 33 COUNTRIES
|
Fernandez, N
|
|
2008
|
11 |
6 |
p. A340-A341
nvt p.
|
artikel
|
Tijdschrift beschrijving